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Abstract 
This study aimed to construct a database of 1500 newly diagnosed patients with epilepsy 
referred to the epilepsy unit at the Western Infirmary in Glasgow between 1982 and 2005. 
These patients commenced their first ever epilepsy treatment at the unit. The database 
included demographic, clinical and investigational information together with a detailed 
account of every drug regimen applied starting from the first AED prescribed until the last 
follow up appointment. Using this database, I was able to identify the efficacy and 
tolerability of different AEDs in relation to various demographic, clinical and 
pharmacological characteristics. This analysis provides a better understanding of the 
natural history of treated epilepsy, an informational aid for the future prescription choice of 
drug and/or drug combination according to different patient characteristics and facilitates 
the study of patients with intractable seizures from a pharmacological point of view.    
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Summary 
It has been almost two decades since the introduction of the second generation AEDs. 
Most of these drugs have been studied in head to head comparisons either with placebo or 
with first generation agents. A limited number of studies has examined the efficacy and 
tolerability of newer AEDs either among other modern drugs or in comparison with older 
generation AEDs. It seems appropriate after two decades of their introduction to 
investigate how these drugs have influenced the outcome of epilepsy and to compare them 
against first generation AEDs as groups regarding their efficacy and tolerability. As this is 
a retrospective study, it focuses more on groups of AEDs with regard to specific 
populations rather than investigation and comparison of the response among individual 
drugs that usually need a properly designed prospective study in order to obtain accurate 
results and appropriate analysis.   
The population of this study was 1098 newly diagnosed patients referred to the Epilepsy 
Unit of the Western Infirmary Hospital, Glasgow, Scotland between 1982 and 2005 and 
followed up until the end of March 2008. The ultimate outcomes of epilepsy along with the 
efficacy of each AED/s combination were collected. Efficacy was calculated based on the 
percentage of patients who achieved a period of at least 12 months seizure freedom on a 
particular AED regimen among all the patients on that drug. Tolerability of AEDs was 
reported using withdrawal of treatment due to side effects as an indicator. With regard to 
the generations of AEDs, total cumulative efficacy and tolerability were also calculated. 
All these parameters were analysed in relation to various demographic, pharmacological 
and clinical aspects.  
Regarding various age groups of recruited patients in this study, elderly patients with 
epilepsy (≥ 65 years old) showed the highest remission rate in comparison to adolescents 
and adults. Also, total cumulative efficacy of first generation AEDs was found to be 
significantly better than newer agents in elderly patients; elderly patients also tolerated 
older AEDs better than modern drugs.  Adults patients showed a lower total efficacy of 
established drugs than newer agents with small difference in terms of tolerability. On the 
other hand, adolescents patients had a higher efficacy of first generation AEDs than second 
generation agents with also minimal difference regarding the tolerability profiles.   
Gender analysis showed a higher remission rate in male patients with epilepsy compared to 
females. Efficacy of the commonly prescribed AEDs and both generations of AEDs were 
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also higher in males than females. In terms of tolerability profiles, males were found to 
tolerate some AEDs better than females. Better tolerability to both generations of AEDs 
was observed in males in comparison to females. Treatment with AEDs acting primarily by 
potentiation of GABA inhibitory effect was found to be significantly more efficacious in 
male patients with idiopathic generalised epilepsy than females.  
Based on epilepsy classification, idiopathic generalised epilepsy (IGE) patients had a 
higher remission rate compared to those with focal epilepsy. First generation AEDs had a 
higher response in IGE patients with slightly better tolerability than modern drugs. AEDs 
acting mainly by potentiation of GABA inhibitory effect were more efficacious in these 
patients than sodium channels blocking AEDs. Sodium valproate was associated with the 
highest efficacy and tolerability in patients with idiopathic generalised epilepsy. In 
contrast, lamotrigine was the AED with the highest efficacy and tolerability among 
patients with focal epilepsy. Second generation drugs were slightly more efficacious than 
older AEDs with minimal difference in terms of tolerability. In terms of mechanisms of 
action, only minimal difference was observed between AEDs acting by sodium channels 
blockage and potentiation of GABA inhibitory effect with regard to remission rate among 
focal epilepsy patients.    
50% of the study population achieved seizure freedom while on the first AED treatment 
regimen with a dramatic decline in subsequent schedules. Most of patients with seizure 
freedom used moderate doses of AEDs even lower than the recommended defined daily 
dose in some cases. Similarly, the majority of patients who withdrew from AEDs due to 
side effects were taking moderate doses of these agents (even lower than the recommended 
daily defined dose) rather than high doses. Various patterns of response to AEDs have 
been noticed in this study; this might be due to the interaction of several factors such as 
epilepsy syndromes, genetics, and brain adaptation to AEDs.   
Analysis of the annual outcome of epilepsy according to years of referral demonstrated a 
modest improvement in the ultimate outcome of epilepsy accompanied by the longer 
duration of follow up of patients. More second generation AEDs have been identified and 
applied in the last two decades which is assumed to contribute to the improvement in the 
epilepsy outcome. Failure of treatment regimen due to poor tolerability was associated 
with a better prognosis of epilepsy than failure due to lack of efficacy of that particular 
regimen. Since a decline in remission with further AED treatment regimens was noted after 
failure of the first AED, it can be assumed that failure of two treatment regimens due to 
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lack of efficacy is associated with an elevation in the risk of developing refractory epilepsy 
subsequently.   
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1.1. Epilepsy 
1.1.1. Introduction 
Epilepsy is characterised by the presence of recurrent seizures.  A seizure can be defined as 
“an episodic disturbance of movement, feeling, or consciousness caused by sudden 
synchronous, inappropriate, and excessive electrical discharges in the cerebral cortex” 
(Brodie and French, 2000).  Epileptic convulsions are expected to have negative 
consequences on the patient’s psychological and social life such as relationships, education 
and employment.  Uncontrolled seizures are associated with physical and psychosocial 
morbidity, dependent behavior, poor quality of life and an increased risk of sudden 
unexpected death.  Therefore, it is often recommended to begin treatment of epilepsy with 
antiepileptic drugs (AEDs) as soon as the patient has reported more than one documented 
or witnessed seizure bearing in mind that the goal of treatment should be to maintain as 
normal a life style through complete seizure control with no or minimal side effects 
(Brodie, 2005). 
The process of epileptogenesis starts when a normal brain experiences an injury e.g. 
trauma, infection, ischemia or the presence of a malformation or mass lesion. Based on the 
patient’s age and genetic background, some acute damage takes place with subsequent 
progressive damage. Although the brain tries to repair itself, after a latent period of time 
(might reach up to years), a condition of hyperexcitability develops and seizures begin 
(Dichter, 2009).  
In the Greek language, epilepsy is derived from epilamvanein or Epilepsia, which means 
‘to be seized’, ‘to be taken hold’ or ‘to be attacked’.  Such terms reflect an outlook of the 
period that considered this disease was the result of possession by evil spirits (Fong and 
Fong, 2001). 
1.1.2. History of epilepsy 
Epilepsy is thought to be one of the oldest recorded diseases that appeared in humans as it 
was reported in the earliest medical documents.  This explains the attitudes of early 
civilisations, with the lack of understanding of its pathophysiology combined with the 
strange movements exerted by patients, that the concept of epilepsy was linked to legends 
and myths.  
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The earliest record of epilepsy was in ancient Indian medicine 4500-1500 B.C.  In 
Ayurvedic literature of Charaka Samhita (literature of traditional medicine in India), 
epilepsy was described as “apasmara” which means “loss of consciousness”.   
All aspects of epilepsy were discussed in that record including symptomatology, aetiology, 
diagnosis and treatment (Pierce, 2002).  
Around 3000 years ago, the ancient Babylonians posited some suggestions regarding the 
causes and symptoms of epilepsy.  Ancient Greeks linked epilepsy to offending the moon 
goddess Selene and proposed a certain technique to cure it.  Probably, the Greek physician 
Hippocrates, the Father of Medicine in 400 B.C., was the first to discuss epilepsy using 
scientific explanations as he connected this disease to the brain. During the Renaissance, a 
different view emerged on the causes of epilepsy in contrast to demonic possession.  Some 
thought these patients were prophets while others believed they were extraordinary as 
some celebrated individuals in the Roman Empire had epilepsy such as Julius Caesar and 
Petrarch.  From the late 1600s on, epilepsy was thought to be a contagious disease and 
therefore, its patients were confined to mental hospitals and separated from the other 
patients.  The beginning of an enlightened approach towards epilepsy as a medical 
condition was between 1859 and 1906 and it was guided by three English neurologists; 
John Hughlings Jackson, Russell Reynolds and Sir William Richard Gowers.  According to 
Jackson’s definition “a seizure is an occasional, an excessive, and a disorderly discharge of 
nerve tissue on muscles”.  Also, he stated that seizures could alter consciousness, sensation 
and behaviour (Schachter, 2004). 
Subsequently, further scientific discoveries on the brain and pathophysiology of epilepsy 
have taken place that enabled a better understanding of epilepsy and was accompanied by 
the introduction of pharmacological intervention in the treatment of epilepsy. 
1.1.3. Epidemiology of epilepsy 
Epilepsy is considered to be the most common neurological disease with an incidence rate 
of 50-70 cases per 100,000 persons per year in most developed countries and a prevalence 
of 5 - 10 cases per 1,000 in a typical European population excluding cases of single 
seizures and febrile convulsions in children (Brodie et al., 1997).  
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The incidence of epilepsy tends to be higher in developing countries than developed ones 
based on a recent study (Kotsopoulos et al., 2002), the estimated median incidence of 
epilepsy is 43.4/100,000 in the developed countries compared to 68.7/100,000 in the 
developing countries.  Age specific incidence of epilepsy is characterised by a “U-shaped 
curve” in which the incidence is high in childhood and the elderly after the age of 55 in the 
industrialised nations.  The developing countries have a different pattern of age specific 
incidence where higher incidence rates are observed in children and young adults 
compared to the elderly (Mac et al., 2007).  First life time seizure has an incidence of 52 - 
59 per 100,000 in the age group 40 - 59 years; these figures reach 127 per 100,000 in those 
who are 60 years and older (Hauser, 1997).  The high incidence rate of epilepsy in the 
elderly might be due to the high rate of developing risk factors related to epilepsy in this 
age group.  Vascular diseases (cerebral infarction and haematoma) tend to be the 
commonest cause of epilepsy (Loiseau et al., 1990).  Other causes include brain tumours, 
metabolic disorders and degenerative diseases e.g. Alzheimer’s disease.  In other cases, the 
cause is unidentified (cryptogenic epilepsy).  
With regard to gender, there is a broad agreement worldwide that females have a lower 
incidence rate of epilepsy compared to males; 46.2 and 50.7/100,000 respectively 
(Kotsopoulos et al., 2002).  This gender difference can be explained by the fact that men 
have a greater exposure to risk factors of epilepsy such as head injuries, stroke and CNS 
infection, even alcohol-related seizures are more common in males.   
Among developing countries that have a higher incidence of epilepsy compared to 
developed ones, Latin America and several African countries proved to have a particular 
high incidence of epilepsy, possibly due to certain parasitic infections with brain 
involvement, perinatal brain damage or hereditary factors (Senanayake and Roman, 1993). 
Among all seizure types, partial seizures - with or without secondary generalisation 
(localisation-related epilepsies) - constitute the major type of seizures in all age groups 
(Sander et al., 1990).  
The prevalence of active epilepsy in the developed world ranges between 4 and 10 per 
1000 of the population (Jallon, 1997a).  On the other hand, incidence of active epilepsy 
varies in developing countries, with ranges from 17 - 57/ 1000 in South America, 5.2 - 43/ 
1000 in African countries and from 1.5 - 14 in Asia (Mac et al., 2007).  
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An estimate of people with active epilepsy in Europe is approximately 3.1 million (based 
on a prevalence of 6/1000), excluding Russia, Belarus and Ukraine (due to sparse 
information on the epidemiology of epilepsy in a large population) while the expected 
number of new cases per year in Europe based on an age-specific rate is 311,000 (Forsgren 
et al., 2005). 
1.1.4. Classification of seizures and epilepsy syndromes 
Determining an accurate classification of seizures for a particular patient is considered a 
crucial factor in the selection of the most appropriate AED to be applied and to provide 
prognostic information on that particular type of epilepsy.  The most commonly used 
classification in clinical practice is that established by the International League Against 
Epilepsy (ILAE) to classify epileptic seizures (Commission, 1981) and epilepsy syndromes 
(Commission, 1989).  
Based on the ILAE classification of epileptic seizures (Commission, 1981), these are 
divided into three groups based on clinical findings and electroencephalograph (EEG) 
readings: general, partial (localisation-related) and unclassified seizures.  Generalised 
seizures are characterised by the involvement of the whole cerebral hemispheres from the 
onset.  Partial seizures are localised to specific foci in the brain responsible for the 
electrical discharge.  Generalised seizures are further subdivided into tonic-clonic, absence, 
myoclonic, atonic, tonic and clonic seizures.  On the other hand, partial seizures have two 
subtypes: simple partial seizures in which the consciousness is preserved and complex 
partial seizures that are accompanied by impairment of consciousness.  Sometimes, 
seizures may start as partial due to a discharge from a focus in the brain then spread to 
involve the whole cerebral hemisphere resulting in secondary generalisation of the seizures 
(Table 1).   
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Seizures type Description 
Simple partial seizures (consciousness preserved) 
a. with motor symptoms 
b. with somatosensory or special sensory symptoms 
c. with autonomic symptoms 
d. with psychic symptoms 
Complex partial seizures (consciousness impaired) 
a. simple partial seizures onset followed by impaired 
consciousness 
b. impaired consciousness at onset  
I. Partial seizures 
(with localised 
onset) 
Partial seizures with secondary generalized seizures  
Absence seizures (whether typical or atypical)  
Myoclonic seizures 
Clonic seizures 
Tonic seizures 
Tonic-clonic seizures 
II. Generalised 
seizures 
Atonic seizures 
III. Unclassified 
seizures 
Includes all seizures unclassified due to inadequate or 
incomplete data e.g. some neonatal seizures presented as 
rhythmic eye movements or chewing 
Table 1. International classification of epileptic seizures (Commission, 1981).  
 
ILAE suggested in 1989 a new classification taking into consideration more factors than 
the 1981 classification.  These factors include seizure type, EEG, prognosis, 
pathophysiological and aetiological data (Commission, 1989).  This new classification has 
retained the main three types of seizures; generalised, partial and unclassified.  But based 
on the cause, each type is further subdivided into idiopathic, symptomatic or cryptogenic 
epilepsy.  Idiopathic epilepsy refers to syndromes assumed to be of genetic origin while 
symptomatic epilepsy is the result of a disorder in the central nervous system.  Cryptogenic 
epilepsy is reserved for those syndromes with an underlying but unidentified focal 
abnormality (Table 2).  
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Seizures type Description 
Idiopathic epilepsy with age related onset 
a. Benign rolandic epilepsy 
b. Childhood epilepsy with occipital paroxysms 
c. Primary reading epilepsy 
Symptomatic epilepsy 
I. Focal 
(localisation-
related or partial) 
Cryptogenic epilepsy 
Idiopathic epilepsy with age related onset 
a. Benign neonatal familial convulsions 
b. Benign neonatal non-familial convulsions 
c. Benign myoclonic epilepsy in infancy 
d. Juvenile absence epilepsy  
e. Juvenile myoclonic epilepsy 
f. Epilepsy with generalized tonic-clonic seizures on 
awakening 
g. Other idiopathic epilepsies  
Cryptogenic or symptomatic epilepsy 
a. West syndrome (infantile spasms) 
b. Lennox-Gastaut syndrome (childhood epileptic 
encephalopathy) 
c. Epilepsy with myoclonic-astatic seizures 
d. Epilepsy with myoclonic absence seizures 
II. Generalised 
Symptomatic epilepsy 
a. Non-specific syndromes e.g. early myoclonic 
encephalopathy 
b. Specific syndromes i.e. epileptic seizures as a complication 
of a disease e.g. phenylketonuria.  
With both generalised and focal features 
a. Neonatal seizures 
b. Severe myoclonic epilepsy in infancy 
c. Epilepsy with continuous spike waves during slow-wave 
sleep 
d. Acquired epileptic aphasia  
e. Other undetermined epilepsies not defined above  
III. Undetermined 
epilepsies whether 
focal or 
generalised 
Without unequivocal generalised or focal features  
Febrile convulsions e.g. febrile convulsions, seizures due t o stress 
or alcohol or sleep deprivation.  IV. Special 
syndromes Isolated, apparently unprovoked seizures 
Table 2. International classification of epilepsies and epileptic syndromes (Commission, 
1989). 
 
With regard to the aetiology of epilepsy, a wide range of causes of epilepsy has been 
identified in the brains of these patients.  These include: cerebrovascular disease 
(ischaemia and haemorrhage), trauma, neoplasm, cerebral infection, degenerative disorders 
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and congenital abnormalities.  In around half of the patients, the aetiology of epilepsy 
could not be identified (Forsgren et al., 2005).  
Although these two classifications are still used today, it has been now more than two 
decades since their establishment by ILAE and this has led some specialists in epilepsy to 
look for an updated version of seizures classification as many of the observations regarding 
this disease have either been changed or discovered since those early days (Engel, 2001).  
1.1.5. Diagnosis of epilepsy 
Several conditions can mimic epileptic seizures (Table 3) such as syncopal attacks that are 
commonly misdiagnosed as epileptic seizures (Smith et al., 1999). Also, pseudoseizures or 
non-epileptic psychogenic seizures that occur in 10 - 45% of patients with apparently 
refractory epilepsy (Devinsky, 1999) are difficult to diagnose as non-epileptic attacks often 
coexist with epilepsy or may develop as a substitute for seizures once the epilepsy is 
controlled (Kuyk et al., 1997). Proper diagnosis of epilepsy is an essential element for the 
definition of the likely prognosis and selection of the most appropriate treatment.  
Diagnosis of epilepsy can be divided into two stages: clinical evaluation and 
investigations.  
It is rare for the patient to have a seizure at the time of a medical examination.  In addition, 
in some seizure types, the patient might lose consciousness and be unable to provide a full 
description of the seizure experienced.  Therefore, a detailed history needs to be obtained 
from the patient and witnesses of seizures as well.  Trevavathan showed that a proper 
detailed history taken from patients led to the correct diagnosis of epilepsy in 96% of cases 
even before performing any investigations (Trevathan, 2003).  One important aspect in this 
regard is to distinguish whether the episode occurred was an epileptic or non-epileptic 
seizure, as the list of differential diagnosis of seizure is long (Table 3).  A physical and 
neurological examination is usually performed to detect any neurological deficit that 
corresponds to an underlying pathology in the brain.  At the other extreme,  around one-
quarter of epilepsy patients in some developed world clinics have been shown not to have 
the disease (Simkiss, 2001), and inadequate history taking and a failure to recognise a 
differential diagnosis were some of the important reasons identified.  
Investigations of epilepsy are used to support the clinical diagnosis, to aid in the 
identification of seizure classification and to detect any underlying brain abnormalities.  
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Electroencephalography (EEG) is an important tool for the diagnosis of epilepsy because 
of its ability to identify epileptiform EEG activity in order to determine seizure 
classification. Since specific EEG patterns can reflect specific epileptic syndromes and also 
because some of the clinical manifestations e.g. aura can be explained through an EEG 
reading by the localisation and lateralisation of epileptogenic EEG foci (Oguni, 2004).  It is 
based on the recording of electrical discharge generated in the brain that in the case of 
epilepsy would be excessive and sometimes characteristic.  
Magnetic Resonance Imaging (MRI) is another essential tool in the diagnosis of epilepsy 
that was first employed in clinical practice in 1984.  It is considered the most sensitive and 
specific structural neuroimaging procedure for epilepsy (Bergen et al., 1989).  It is used to 
detect the underlying brain lesion that might be responsible for seizure development.  The 
most common abnormalities that can be identified by MRI include: hippocampal sclerosis, 
malformations of cortical development, vascular malformations, tumours and acquired 
cortical damage (Duncan, 1997).  MRI is particularly useful in symptomatic epilepsy and 
complex partial seizures (Oguni, 2004).  In certain situations, the use of Computed 
Tomography (CT) scan is preferred to MRI in cases where patients have metal aneurysm 
clips, cardiac pacemakers, severe claustrophobia, acute intracranial haematomas and skull 
fractures.  Various other techniques used in the functional imaging of the brain have been 
developed and are being applied in the evaluation of epilepsy.  Such techniques include: 
functional MRI, magnetoencephalography, magnetic resonance spectroscopy, single 
photon emission computed tomography and positron emission tomography (Duncan, 
1997).  
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Disorder Description 
Transient ischemic attack 
Transient global amnesia 
Migraine 
Narcolepsy 
Neurological disorders 
Panic attacks 
Vasovagal syncope 
Reflex anoxic seizure 
Sick sinus syndrome 
Arrythmias 
Cardiac disorders 
Hypotension 
Hypoglycaemia 
Hyopnatremia 
Endocrine/ metabolic 
disorders 
Hypkalemia 
Acute dystonic reactions 
Hemifacial spasm 
Paroxysmal movement 
disorders 
Non-epileptic myoclonus 
Obstructive sleep apnea 
Hypnic jerks 
Benign neonatal sleep myoclonus 
Rapid eye movement sleep disorder 
Parasomnias 
Sleep disorders 
Cataplexy 
Psychological Non-epileptic psychogenic seizures 
Table 3. Common differential diagnoses in epilepsy (Benbadis, 2009;Brodie et al., 2005). 
 
 
Serious consequences can result from epilepsy misdiagnosis. These include inappropriate 
treatment supplied to patients who are deprived of the correct management (Petkar et al., 
2005). Other consequences include the psychological impact related to the diagnosis of 
epilepsy, socio-economic disadvantages affecting car driving, education, employment and 
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insurance. Additional problems include harmful consequences related to AEDs such as 
serious side effects and risk of teratogenicity in women of childbearing age (Chowdhury et 
al., 2008;Smith et al., 1999).  
1.1.6. Measuring the outcome of epilepsy 
Outcomes research is a comprehensive approach used to evaluate the medical care offered 
to patients based on a variety of data sources and measurement methods.  In the field of 
epilepsy, there are several measures that can be used for different purposes. These tools 
include the measurement of: seizure frequency and seizure severity, impact on physical 
and psychosocial function, the consequences of pharmacotherapy, the results of surgical 
therapy and the composite effect of epilepsy and treatment expressed as quality of life 
(QOL) (Baker et al., 1998).  
Measuring outcome in epilepsy and determining the effect of an AED have proved to be 
difficult and elusive.  This is due to several factors such as the unpredictable nature of the 
disease and the lack of clear recommendations for the minimum standards to be used to 
measure epilepsy outcomes during the conduct of randomised controlled trials.  Baker and 
colleagues reported that in 44 randomised controlled trials of AEDs, a total of 54 different 
measures were used (Baker et al., 2000).  As a result, the opportunity to make meaningful 
comparisons between these studies will be minimised without the ability to establish any 
useful conclusions about the effects of these AEDs.  
Sometimes, even in the presence of a clear and accurate measure of outcome, its 
application in the real world would be difficult as in the case of using seizure frequency as 
an indicator of the outcome of epilepsy.  The Commission on Outcome Measurement in 
Epilepsy (COME) report suggested that seizure frequency is the most sensitive measure for 
the assessment of efficacy amongst AEDs and recommended its use whenever possible 
(Baker et al., 1998).  But, the reliance of investigators on seizure records compiled by 
patients themselves might lead to inaccurate results because some patients may not 
recognise genuine seizures events and others may have ulterior motives for censoring their 
disclosure, especially given the potential impact on employment and driving. In other 
cases, long intervals between clinic appointments might result in lapses in the recording of 
seizures.  Engel’s score is one of the widely used measures to quantify seizure frequency 
(Engel et al., 1993).  It is mainly used to assess the surgical (and sometimes 
pharmacological) intervention to treat patients with epilepsy (Table 4).  
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Rating Description 
Class I Free of disabling seizures 
A Completely seizure free since surgery 
B Non-disabling simple partial seizures only since surgery 
C Some disabling seizures after surgery, but free of disabling seizures for 
at least 2 years 
D Generalised convulsions with AED discontinuation only 
Class II Rare disabling seizures (“almost seizure free”) 
A Initially free of disabling seizures but has rare seizures now 
B Rare disabling seizures since surgery 
C More than rare disabling seizures since surgery, but rare seizures for the last 2 years 
D Nocturnal seizures only 
Class III Worthwhile improvement 
A Worthwhile seizure reduction 
B Prolonged seizure free intervals amounting to greater than half the followed up period, but not < 2 years 
Class IV No worthwhile improvement 
A Significant seizure reduction 
B No appreciable change 
C Seizure worse 
Table 4. Engel's score used for classification of postoperative outcome. 
 
 
Other than seizure frequency, seizure severity is another measure of the outcome in 
epilepsy that is now considered an important additional aspect of epilepsy (Mattson and 
Cramer, 1993).  Seizure severity represents any change in the severity of habitual seizures, 
possibly independent of seizure frequency such as more rapid recovery from seizures or 
fewer falls or injuries (ODonoghue et al., 1996).  But similar to seizure frequency, 
measuring seizure severity is also associated with difficulty as the physician and the patient 
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can judge it differently.  To quantify seizure severity, three scales have been developed 
(Table 5):   
1. The Veterans Administration Seizure Frequency and Severity Rating Scale.  
This was the first scale designed to quantify seizure frequency and severity in 
clinical trials.  It can be used for various types of seizure and represents an 
interview based assessment relying on the important factors frequently reported by 
patients that determine severity of their seizures such as sleep deprivation, 
warning/aura and missed doses of AEDs (Cramer et al., 1983).  
2. The Liverpool Seizure Severity Scale.  
This is a patient filled questionnaire composed of 16 questions distributed into two 
categories; the first category is composed of 10 questions related to ictal and post-
ictal phenomena, while the second category is composed of 6 questions concerned 
with the predictability of seizures.  In this scale, seizures are either classified as 
major or minor seizures on a 5-point scale.  Their definition is left to patients and 
does not necessary employ major seizures for Generalised Tonic Clonic Seizures 
(GTCS) and minor ones for Complex Partial Seizures (CPS).  Such a decision is 
difficult to make by some patients.  A newer version of this scale has been 
developed (Baker et al., 1991).  
3. The National Hospital Seizure Severity Scale (NHS3) (formerly known as the 
Chalfont Seizure Severity Scale).  
NHS3 is performed through interviewing the patients and witnesses to the seizures.  
It is mainly designed to score the seizures according to interference with patient 
function.  It can be used for various types of seizures (ODonoghue et al., 1996).  
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Item VA L N 
Seizure type + + + 
Seizure duration - + + 
Post-ictal events and duration - + + 
Automatisms + + - 
Seizure clusters + - + 
Cyclic and diurnal patterns + - + 
Ability to predict seizures + + + 
Stopping seizures - - + 
Tongue biting and incontinence - + + 
Other injuries - + + 
Remediable precipitating factors + - - 
Drug levels and compliance + - - 
Functional impairment + + + 
Table 5. Comparison of the Veterans Administration (VA), Liverpool (L) and NHS3 (N) 
seizure severity scales (Baker et al., 1998).  
 
 
As a part of the evaluation of medical care provided for patients with epilepsy, an 
evaluation of the AED therapy offered to these patients needs to be considered.  The most 
important clinical characteristic of any drug is its effectiveness in the treatment of the 
disease.  Effectiveness of a drug is a measure that includes both its efficacy and tolerability  
(Chadwick et al., 1998).  
Achieving complete seizure control is the main target of AED treatment and is considered 
as the main indicator of treatment success. The probability of achieving complete seizure 
freedom varies depending on the efficacy of AED applied. Efficacy of AEDs can be 
defined as “the reduction in seizure frequency and/or severity directly attributable to 
treatment” (Chadwick et al., 1998).  According to this definition, seizure frequency in 
which seizures can be simply counted over a defined period of time and seizure severity 
represent the most reliable measures to assess the efficacy of a particular AED.  A variety 
Chapter 1. Introduction.   32 
of other alternative measures might be considered in the assessment of AED efficacy such 
as the percentage reductions in seizure frequency or time required to develop the first 
seizure after starting treatment or percentage of patients with seizure freedom (length of 
seizure freedom period should be defined).   
Use of greater than or less than 50% reduction in seizure frequency is not a preferred 
measure due to the chance of missing important differences between treatments by relying 
on an arbitrary cut-point of 50%.  A more informative and less misleading alternative 
would be to select multiple categories of seizure frequency such as 0 - 20%, 21 - 40%, 41 - 
60% etc.  “Time to first seizure recurrence” has the capability of dealing with 
heterogeneous seizure counts and low seizure frequencies. It has several variants such as 
time to first seizure after the first 6 weeks post randomisation (thus seizures taking place 
during this 6 week period of dose adjustment will be ignored), time to first tonic-clonic 
seizure, time to nth seizure recurrence, time to first seizure after commencing therapy, time 
to discontinuation of medication, and time to 6-months or 12-months seizure freedom.  
When the period of follow up is the same for all patients included in a particular study and 
none are lost to follow up, then percentage of patients with seizure freedom is a good 
measure with the necessity to define the length of seizure freedom period (Baker et al., 
1998).  The proportion of patients achieving a pre-defined duration of seizure freedom is 
the clinically most meaningful endpoint and is recommended for trials conducted in newly 
diagnosed or previously untreated epilepsy (Perucca, 1997). The seizure severity measures 
discussed earlier can also be applied to evaluate the efficacy of AED therapy (Table 6).   
The other important aspect in the effectiveness of any drug is its tolerability. Tolerability is 
a factor directly related to the side effects exerted by the drug.  It is assessed based on the 
incidence, severity and impact of side effects of a particular agent on the patients. The 
main difficulty associated with the evaluation of side effects is that it is often based on 
spontaneous reporting by the patients. Although spontaneous reporting highlights the 
clinically relevant effects, it is accompanied by variability in the accuracy of detection of 
side effects (Mattson and Cramer, 1993). Further problems include the difficulty to assess 
the severity of these side effects quantitatively and to differentiate the side effects of an 
added AED from those resulting from concomitant medications or drug interactions 
(Cereghino, 1992). In addition, most clinical trials have allowed a limited flexibility for 
dose adjustment or dosage escalation (Perucca, 1996). Other less common methods of 
assessing side effects include physical examination and laboratory tests.  Adverse effects 
have been shown to be the most common cause of AED withdrawal in many trials 
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(Fakhoury et al., 2004;Reunanen et al., 1996). Discontinuation of a certain drug due to 
intolerable adverse reactions is the most important measure in this regard, although the 
potential for precipitating idiosyncratic reactions should not be understated (Chadwick et 
al., 1998).  
 
Study type  Efficacy endpoint 
Short-term studies 
• Retention of patients in the trial over time.  
• Time to nth seizure. 
• Absolute and percent change in seizure frequency 
over time.  
• Proportion of patients achieving 50%, 75% and 100% 
reduction in seizure frequency. 
Long-term studies 
• Retention of patients in the trial over time. 
• Absolute and percent change in seizure frequency 
over time. 
• Proportion of patients maintaining 50%, 75% and 
100% reduction in seizure frequency over time. 
• Proportion of patients achieving 6, 12, 24 or 36 
months remission rates. 
Table 6. Commonly used efficacy endpoints in antiepileptic drug trials (Perucca, 1997). 
 
For the purposes of this project, efficacy of AED is measured based on the percentage of 
patients achieving seizure freedom for a minimum period of 12 months at last recorded 
follow up.  Several studies suggest that seizure freedom is the only outcome with a 
significant impact on quality of life.  On the other hand, discontinuation of a drug because 
of side effects is applied as a measure for the assessment of AED tolerability.  In terms of 
the outcome of epilepsy, this project will consider it as the final response on the maximum 
tolerated dose of the last AED/ AED combination prescribed to each patient in this study 
on the last follow up appointment.  
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1.1.7. Natural history of epilepsy 
Newly diagnosed patients with epilepsy can be broadly categorised in three groups of 
treatment outcome based clinical characteristics (Figure 1). These include:  
1. Excellent prognosis with or without treatment. This group of patients represent 
around 30%. These patients enter long term remission probably even without AED 
treatment. If treated, they will achieve seizure freedom usually on the first or 
second treatment regimen. Usually, moderate doses of AEDs are sufficient for 
remission, treatment can be successfully withdrawn after a period of seizure 
freedom (Shafer et al., 1988). Epilepsy syndromes that belong to this group 
include benign neonatal seizures, benign rolandic epilepsy and childhood absence 
epilepsy.  
2. Remission with treatment only. Around 30% of epilepsy patients will need to 
continue on AED treatment in order to remain in a state of complete seizure 
control. They may need multiple trials of AEDs/ combinations to find the right 
treatment for the individual patients. Withdrawal of treatment after a period of 
seizure freedom will usually be accompanied by higher chances of recurrence. The 
majority of localisation related epilepsy and juvenile myoclonic epilepsy are 
examples of this group (Kwan and Sander, 2004).  
3. Continuing seizures despite treatment. The remainder (around 40%) consists of 
patients who continue to have seizures with variable degrees of frequency and 
severity despite the application of multiple treatment regimens (monotherapy or 
combined therapy). These patients can be considered as having intractable seizures 
or refractory epilepsy. Conditions in this category include epilepsy with mesial 
temporal sclerosis, cortical dysplasia and gross structural brain lesions (Kwan and 
Brodie, 2006).  
Another categorisation of the natural history of epilepsy has been applied taking into 
consideration the outcome of epilepsy in relation to various epilepsy syndromes. This 
classification is composed of four groups (Sander, 2003). In contrast to the three groups 
proposed by Kwan and Sander (2004), Sander’s classification (2003) has one further 
group added to represent patients with excellent prognosis in whom seizures are self-
limiting and very benign and patients usually do not require AED treatment as 
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spontaneous remission is the rule. This classification has taken into account the natural 
history of both treated and untreated epilepsy although limited information is available 
about the natural history of untreated epilepsy (Sander, 1995;Sander, 1993).    
 
30%
30%
40%
Group 1
Group 2
Group 3
 
Figure 1. Natural history of epilepsy (Kwan and Sander, 2004).   
Group 1: Excellent prognosis with or without treatment, Group 2: Remission with treatment 
only, Group 3: continuing seizures despite treatment.  
 
1.2. Treatment of epilepsy 
Options used in the treatment of epilepsy are in fact very limited.  Furthermore, the use of 
some of these options is still a controversial issue.  Antiepileptic drugs (AEDs) are the 
mainstay of epilepsy management.  Around 60 - 70% of epileptic patients with seizures 
can be treated successfully with AED therapy (Kwan and Brodie, 2000a). 
1.2.1. History of AED development 
Seeking a treatment for epilepsy began as early as the discovery of the disease itself. 
Primitive procedures, materials and herbs have been employed since ancient times. In 
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1857, Sir Charles Lococock advocated the use of potassium bromide for the treatment of 
epilepsy citing a German report and making bromide the first drug to be used against this 
disease (Pearce, 2002).  But unfortunately, the side effects associated with bromide have 
limited its efficacy. 
The beginning of modern pharmacotherapy of epilepsy was in 1912 when the anti-
convulsant properties of phenobarbital were discovered accidentally by Hauptmann (1881-
1948) when studying the anxiolytic effects of various drugs used to sedate a ward of noisy 
psychiatric patients and those with epilepsy during the night (Pearce, 2002).  Therefore, 
phenobarbital is considered as the oldest among all the antiepileptic drugs available today 
(Hauptmann, 1912).  It was initially synthesised in 1904 by a German chemist Fischer and 
was known to possess sedative and hypnotic properties but it was only in 1912 that its 
anticonvulsant effects were discovered.   
In 1908, phenytoin (sodium diphenyl hydantoinate) was synthesised and in 1938, it was 
applied in clinical practice following the studies of Merritt and Putnam who showed 
favourable anticonvulsant efficacy of this agent against various seizure types without the 
sedative effect associated with phenobarbital (Merritt and Putnam, 1984).  
Carbamazepine was synthesised in 1953 by Schindler at the Geigy laboratories in 
Switzerland (Schmutz, 1985).  Initially in 1962, it was marketed to treat trigeminal 
neuralgia, and then in 1963, it was applied clinically to treat epilepsy in the United 
Kingdom (UK). 
Sodium valproate was first synthesised in 1882 by Burton and for many decades was used 
as a solvent for organic compounds in research laboratories (Burton, 1882).  Its 
anticonvulsant properties were discovered accidentally in 1963 by Pierre Eymard (Meunier 
et al., 1963).  
Almost a century of AED research, development and practice has followed and there are 
now more than 15 AEDs available for the treatment of seizure disorders.  AEDs introduced 
in the market during this period showed a variable extent of efficacy toward epilepsy 
syndromes and seizure types.  They also displayed variable degrees of tolerability.   
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1.2.2. Generations of AEDs   
AEDs can be classified on a chronological basis e.g. date of discovery or date of approval 
for clinical practice.  Also, as there are several mechanisms of action by which AEDs exert 
their anticonvulsion activity, other classifications may depend on the primary mechanism.  
When classifying AEDs based on their dates of approval for clinical practice, these dates 
will vary between different countries. Also, certain AEDs are not licensed in particular 
countries.  With reference to AED approval in the UK, phenobarbital was the first AED 
licensed officially for clinical practice in patients with epilepsy in 1912.  Approval of other 
AEDs continued in the following years until the present. The period between 1979 and 
1989 showed a hiatus in AED development resulting in a distinct separation of AEDs into 
two groups (generations); older or established (first generation) AEDs which represent 
AEDs introduced on or before 1979 and newer or modern (second generation) AEDs 
which were introduced on or after 1989.  Table 7 shows AEDs introduced in the market in 
a chronological order according to their dates of license in the UK.  Established agents 
comprise phenobarbital, phenytoin, primidone, ethosuximide, carbamazepine, clonazepam, 
clobazam and sodium valproate.  On the other hand, vigabatrin was the first modern AED 
and has been followed by lamotrigine, gabapentin, felbamate, topiramate, tiagabine, 
oxcarbazepine, levetiracetam, pregabalin and zonisamide.   
Many agents of the first and second generations are still being used to this day, while 
others are either not commonly prescribed or have been discontinued because of their 
serious side effects.  
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AED UK approval date 
Established (Older) AEDs 
Phenobarbital 1912 
Phenytoin 1938 
Primidone 1952 
Ethosuximide 1955 
Carbamazepine 1965 
Sodium valproate 1973 
Clonazepam 1974 
Clobazam 1979 
Modern (newer) AEDs 
Vigabatrin 1989 
Lamotrigine 1991 
Gabapentin 1993 
Topiramate 1995 
Tiagabine 1998 
Oxcarbazepine 2000 
Levetiracetam 2000 
Pregabalin 2004 
Zonisamide 2005 
Table 7. Dates of AED licences in the UK.   
 
 
Although several first generation AEDs are still used in clinical practice, these agents have 
some disadvantages that include a narrow therapeutic index, suboptimal response rates, 
non-linear pharmacokinetics, significant adverse effects and drug-drug interactions 
(Battino et al., 2000).  
On the other hand, AED therapy using first generation agents has the advantage of being 
applied clinically for almost a century (since 1912).  Such a long interval has enabled these 
agents to be studied extensively in terms of spectrum of efficacy against several seizure 
types, side effects, idiosyncratic reactions, drug-drug interactions, pharmacokinetic profiles 
Chapter 1. Introduction.   39 
and the underlying mechanisms of action.  This has led to the fact that consequences of 
treatment using these agents are known and predictable in many cases compared to second 
generation AEDs that have only been approved for clinical practice in the last two decades.  
Some characteristics of these agents are still under investigation e.g. mechanism of action, 
risk of teratogenicity and effects on bone health (LaRoche, 2007).  
Most of the newer AEDs have multiple mechanisms of action compared to the established 
agents that usually have a single predominant mechanism of action, this has enabled the 
second generation drugs to be applied against several seizure types (Table 9).  In terms of 
tolerability, the newer AEDs tend to have fewer side effects and fewer drug-drug 
interactions compared with the established drugs (Brodie et al., 1995;Dam et al., 
1989;Meador et al., 1999;Perucca, 2001a).  In addition, hepatic enzyme induction is a 
common characteristic of first generation agents e.g. carbamazepine, phenobarbital and 
phenytoin (Radtke, 2001;Radulovic et al., 1994), while it was found that most second 
generation agents lack this effect.  The broader spectrum of anticonvulsant activity of 
second generation AEDs (lamotrigine, topiramate and zonisamide) in comparison to the 
first generation agents (sodium valproate) is a crucial issue as well (Beran et al., 
1998;Biton et al., 1999;Kyllerman and Ben Menachem, 1998). 
As a result of these issues, modern AEDs have been widely accepted by clinicians and 
prescribed to patients.  It was found that 20% of the total prescriptions in 2002 were for 
newer AEDs and that these newer agents accounted for 69% of the total AED expenditure 
in the UK (£99m of £142m) (NICE, 2004).  Modern AEDs are significantly more 
expensive than their established counterparts and it remains to be seen whether the 
expected novel characteristics of the newer AEDs justify their increase in costs (Chadwick, 
1998;Perucca, 2002). 
With the introduction of second generation AEDs, the number of AEDs available for 
treatment of epilepsy has almost trebled (Perucca, 2001a).  But, although the availability of 
newer AEDs has widened the options for physicians to treat epilepsy, it has become more 
complicated to choose the most suitable agent to treat certain seizure types or specific 
epilepsy syndromes. However, despite the availability of wide range of AEDs these days, 
further newer agents are needed preferably working by unique modes of action (Brodie, 
2001). It is hoped that these future agents (1) are safe, (2) can prevent epilepsy and its 
progression, (3) can reverse and treat pharmacoresistant epilepsy, and (4) can prevent 
epilepsy in patients at risk (Schmidt, 2002). These advances need to be coupled with better 
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understanding of the pathophysiology of seizures and the biological basis of 
pharmacoresistance in order to improve the outcome of epilepsy.   
Since the beginning of development of second generation AEDs, their comparison with the 
first generation drugs has become an essential clinical issue. Such comparisons can include 
several factors such as efficacy, tolerability, mechanism of action, cost and ease of use. 
Some of these factors favour older agents while others are on the side of newer drugs. 
Clinicians usually make the decision to select the most appropriate AED of either first or 
second generation according to each patient situation. e.g. phenytoin is the most commonly 
prescribed medication against seizure in the United States (LaRoche, 2007). Therefore, 
after two decades of application of second generation AEDs, it is appropriate to examine 
the clinical impact of these agents on seizure control, tolerability and the overall outcome 
of epilepsy in comparison to first generation agents.  
1.2.3. Animal seizure models 
During the process of developing second generation AEDs, two tests are commonly 
applied to evaluate the anticonvulsant activity of this new agent, the Maximal Electroshock 
(MES) test and the subcutaneous pentylenetetrazol (scPTZ) test. The MES test is a model 
of seizure spread; capable of identifying drugs with activity against partial and generalised 
tonic clonic seizures e.g. MES test gives positive results when applied on carbamazepine 
that is effective against tonic and/or clonic seizures (Table 8).  In contrast, the scPTZ test is 
a model of seizure threshold that can predict agents effective against generalised absence 
and myoclonic seizures e.g. scPTZ is positive with ethosuximide that is used against 
absence seizures (Table 8) (Rho and Sankar, 1999).  To identify activity against complex 
partial seizures, the kindling model in rodents that have many behavioural similarities with 
complete partial seizures in humans may be the model of choice e.g. phenytoin that is 
effective against partial seizures is positive in the electrical kindling test (Table 8).  In the 
kindling process, the rat amygdale is subjected to a repeated sub-convulsive electrical 
stimulus that induces electrographic seizures or after discharges and with each further 
stimulus the seizure peak grows longer spreading to wide areas of the brain until complete 
(full blown) seizures are elicited (Racine, 1972). 
The only exception is phenobarbital that is active against scPTZ in rodents but ineffective 
against absence seizures in humans.  If the AED has multiple mechanisms of action such as 
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sodium valproate, it will be more likely to have a wide range of anticonvulsant applications 
and display activity in several anticonvulsant models (White et al., 1995).  
 
Generalised seizures 
Experimental model Tonic 
and/or 
clonic 
Absence 
Partial 
seizures AEDs 
MES (tonic extension) +   CBZ, PHT, VPA, PB 
ScPTZ  
(clonic seizures)  +  
VPA, ESM, PB, 
BZD 
Electrical kindling  
(focal seizures)   + 
CBZ, PHT, 
VPA, PB, BZD 
Table 8. Correlation between experimental animal models and clinical applications of 
established AEDs.  
 
 
1.2.4. Mechanisms of anticonvulsion activity 
With regard to the mechanisms of action of AEDs, multiple mechanisms have been 
identified to play a role in the anticonvulsion activity exerted by these drugs.  The four 
main mechanisms by which most of the established as well as the modern AEDs act are: 
blockade of voltage gated sodium channels, blockade of voltage gated calcium channels, 
potentiation of GABA (gamma aminobutyric acid) inhibitory effect and inhibition of the 
glutamate excitatory mechanism (Kwan et al., 2001;Rogawski and Loscher, 2004).  Other 
mechanisms include: potentiation of potassium channels and inhibition of carbonic 
anhydrase. 
1.2.4.1. Blockade of voltage gated sodium channels 
Sodium channels control the passage of sodium ions across the cell membrane, an essential 
step in the action potential.  They play a central role in the generation and transmission of 
action potentials in the excitable membranes of heart, muscle and nerve, leading to 
muscular contraction and neuronal discharge.  
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The major component of sodium channels is the single large α subunit. It has two main 
functions; it represents the channel gate for regulating sodium passage and acts as the ion 
conducting pore.  Other components of sodium channels are one or two smaller β subunits 
that do not participate in the functional role of these channels (Catterall, 1992).  Sodium 
channels are voltage gated channels i.e. certain changes in the membrane potentials will 
trigger these channels to open or close.  
These channels are closed at resting membrane potential; once depolarization of the neuron 
takes place (after reaching the action potential threshold) a conformational change in these 
channels occurs converting them from the inactivated closed (resting) non-conducting state 
to the activated, opened conducting state.  This permits sodium ion influx across the 
channel pore, followed by a return to the inactivated state when all these channels will be 
closed.  Eventually repolarisation brings these channels to the resting membrane state 
making them ready for a new depolarisation action. These three stages only last for a few 
milliseconds.  It is necessary for neurons to have states of such very short duration in order 
to fire high frequency trains of action potentials, a requirement of a normally functioning 
brain and for convulsion development as well (Rogawski and Loscher, 2004).  
As these channels control the action potentials by controlling passage of sodium ions 
across the neuronal membranes, blockage of these channels by certain AEDs will lead to 
blocking of action potentials and consequently, prevention of neuronal high frequency 
repetitive spike firing that takes place during the spread of seizure activity without 
interfering with normal neuronal activity.  Therefore, seizure control will be achieved.  
AEDs acting by blocking of sodium channels are found to share some characteristics.  
These agents are effective against partial and generalised tonic-clonic seizures in humans 
and inhibit sustained repetitive firing of action potentials.  Inhibition of sodium channels 
by these agents tends to be voltage and activity dependent that might be responsible for 
their clinical efficacy (Ragsdale and Avoli, 1998).  Further evidence for the role of sodium 
channels in epilepsy, is shown by a number of epilepsy syndromes that have been linked to 
genetic defects in genes encoding certain subunits of sodium channels such as generalised 
epilepsy with febrile seizures plus and benign familial neonatal infantile seizures (Baulac 
et al., 2001;Berkovic et al., 2004). 
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1.2.4.2. Blockade of voltage gated calcium channels 
Voltage Dependant Calcium Channels (VDCCs) play an essential role in translating 
electrical signals into biochemical events that eventually lead to cell excitability, hormone 
and transmitter release, muscle contraction and gene expression.  They play this role by 
controlling the action potential through regulating the passage of calcium ions across the 
excitable membranes (Van Petegem et al., 2004). 
VDCCs can be classified into two major subtypes: High Voltage Activated calcium 
channels (HVA) that include P/Q, N, L and R-VDCCs and Low Voltage Activated calcium 
channels (LVA) that are T-VDCCs.  This classification is based on the biophysical and 
pharmacological properties of these channels. 
HVA channels are responsible for calcium flux across the cell membrane and 
neurotransmitter release from the presynaptic nerve terminals that make them important 
targets for AEDs.  This type of channel (as their name indicates) requires a strong 
membrane depolarisation for opening the gates.  On the other hand, by participating in 
bursts and intrinsic oscillations, LVA channels can control neuronal firing. 
Structurally, VDCCs are composed of three subunits, α1 that is the ion channel pore with 
gating properties, α2/δ and β subunits which are responsible for cell surface expression and 
channel kinetics.  They are found in a 1:1:1 stoichiometry. α1 subunits are encoded by 10 
genes, 3 genes encode α2/δ subunits while 4 genes encode β subunits.  It is highly 
significant that these subunits have diverse genetic compositions, since it is the nature of 
these gene products that determines the biophysical and pharmacological properties of 
VDCCs (Catterall, 2000).  Distribution of VDCCs varies in discrete brain regions and even 
within the individual neurons (Elliott et al., 1995).  In addition, a new subunit of VDCCs 
has been found in the brain with γ2, γ3 and γ4 subunits (Letts et al., 1998). 
VDCCs have been linked to epilepsy since it was documented more than twenty years ago 
that an elevation of calcium ion influx with a subsequent reduction in extracellular free 
calcium ions stimulates seizure activity in the brain.  Such evidence has been provided (in 
part) by studies employing the kindling animal seizure model.  Therefore, blocking these 
channels represents a target for several antiepileptic drugs. 
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1.2.4.3. Potentiation of GABA 
GABA (gamma-aminobutyric acid) is the major inhibitory neurotransmitter in the brain.  It 
is formed from glutamic acid with the aid of Glutamic Acid Decarboxylase (GAD) and 
metabolised to succinic semialdehyde by the action of GABA transaminase (GABA–T).  
GABA acts as an inhibitory neurotransmitter, so once it binds to its own receptor, it 
inhibits the signals transmission across the neuronal membrane limiting the spread of 
action potentials across the brain and controlling seizure propagation.  After GABA is 
released from the presynaptic terminal into the synapse, using a specific sodium/chloride 
voltage dependent reuptake system, around 80% of the released GABA is taken back into 
the presynaptic terminal.  The remaining proportion is metabolised to succinic 
semialdehyde by GABA–T (Treiman, 2001). 
Potentiation of GABA inhibitory effect constitutes the mechanism by which several 
antiepileptic drugs work as they cause an increase in GABA concentration in the brain 
limiting the spread of convulsant activity across the neuronal network and controlling 
seizure development.  
There are three types of GABA receptors: GABA-A, GABA-B and GABA-C receptors.  
GABA-A and GABA-C receptors are ligand gated ion channels while GABA-B receptors 
are G protein coupled receptors.  
GABA-A receptors constitute the target at which multiple antiepileptic drugs act; they are 
mainly located on the postsynaptic terminals (Fritschy et al., 1999).  The GABA-A 
receptor is composed of five subunits that together form the pore; once GABA-A receptors 
on the postsynaptic neuron have been occupied, chloride ions enter through these pores.  
Consequently, hyperpolarisation of these neurons takes place with a decrease in the rate of 
neuronal firing.  The greater the frequency of chloride channel opening, the greater is the  
reduction in the rate of neuronal firing (Sieghart et al., 1999).  Bromide, the first historical 
AED increases the sensitivity of GABA-A receptors to GABA, resulting in an increase in 
GABA-A receptor mediated inhibition (Akaike et al., 1989). 
GABA-B receptors are found on pre and postsynaptic GABAergic terminals.  Those 
located on the presynaptic terminals (autoreceptors) regulate the release of GABA; once 
they have been stimulated they cause a decrease in the release of GABA (either through 
opening of potassium channels or inhibition of calcium influx or both). Therefore, 
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antagonising these receptors can represent a target for anticonvulsant activity (Figure 2) 
(Bonanno and Raiteri, 1993). 
 
 
 
Figure 2. GABAergic synapse (Suzdak and Jansen, 1995).  
 
 
 
1.2.4.4. Inhibition of glutamate excitatory mechanism 
Glutamate gated cation channels are responsible for the bulk of fast excitatory 
neurotransmission in the central nervous system.  Their subtypes include NMDA (N-
methyl-D-aspartate) and AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic 
acid) receptors, the blockage of which can lead to seizure control.  Another subtype of 
glutamate receptors comprises kainite receptors.  Kainate receptors (GluR5) play a role in 
postsynaptic excitation, control of presynaptic glutamate release from excitatory afferents 
and suppression of GABA release (Rogawski et al., 2003) that also makes them a potential 
target for AEDs. 
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A relationship has been established between NMDA receptors and seizures development. 
The NMDA receptor operated complex is composed of an ion channel responsible for 
influx of calcium and sodium ions and efflux of potassium ions. Various binding sites have 
been identified on this complex, where antagonism could show anti-convulsant activity 
(Davies, 1995).  Some AEDs have been found to be capable of reducing NMDA evoked 
depolarisations e.g. carbamazepine (at certain concentrations) and felbamate.  NMDA 
receptors have multiple recognition sites for glutamate, glycine, polyamine, ions and use 
dependant channel blockers.  Occupation of glycine and glutamate sites by an agonist is an 
essential requirement for NMDA channel opening and neuronal depolarisation (Monaghan 
et al., 1989). 
Although AMPA receptors are considered to have a potential role in seizure control, no 
currently marketed AEDs have a major effect at these receptors. 
1.2.4.5. Potentiation of potassium channels 
Potassium (K+) channels possess a regulatory role in the development of seizure activity 
for three reasons. Blockade of potassium channels is accompanied by the development of 
epileptic activity (Pena and Alavez-Perez, 2006;Wickenden et al., 2000).  Also, benign 
familial neonatal convulsions (BFNC) a genetic disorder, is a generalised epilepsy 
syndrome that was found to be associated with a defect in the genes encoding voltage 
dependant potassium channels (Singh et al., 1998).  Finally, potassium channels blockers 
provoke the development of animal seizure models (Bagetta et al., 1992).   
K+ channels are composed of four alpha subunits; auxillary beta subunits are present in 
some potassium channels.  S4 is considered to be the voltage sensor segment while S5 and 
S6 constitute the channel pore.  There are different types of voltage gated potassium 
channels, these include: A-type channels which rapidly activate and deactivate, delayed 
rectifier channels that open on depolarisation and inward rectifying channels that are 
blocked on depolarisation under the effect of internal ions. Several types of inward 
rectifying channels exist, such as ATP sensitive channels.   
The M-type is a specific form of potassium channel; these channels are slowly activated by 
depolarisation while muscarinic stimulation causes their inhibition. The M-current plays a 
role in controlling neuronal excitability and firing properties.  In the case of neuronal 
depolarisation evoked by excitatory stimuli, activation of M type K+ current takes place 
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leading to repolarisation of the neuronal membrane with subsequent firing suppression 
limiting seizure propagation.  Therefore, suppression of M-current is considered a 
mechanism that can lead to convulsions. 
It has been found that the M-current in the neurons is subserved by KCNQ2 and KCNQ3 
potassium channel subunits (Wang et al., 1998) and consequently, dysfunction of these 
subunits results in epileptic disorders. 
1.2.4.6. Inhibition of carbonic anhydrase 
Carbonic anhydrase catalyses the chemical reaction of CO2 and H2O to form carbonic acid.  
Brain carbonic anhydrase regulates (with the aid of Na/K ATPase anion exchanger) the 
exchange of extracellular chloride ions for intracellular bicarbonate ions (HCO3-) 
(Woodbury et al., 1984).  Carbonic anhydrase II represents 97% of brain carbonic 
anhydrase activity that makes it the major brain isozyme.  The anticonvulsant effect of 
carbonic anhydrase inhibition is confirmed as acetazolamide is an AED that is a carbonic 
acid inhibitor. 
Inhibition or deficiency of carbonic anhydrase will lead to an accumulation of carbon 
dioxide (CO2) in the brain with a subsequent anticonvulsant effect. Deficiency of carbonic 
anhydrase II is accompanied by reduced susceptibility (more resistant) to flurothyl and 
scPTZ induced seizures (Velisek et al., 1993).  CO2 accumulation leads to a drop in pH 
level that acts to antagonise NMDA receptors.  Severe systemic acidosis in mice with 
carbonic anhydrase II deficiency leads to a decrease in NMDA receptor function and 
consequently anticonvulsant activity (Velisek and Veliskova, 1994).  
1.2.5. Mechanisms of action of commonly prescribed AEDs  
1.2.5.1. Phenobarbital 
In 1912, phenobarbital was licensed in the UK making it the oldest AED available today.  
Phenobarbital belongs to the barbiturates group that includes: phenobarbital, 
mephobarbital, metharbital and primidone.  Despite its side effects that include cognitive 
(behavioural) changes, it is still used in clinical practice especially in the developing world 
as it is inexpensive and easy to use (Brodie and Kwan, 2004). Beside its application as an 
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anticonvulsive drug, phenobarbital can also be used as an anaesthetic and sedative-
hypnotic agent. 
Phenobarbital’s mechanism of anticonvulsant activity is through augmenting the inhibitory 
effect of GABA (Macdonald and Barker, 1979); it binds to a specific binding site of 
chloride channels in GABA-A receptors present on postsynaptic terminals.  This binding 
increases the mean opening time of chloride channels without interfering with the 
frequency of opening (Twyman et al., 1989).  The net result is increased stimulation of the 
inhibitory effect of the GABA system leading to a decrease in the rate of neuronal firing 
with subsequent control of seizures. 
Other less important mechanisms include a slight inhibitory effect on high voltage 
activated calcium channels (Ffrenchmullen et al., 1993).  At high concentrations, 
phenobarbital is also capable of inhibiting high frequency repetitive firing of action 
potentials, compatible with actions on voltage gated sodium channels (Mclean and 
Macdonald, 1988). 
1.2.5.2. Phenytoin 
Phenytoin is the longest established AED that is capable of inhibiting abnormal brain 
activity characteristic of seizures with a non-sedative effect (without affecting normal brain 
activity).  As a result of this unique property, phenytoin has been extensively studied since 
its availability in 1938 in the UK.  
In terms of its mechanism of action, phenytoin’s inhibition of sodium channels is strongly 
related to the voltage of membrane potentials.  
This was confirmed when phenytoin was found to be a weak blocker of hyperpolarised 
sodium channels (more negative than – 80 mV) with gradual elevation in blocking 
capability occurring at progressively more depolarised potentials (from –80mV to –30mV).  
Another important characteristic of phenytoin is its inhibition of high frequency repetitive 
firing of action potentials rather than slow or individual firing (without affecting 
spontaneous neuronal activity) (Matsuki et al., 1984).  Also, inhibition by phenytoin is 
time dependant, as the time required to recover from depolarisations is prolonged 
(Macdonald, 1989).  In addition to a delayed recovery from suppression of sodium 
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channels, blockade by phenytoin is also slow in onset, stable and tight (Kuo and Bean, 
1994). 
These properties of phenytoin explain the reason of its selective control of seizures without 
producing sedation.  Phenytoin is a weak blocker of sodium channels in the resting state 
(during normal brain activity) while seizures (abnormal brain activity) are characterised by 
high frequency trains of depolarisations, on a background of prolonged depolarisation 
episodes, a condition which favours phenytoin’s mechanism of blocking sodium channels 
(Remy et al., 2003). Phenytoin’s block of sodium channels is also use dependent, so that 
blockade accumulates with prolonged or repetitive activation.  This is because phenytoin 
binds preferentially to the sodium channels in an inactivated state (Rogawski and Loscher, 
2004). 
A mutation of the gene encoding the β1 subunit of sodium channels linked to an inherited 
epilepsy syndrome results in reduction in both sensitivity of these mutant channels toward 
the inhibitory effects exerted by phenytoin and frequency dependant inhibition by 
phenytoin. These effects are due to changes in the gating properties of these mutant 
channels (Lucas et al., 2005). 
It has been proposed that phenytoin, carbamazepine and lamotrigine bind to a common 
binding site on sodium channels that does not exist in the resting state as the affinity of 
these drugs for binding is much higher in the inactivated state than the resting state (Kuo, 
1998). 
Also, Granger and colleagues showed that phenytoin enhances the effect of GABA  at the 
α1β2γ2 subtype of GABA-A receptors (Granger et al., 1995).  
On seizure development, there is elevation of potassium concentration extracellularly 
leading to depolarisation. This is accompanied by a decrease in extracellular calcium 
concentration due to calcium influx through the opened voltage operated calcium channels 
into the neuron.  Increased calcium concentration intracellularly enhances excitatory 
neurotransmission.  Phenytoin’s ability to block calcium entry results in limiting 
neurotransmission excitation and subsequently, seizure control (Pincus and Lee, 1973).  
Voltage and use-dependant inhibition of potassium channels by phenytoin has also been 
reported (Nobile and Vercellino, 1997). 
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1.2.5.3. Ethosuximide  
Although ethosuximide was introduced in the UK in 1955, its mechanism was not 
documented until 1989.  This process was elucidated as inhibition of voltage dependent T-
type (low threshold) calcium channels at therapeutic levels in the thalamic neurons.  
Initially, this mechanism of action was identified theoretically based on the observation 
that methyl-phenylsuccinimide (an active metabolite of a related compound) also blocks T-
type calcium channels and no inhibition was observed when using the inactive analogue 
succinimide (Coulter et al., 1990).  Although several studies using therapeutically relevant 
concentrations showed a contradictory view of ethosuximide mechanism regarding 
blockage of T-VDCCs, Gomora et al. were able to show that ethosuximide and methyl-
phenyl suximide (the active metabolite of a related compound methsuximide) were capable 
of blocking T-VDCC currents with a higher affinity for inactivated channels (Gomora et 
al., 2001).  Furthermore, analogues of ethosuximide without anticonvulsive property were 
found to be poor blockers of calcium channels.  The blockage was found to be  voltage 
dependent at therapeutic concentrations (Coulter et al., 1989).  
Absence seizures are characterised by the presence of 3Hz spike wave rhythms. As T-type 
calcium currents in thalamocortical neurons have an activity of low frequency (around 
3Hz), it is believed that this is the reason why absence seizures can be affected by 
ethosuximide (Davies, 1995). 
In addition, ethosuximide may lead to a slight reduction in persistent sodium currents, that 
are slowly inactivating and with relatively small depolarising potential (Niespodziany et 
al., 2004).  
1.2.5.4. Carbamazepine  
Carbamazepine was licensed in the UK in 1965.  It is an iminostilbene derivative of 
tricyclic anti-depressants and among antiepileptic drugs, it is one of the most widely 
prescribed agents.  Since carbamazepine and phenytoin have similar characteristics in their 
structures and mechanisms of action regarding blocking of voltage gated sodium channels 
with some differences, the spectrum of activity of these two agents is also very similar 
(Rogawski and Porter, 1990).  
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At therapeutic concentrations, carbamazepine or its metabolite 10,11-epoxycarbamazepine 
inhibit the high frequency firings of action potentials (repetitive action potentials) rather 
than low or individual polarisations.  It inhibits sodium currents in a voltage and use 
(frequency) dependant manner (Kuo et al., 1997) and sodium channel inhibition by 
carbamazepine might also be considered time dependant as it can shift the current voltage 
dependence toward hyperpolarisation direction delaying the recovery of sodium channels 
from inactivation (Reckziegel et al., 1999). Carbamazepine tends to bind to sodium 
channels in the inactivated state that results in blockade accumulation with prolonged or 
repetitive activation (Rogawski and Loscher, 2004).    
Although carbamazepine and phenytoin have a similar mechanism of action, the patients’ 
response to these two agents is not same.  There might be some molecular basis for the 
observation that some patients respond better to phenytoin while others find 
carbamazepine more effective in treating their seizures. Carbamazepine has a 3-fold lower 
affinity for depolarised sodium channels with a five times faster binding rate compared 
with phenytoin (Kuo et al., 1997).   
Therefore, it would be more appropriate to use carbamazepine rather than phenytoin in 
treating patients with seizures of relatively short rather than prolonged depolarisations 
shifts. 
Carbamazepine can at certain concentrations reduce NMDA (NMDA subtype of the 
glutamate receptor) evoked depolarisations while at higher concentrations, the effect is to 
potentiate depolarisations (Lancaster and Davies, 1992) and reduce presynaptic glutamate 
release. Carbamazepine is also able to potentiate GABA inhibitory effect at α1β2γ2 
subtype of GABA-A receptors (Granger et al., 1995).  
Carbamazepine has the capability to enhance the activity of glutamate transporters. 
Glutamate transporters help in the regulation of glutamate neurotransmission and GABA 
mediated inhibitory neurotransmission.  Dysfunction of these transporters is associated 
with seizure development in rats.  Carbamazepine potentiates the activity of glutamate 
transporter type 3 (the major glutamate transporter) (Lee et al., 2005).  
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1.2.5.5. Sodium Valproate  
Valproic acid (a branched fatty acid) was one of the first drugs to be used in the treatment 
of epilepsy.  It has been in clinical practice since 1962 and it has been licensed in the UK 
since 1973. 
Sodium valproate (the sodium salt of valproic acid) has multiple mechanisms of action that 
can explain its wide range of clinical applications in epilepsy.  It enhances GABA 
inhibitory effect by increasing the turnover of the GABA transporter (Whitlow et al., 2003) 
and elevating the synthesis of GABA through the stimulation of glutamic acid 
decarboxylase.  Cunningham and colleagues identified a potentiating role of sodium 
valproate on postsynaptic GABA-A receptors (Cunningham et al., 2003).  Sodium 
valproate can reduce the excitatory synaptic activity as increases in the frequency and 
amplitude of spontaneous excitatory postsynaptic currents are reduced resulting in 
suppression of epileptiform activity (Martin and Pozo, 2004).  
Sodium valproate is also able to suppress persistent sodium currents (Taverna et al., 1998).  
Inhibition of NMDA evoked depolarisations by sodium valproate has been observed (Zeise 
et al., 1991) and at high concentrations, sodium valproate is able to reduce T-type calcium 
currents.  Potassium conductance can also be activated by sodium valproate leading to 
potassium efflux and hyperpolarisation (Franceschetti et al., 1986).  
1.2.5.6. Benzodiazepines 
This group of drugs has four major pharmacological effects: sedative-hypnotic, muscle 
relaxant, anxiolytic and anticonvulsant properties.  The benzodiazepine group includes 
about 50 agents, only four of which can be used as AEDs: diazepam, lorazepam, 
clonazepam and clobazam.  Structurally, all benzodiazepines are 1,4-benzodiazepines with 
the exception of clobazam that is 1,5-benzodiazepine (the numbers represent nitrogen atom 
locations on the diazepine ring) (Nakajima, 2001).  The chemical structure of clobazam 
was designed to be different from other benzodiazepines in order to exert different 
pharmacological properties. The most widely prescribed benzodiazepines agents used as 
AEDs are clonazepam and clobazam.  Clonazepam was introduced in the UK in 1974 
while clobazam was licensed in the UK in 1979 initially as an anxiolytic agent.  
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Clobazam’s mechanism of action is by augmenting GABA-A receptors inhibitory effect on 
neurotransmission, thereby increasing the frequency of chloride channel opening that 
eventually results in a decrease in neuronal firing (Nakamura et al., 1996). 
Clobazam (1,5-benzodiazepine) has an anticonvulsant action different from other 
benzodiazepines (1,4-benzodiazepines) as it inhibits the appearance of generalised tonic 
clonic seizures on which clonazepam (1,4-benzodiazepine) has no effect. This might be 
explained by the difference in chemical structure (Miura et al., 2002). 
Benzodiazepines at high concentrations (in status epilepticus) can inhibit voltage gated 
sodium channels (Mclean and Macdonald, 1988) and to a lesser extent calcium channels 
(Skerritt et al., 1984). 
1.2.5.7. Vigabatrin  
Vigabatrin (gamma-vinyl GABA) is a structural analogue of GABA.  Vigabatrin is present 
in two forms: an S (+) enantiomer that is the active form and an R (-) enantiomer that is 
inactive (Haegele and Schechter, 1986).  Vigabatrin was the first of the modern AEDs to 
be licensed in the UK in 1989.  
Vigabatrin increases the concentration of GABA at the synapse and postsynaptic GABA 
receptors.  It achieves this through the irreversible inhibition of GABA transaminase 
(GABA-T), which converts GABA into succinic semialdehyde, the rate-limiting enzyme 
responsible for the metabolism of GABA (Jung et al., 1977).  This results in an increase in 
synaptic and terminal GABA levels in the brain.  In cortical astrocytes, vigabatrin is also 
able to reduce GABA uptake (Sills et al., 1999).  These effects will eventually lead to those 
neurons involved in seizure activity being inhibited.  
1.2.5.8. Lamotrigine  
Initially, there was a mistaken belief that inhibition of folic acid had anticonvulsant 
activity.  Therefore, lamotrigine was designed to act as a folic acid inhibitor.  In the UK, it 
was approved for clinical practice in 1991.  
In the beginning, the similarity in the range of anticonvulsant activity of lamotrigine to that 
of phenytoin and carbamazepine raised the suggestion of the possible role of sodium 
channel inhibition in the mechanism of action of this agent.  It is now documented that 
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lamotrigine has a complex mechanism of action including blockade of sodium channels.  
Lamotrigine causes a reduction in the excitation of sodium channels in a voltage and use 
(frequency) dependant manner (Zona and Avoli, 1997).  Lamotrigine binding to sodium 
channels tends to be slow in onset, tight and slow in recovery from blockade (unbinding) 
(Kuo and Lu, 1997). 
Another mechanism by which this drug exerts its anticonvulsant activity is through the 
enhancement of potassium mediated hyperpolarising conductance in the neurons leading to 
inhibition of epileptiform discharges (Zona et al., 2002). Lamotrigine results in the 
reduction in both peak amplitude and time to peak A-type potassium currents in the 
hippocampal neurons (Huang et al., 2004).   
Also, lamotrigine inhibits glutamate release and presynaptic calcium influx (Wang et al., 
2001).  The effect on calcium channels is restricted to high voltage activated types (Stefani 
et al., 1996). Both lamotrigine and levetiracetam act as antagonists of calcium channels 
preventing the elevation of intracellular calcium concentration, a process that results in an 
epileptiform activity (Pisani et al., 2004).  
1.2.5.9. Gabapentin 
Gabapentin (1-aminoethyl cyclohexane acetic acid) was synthesised to act as a GABA 
mimetic agent facilitating GABA inhibition but its mechanism of action appeared to be 
different from what was expected.  It received approval for use in the UK in 1993. 
Gabapentin’s mechanism of action has long been a mystery and represents one of the most 
intriguing stories to emerge in the understanding of VDCCs.  
Various studies initially showed that gabapentin does not act on GABA-A or GABA-B 
receptors and does not elevate GABA levels in nerve terminals (White, 1997).  Also it does 
not act on glutamate, glycine or NMDA receptors.  Additionally, its mechanism of action 
does not affect sodium channels.  
Eventually, it was shown that gabapentin exerts its anticonvulsant activity through 
inhibition of HVA calcium currents in a concentration dependent manner with L-type 
calcium channels as the predominant type involved (Stefani et al., 1998).  Gabapentin 
binds (in high affinity) and blocks the α2δ subunit of VDCCs (Gee et al., 1996), making 
gabapentin the first ligand for this auxiliary subunit.  This binding is subtype specific with 
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a higher affinity to α2δ-1 than α2δ-2 subunits.  The third type of subunits (α2δ-3) does not 
bind to gabapentin (Marais et al., 2001).  
Some studies have suggested that inhibition of VDCCs by gabapentin might be indirectly 
due to activation of GABA-B receptors (Mintz and Bean, 1993).  Although Ng and 
colleagues (2001) showed that gabapentin is an agonist at GABA-B gb1a-gb2 heterodimer 
coupled to inwardly rectifying potassium conductance (Ng et al., 2001), several studies 
have disputed this theory. There is still a possibility that gabapentin is involved in the 
activation of GABA-B receptors (Bonhaus et al., 2002) with a more predominant effect on 
presynaptic GABA-B heterorecptors (Parker et al., 2004).  Also, gabapentin has been 
shown to be capable of increasing GABA level in human brain tissues resected during 
epilepsy surgery while this effect was not observed in normal brain tissues (Errante et al., 
2002).  
Gabapentin can also inhibit presynaptic glutamic excitatory neurotransmission with a 
postsynaptic enhancement of NMDA receptor transmission (Shimoyama et al., 2000). In 
addition, it has the capability to enhance NMDA currents selectively in GABAergic 
neurons of the spinal dorsal horn (Gu and Huang, 2002). 
1.2.5.10. Topiramate 
Topiramate (a sulfamate substituted monosaccharide) is considered to be an AED with a 
wide range of anticonvulsant activity.  It was licensed in the UK since 1995. 
Topiramate has multiple mechanisms of action.  It can inhibit L-type calcium channels of 
the high voltage activated currents controlling neuronal depolarisation with subsequent 
anticonvulsant activity (Zhang et al., 2000).  
Also, topiramate enhances GABA mediated chloride flux by increasing the opening and 
burst frequency of GABA-A receptor channels (Browm et al., 1993;White et al., 1997).  
Beside its action on GABA-A receptors, Kim and colleagues have suggested that 
topiramate can selectively inhibit pre/postsynaptic GABA-B receptors in the interneurons, 
an action that eventually results in elevation of GABA release (Kim et al., 2005). 
Voltage gated sodium channels can also be blocked by topiramate through the inhibition of   
sustained repetitive firing in neurons (Taverna et al., 1999).  In addition, it can also 
positively modulate potassium channels (Herrero et al., 2002).  
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At glutamate receptors, topiramate is capable of blocking kainate–induced excitatory 
conductance reducing neuronal excitability (Gibbs et al., 2000); this blockade is specific to 
kainite receptors containing GluR5 subunits.  Topiramate can also block AMPA receptors 
but to a lesser extent (Gryder and Rogawski, 2003).  It has the capability to reduce the 
levels of glutamate and aspartate release (Kanda et al., 1996) and to inhibit carbonic 
anhydrase isozymes II and IV more potently than other isozymes (Dodgson et al., 2000).  
Reduction of glutamate levels by topiramate has anticonvulsive consequences as AMPA 
receptors activation by glutamate will result in an inhibitory effect on inwardly rectifying 
potassium channels with a subsequent potentiation on neuronal excitability (Schroder et 
al., 2002).  
1.2.5.11. Tiagabine 
Tiagabine is an antiepileptic drug that has a clearly defined mechanism of action.  It is a 
derivative of nipecotic acid and was licensed in the UK in 1998.  
Tiagabine acts as a selective inhibitor of the reuptake of GABA at the synapse by 
irreversible binding to the transporter isoform-1 (carrier protein) i.e. GAT-1 responsible for 
GABA reuptake into the presynaptic terminal (Braestrup et al., 1990). As a result the 
concentration of GABA increases at the postsynaptic GABA receptor complex exhibiting 
its inhibitory effect on seizure development. 
1.2.5.12. Levetiracetam 
Levetiracetam [(S)-[alpha]-ethyl-2-oxo-1-pyrrolidine acetamide] was approved in the UK 
in 2000.  Chemically, it is not related to any other antiepileptic drugs but structurally, it is 
similar to piracetam which is a nootropic drug used against myoclonus and to enhance the 
memory.  
Levetiracetam is considered to be exceptional among other AEDs because of unique 
properties. For instance, it is inactive against acute seizure models usually used to test the 
antiepileptic activity of AEDs i.e. MES and scPTZ tests (Klitgaard et al., 1998), it can 
counteract the development of amygdala electrical kindling even after termination of drug 
dosing (Loscher et al., 1998) and in rats, it has the capability to inhibit neuronal 
hypersynchronisation when epileptiform activity is evoked (Niespodziany et al., 2003).  
Also its main mechanism of action does not include any of the usual known targets of 
AEDs (LaRoche and Helmers, 2004).   
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Although its exact mechanism of action was not yet been identified, it is believed that 
levetiracetam has a unique stereo-selective binding site in the brain. This binding site may 
be involved in an interaction with the GABA system in the brain since levetiracetam 
causes a significant increase in GABA aminotransferase activity and a marked decrease in 
glutamic acid decarboxylase GAD activity (Loscher et al., 1996).  Further attempts were 
made to characterise this binding site and eventually it was classified as an integral 
membrane protein enriched in the synaptic vesicles and called synaptic vesicle protein 2A 
(SV2A). Levetiracetam derivatives are unable to bind to neurons lacking SV2A on their 
membranes which indicate the essential role of these binding sites in binding to 
levetiracetam.  Other isoforms (SV2B and SV2C) do not seem to exhibit any binding to 
levetiracetam (Lynch et al., 2004).  
Another mechanism of this agent is its minor inhibitory effect on high voltage activated 
calcium channels (Niespodziany et al., 2001), predominantly N-type channels (Lukyanetz 
et al., 2002). 
Levetiracetam has an indirect effect on GABA-A receptors through the occlusion of the 
inhibitory action of GABA-A receptors antagonists (mainly bicuculline) that are usually 
responsible for neuronal epileptiform excitability in the hippocampus (Poulain and 
Margineanu, 2002).  
A view different from that commonly accepted regarding potassium channels and epilepsy 
was suggested by (Madeja et al., 2003).  It concluded that levetiracetam application 
resulted in a reduction of delayed rectifier potassium current and repetitive action potential 
generation in the hippocampal neurons that eventually leads to anticonvulsant activity.  
This conclusion was explained by levetiracetam interference with the duration of action 
potential through the reduction of delayed rectifier potassium current, an action that 
ultimately resulted in a decrease in amplitude and/or decrease of frequency of discharge. 
1.2.5.13. Oxcarbazepine 
Oxcarbazepine (10-keto-carbamazepine) is an analogue of carbamazepine.  It was 
introduced in the UK in 2000.  Oxcarbazepine was designed to have the same efficacy of 
carbamazepine with fewer side effects.  Chemically, a keto group was added to 
oxcarbazepine at the position 10 of the azepine ring. This keto ring is reduced to a 
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monohydroxy derivative (MHD) that is responsible for the anticonvulsant activity of the 
drug.   
The difference in the chemical structure between oxcarbazepine and carbamazepine due to 
the presence of the keto group has lead to differences in the metabolic pathways and 
properties of each drug e.g. side effects and enzyme induction.  Unlike carbamazepine, 
oxcarbazepine is not metabolised to an epoxide metabolite responsible for the toxic effects 
of carbamazepine (Faigle and Menge, 1990).  Instead, oxcarbazepine is metabolised to a 
monohydroxy derivative responsible for its pharmacological effects. 
Oxcarbazepine acts by blocking voltage sensitive sodium channels inhibiting repetitive 
neuronal firings and stabilising hyperexcited membranes (Mclean et al., 1994).  Another 
mechanism is through the inhibition of voltage activated calcium currents, an effect 
observed in cortical and striatal neurons (Stefani et al., 1997).  An inhibitory effect of 
oxcarbazepine on excitatory glutamate release was also noted (Calabresi et al., 1995). 
Hippocampal dopamine and serotonin have been found to have anticonvulsant properties 
against limbic seizures through stimulation of D2 and 5-HT1A receptors (Clinckers et al., 
2004).  Oxcarbazepine and its metabolite 10,11-dihydro-10-hydroxycarbamazepine 
(MHD) promote the release of hippocampal dopamine and serotonin (Clinckers et al., 
2005) which might contribute at least partly to the anticonvulsant effects of oxcarbazepine. 
1.2.5.14. Pregabalin 
Pregabalin was licensed in 2004.  Pregabalin (S-(+)-3-isobutylgaba) is a lipophilic 
structural analogue of GABA, it is substituted at the 3 position so that it can traverse the 
blood brain barrier.  
Although it is an analogue of GABA, pregabalin is inactive at GABA receptors. Similar to 
gabapentin, it binds with high affinity to voltage gated calcium channels subunit α2δ (Ben 
Menachem, 2004).  This binding is restricted to the α2δ type 1 subunit of voltage gated 
calcium channels (Bian et al., 2006).  This results in a reduction in calcium influx at nerve 
terminals and a reduction in the release of several neurotransmitters including glutamate, 
noradrenaline and substance P (Fink et al., 2002), which might be the reason for its 
anticonvulsant activity.   
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Although, pregabalin does not act directly on postsynaptic GABA receptors, it causes a 
small inhibition of synaptic vesicle exocytosis in GABAergic and glutamatergic neurons 
(Micheva et al., 2006).  Although this effect seems to counterintuitive for an AED, the 
existence of depolarising GABA responses in certain excitatory neurons has been reported; 
these were suggested to be capable of initiating epileptic discharges (Cohen et al., 2002).  
Therefore, inhibition of synaptic vesicle exocytosis of GABA will result in an anti-
convulsant activity. 
In addition, a recent study suggested a role for pregabalin in the activation of GABA-B 
receptors based on the finding that long-interval intracortical inhibition (a measure of 
human motor cortex excitability) mediated by GABA-B activation was increased following 
pregabalin administration (Lang et al., 2006).  
Pregabalin activates ATP-sensitive potassium channels (KATP) in the differentiated 
hippocampal neuron derived H19-7 cells in a concentration dependant manner; this 
activation was associated with a significant increase in the mean open lifetime of these 
channels (Huang et al., 2006) which will hyperpolarise the cell membranes and aid in 
seizure control.  
1.2.5.15. Zonisamide 
Zonisamide (1, 2-benzisoxazole-3-methanesulfon-amide) is structurally a derivative of 
sulfonamide. It was developed and licensed in Japan in 1989 while in the UK, it was 
licensed in 2005.  
Probably, zonisamide is the AED with the highest multiple known mechanisms of action.  
These mechanisms include: reduction of sustained repetitive firing of neurons through 
blockage of voltage dependant sodium channels (Rock et al., 1989), reduction of voltage 
dependant T-type calcium currents (Suzuki et al., 1992), facilitation of dopaminergic 
(Okada et al., 1995) and serotonergic (Okada et al., 1999) neurotransmission, potentiation 
of GABA release as it reacts with the GABA receptor complex (Mimaki et al., 1990) and 
weak inhibition of carbonic anhydrase (Masuda and Karasawa, 1993).  Rather than a weak 
inhibitor, De Simone and colleagues showed that zonisamide is in fact an effective 
inhibitor of carbonic anhydrase isozymes II in the cytosole and isozymes V in the 
mitochondria (De Simone et al., 2005). However, other investigators suggested that 
inhibition of carbonic anhydrase does not participate in the anticonvulsant properties of 
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zonisamide (Masuda et al., 1994). Also, it can lead to blockage of potassium evoked 
glutamate response (Okada et al., 1998). Zonisamide was found to be able to offer 
protection of neurons against free radicals damage through scavenging of these free 
radicals (Mori et al., 1998).  
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AED Main mechanism of action Other mechanisms 
Established AEDs 
Phenobarbital Potentiation of GABA inhibition Inhibition of glutamate 
excitatory mechanism 
Phenytoin Blockade of voltage gated sodium channels 
 
Ethosuximide Blockade of LVA (T-type) calcium channels  
Carbamazepine Blockade of voltage gated sodium channels 
 
Valproic acid Potentiation of GABA inhibition 
Blockade of voltage gated 
sodium channels and LVA 
(T-type) calcium channels 
Clobazam Potentiation of GABA inhibition  
Modern AEDs 
Vigabatrin Potentiation of GABA inhibition  
Lamotrigine Blockade of voltage gated sodium channels Blockade of HVA calcium 
channels  
Gabapentin Blockade of HVA calcium channels  
Topiramate 
Equal multiple mechanisms of action: blockade of voltage gated sodium 
channels, HVA calcium channels, potentiation of GABA inhibition and 
inhibition of glutamate excitatory mechanism 
Tiagabine Potentiation of GABA inhibition  
Oxcarbazepine Blockade of voltage gated sodium channels Blockade of calcium and potassium channels 
Levetiracetam Equal multiple mechanisms of action: binding to SV2A receptors and blockade of HVA calcium channels.  
Pregabalin Blockade of HVA calcium channels  
Zonisamide 
Equal multiple mechanisms of action: Blockade of voltage gated sodium 
channels, LVA (T-type) calcium channels and potentiation of GABA 
inhibition.  
Table 9. The mechanisms of action of AEDs.  
(HVA = high voltage activated, LVA = low voltage activated, SV2A: synaptic vesicle protein 
2A; (Ben Menachem, 2004;Kwan et al., 2001;Lynch et al., 2004;Rogawski and Loscher, 
2004;White et al., 2007). 
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1.2.6. Future directions of AEDs 
Advanced molecular biology techniques have enabled investigators to define the 
mechanism of action of several AEDs, to understand the process of epileptogenesis and to 
discover the link between targets for AEDs and epilepsy. Nevertheless, it seems that much 
remains to be discovered in the continuous process for developing new novel AEDs. Some 
of the future promising directions include: 
1.2.6.1. Future mechanisms of AEDs 
Inhibition of sodium channels has proven to be a very effective target for controlling 
seizures. As several isoforms of sodium channels with different functions exist throughout 
the brain, development of blockers against these specific sodium channels isoforms might 
improve the pharmacological outcome of epilepsy. 
Serotonergic receptors are believed to be potential targets for future AEDs. Elevation of 
extracellular concentration of serotonin (5-HT) is accompanied by inhibition of limbic and 
generalised seizures while its depletion will lower seizure threshold. This was confirmed 
by the discovery of anticonvulsant activity in a 5-HT2B/2C receptor agonist (Isaac, 2005). 
Such findings indicate that serotonin receptors will play a role in the design of future 
AEDs. 
H-channels are hyperpolarization activated cation channels constituted by a depolarising, 
non-activating, mixed Na-K current. They control neuronal excitation and inhibition in 
neuronal and cardiac tissues. These channels represent a new potential target for AEDs as 
recent evidence has established the effects of their modulation on neuronal excitability and 
consequently a net antiepileptic effect (Chen et al., 2002). For example, after febrile 
convulsions, an inhibition of H-channels in the limbic system has minimized 
hyperexcitability generated by the post inhibitory rebound firing in principal cells (Chen et 
al., 2001). Experiments have also showed that certain manipulations could either increase 
e.g. febrile convulsions or decrease e.g. diabetic neuropathy neuronal activity of H-
channels and that the recurrent burst firing has been stopped by changing the activity of 
these channels (Soltesz et al., 1991).  
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Therefore, it is possible that decreasing H-channels activity in epileptic cortical structures 
may lead to antiepileptic activity making the inhibitors of these channels potential future 
AEDs. 
1.2.6.2. Future concepts of AEDs 
A clear distinction should be made between anti-epileptogenesis (suppression of 
progressive development of epilepsy) and anti-convulsion (suppression of seizures). 
Almost all AEDs used today are anticonvulsants and they attract almost all the attention in 
laboratory studies and clinical trials. Although some of the anti-convulsant agents (AEDs) 
have been noted to possess some anti-epileptogenesis activity in selected experimental 
models (Loscher et al., 1998;Pitkanen, 2002), a limited number of clinical trials has 
addressed this issue. It seems that anti-epileptogenesis deserves more attention as its role 
should not be ignored in preventing early development of epilepsy particularly when 
studies on this issue are encouraging (Silver et al., 1991;Stasheff et al., 1989). 
1.2.7. Clinical trials of AEDs 
Clinical trials of antiepileptic compounds are essential to assess the efficacy and, perhaps 
more importantly, the safety of these novel agents before their application in clinical 
practice in epilepsy patients.  For modern AEDs, these are basic requirements for 
regulatory approval. Some clinical trials are primarily designed to meet the demands of 
regulatory agencies providing information of little relevance to clinical practice. For 
instance, to examine the effects of certain newer AEDs, “pseudo-placebo” controlled 
monotherapy trials are conducted in which the second generation drug is compared to a 
sub-optimal dose of comparator e.g. a first generation agent. As the comparison of this 
kind of studies is not clinically relevant, these trials do not provide data suitable for clinical 
guidance (Perucca and Tomson, 1999;Tomson, 2004). Another disadvantage shared by 
many clinical trials is their short duration that is not sufficient to examine AED efficacy 
and tolerability. Much of what we understand about the effectiveness of any given 
antiepileptic agent is actually gained through clinical experience in the post-marketing 
period.  Instead of being concerned about short term efficacy and adverse effects seen in 
clinical trials, it is often only at the stage of clinical experience that drug-drug interactions, 
efficacy to reduce seizure frequency and/or severity and issues of long term safety become 
apparent (Brodie and Kwan, 2001).  For instance, the correlation of felbamate with aplastic 
anaemia was only evident after administration in the clinical setting.   
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Therefore, if we are to take advantages of this unprecedented expansion in the 
pharmacological armamentarium and genuinely seek the most appropriate drug or 
combination of drugs for any given patient, then comparative long-term efficacy and 
tolerability studies are essential.  
Some of the clinical trials performed on AEDs to investigate their efficacy and tolerability 
were conducted on first generation AEDs in comparison with either, other first generation 
agents or using a placebo, while other studies have made comparisons between second 
generation AEDs and either placebo or first generation AEDs (Kwan and Brodie, 2003).  
Unfortunately, a very limited number of studies has been performed to compare the 
efficacy and tolerability of modern AEDs (Brodie et al., 2002).  Also, all these comparative 
studies examined certain specific drugs with little attention to the comparison between 
generations of AEDs as a whole.  
Therefore, there is a need to compare different individual modern AEDs using a long 
period of follow up on patients with epilepsy with an emphasis on their efficacy against 
different seizure types and their adverse effects in every day clinical practice.  In addition, 
a comparison between first and second generations AEDs as a whole in terms of efficacy 
and tolerability is required.  
1.2.8. Indications of AEDs 
Starting a patient on AED therapy is not an easy step. Such a decision is going to have a 
significant influence on the patient’s life regarding side effects (along with their 
consequences), compliance (with the risk of relapse in case of poor compliance) and 
financial impact, bearing in mind that treatment might be life long.  Therefore, this 
decision should be made only by a person qualified in this field and only when a definite 
diagnosis has been made using proper clinical evaluation and investigations.  
Table 10 shows the therapeutic uses in epilepsy of both first and second generation AEDs.  
Second generation AEDs include more agents with broad spectrum of anticonvulsant 
activity against almost all seizure types compared to drugs of the first generation.  
Following the introduction of second generation AEDs, more agents are available for 
treating epilepsy, which has made the selection of the most appropriate agent for a 
particular patient with a particular seizure type by clinicians a more complicated issue.  
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1.2.9. Side effects of AEDs  
Adverse drug reaction to any therapeutic intervention for any disease including epilepsy 
has been defined by the WHO (World Health Organization) as “a response to a drug that is 
noxious and unintended and occurs at doses normally used in man for the prophylaxis, 
diagnosis or therapy of disease, or for modification of physiological function” (Edwards 
and Aronson, 2000;World Health Organization, 1972).   
Epilepsy patients on treatment with AEDs are subject to side effects that can be considered 
as either biological or cognitive (behavioral).  Biological side effects such as rash or hair 
loss can be detected by physical examination or using laboratory tests. They are divided 
into two types, acute and chronic organ effects.  Acute reactions as in idiosyncratic 
reactions which are not predicted e.g. hepatitis, or chronic organ effects that take place as a 
result of cumulative toxicity e.g. gingival hyperplasia.  Felbamate has been identified as 
the reason for fatal cases of aplastic anaemia and liver failure; this has restricted its use to a 
drug of last choice for refractory epilepsy (Pellock and Brodie, 1997).  On the other hand, 
cognitive (behavioral) side effects such as depression and aggressiveness may not usually 
be evident to physicians on examination but reported by patients or families (Camfield and 
Camfield, 1994) (Table 11). Neurotoxic side effects (e.g. nausea, diplopia, dizziness, 
headache, fatigue, tiredness, ataxia) are considered as some of the common dose-related 
side effects (Brodie, 2001).  
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AED 
Partial 
seizures 
GTC 
seizures 
Absence 
seizures 
Myoclonic 
seizures 
Infantile 
spasms 
First generation 
Phenobarbital + + - - - 
Phenytoin + + - - - 
Ethosuximide - - + - - 
Carbamazepine + + - - - 
Sodium valproate + + + + - 
Benzodiazepines + + + + - 
Second generation 
Vigabatrin + + - - + 
Lamotrigine + + + (+/-) - 
Gabapentin + + - - - 
Topiramate + + (+) (+) (+) 
Tiagabine + + - - - 
Levetiracetam + (+) (+) (+) - 
Oxcarbazepine + + - - - 
Pregabalin + - - - - 
Zonisamide + + (+) (+) (+) 
Table 10. Indications for AEDs (arranged in chronological order).  
GTC seizures: generalized tonic clonic seizures, +: Evidence of efficacy, (+): Less extensive 
base of evidence, __: Evidence of lack of efficacy or worsening; (Perucca, 2001a;Rogawski 
and Loscher, 2004). 
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AED Side effects 
Phenobarbital 
Fatigue, tiredness, depression, in children: insomnia, 
distractability, hyperkinesias, irritability 
Phenytoin 
Nystagmus, ataxia, acne, gum hypertrophy, coarse 
facies, hirsutism 
Ethosuximide Nausea 
Carbamazepine Diplopia, dizziness, headache, nausea, rash 
Sodium valproate Tremor, weight gain, hair fall 
Benzodiazepines Fatigue, drowsiness, sedation 
Vigabatrin 
Dizziness, headache, weight gain, agitation, 
depression 
Lamotrigine 
Diplopia, dizziness, headache, nausea, ataxia, tremor, 
insomnia, rash 
Gabapentin 
Dizziness, fatigue, somnolence, weight gain, ataxia, 
tremor 
Topiramate 
Dizziness, ataxia, fatigue, paraesthesia, somnolence, 
word finding difficulties, mental slowing, poor 
concentration 
Tiagabine 
Dizziness, somnolence, fatigue, headache, tremor, 
nervousness, impaired concentration, depression 
Levetiracetam 
Dizziness, fatigue, headache, somnolence, 
nervousness, depression, agitation 
Oxcarbazepine Fatigue, headache, dizziness, ataxia, sedation, nausea 
Pregabalin Dizziness, somnolence, headache, ataxia 
Zonisamide 
Fatigue, dizziness, ataxia, somnolence, impaired 
concentration, mental slowing, nausea, agitation 
Table 11. Common side effects of the commonly prescribed AEDs  
(Brodie and Dichter, 1997;Perucca, 2001a).  
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1.2.10. Hypothesis 
With evidence to suggest that modern AEDs have multiple cellular effects at 
therapeutically relevant concentrations and that they are associated with fewer adverse 
effects, it is my hypothesis that the introduction of these agents has significantly improved 
the effectiveness of drug treatment in epilepsy, as assessed by long-term outcome.  Almost 
one hundred years after the introduction of phenobarbital we have multiple treatment 
options for epilepsy and still no indication of how these might best be employed. This 
project builds on previous investigations at the Epilepsy Unit, Western Infirmary, 
Glasgow, but focuses specifically on the employment of antiepileptic agents in newly 
diagnosed epilepsy.  I aimed to distinguish outcome on the basis of pharmacology and to 
assess the clinical impact of modern AEDs in relation to their more established 
compounds. 
1.2.11. Research questions  
On completion of data collection of this project, the database was applied to answer the 
following research questions of interest to the study.  Further analyses were performed on 
the basis of initial results and findings of concern were pursued in detail. 
1. To determine the annual outcome of epilepsy according to year of referral to the 
Epilepsy Unit during the study period. 
2. To identify the impact on epilepsy outcome after the introduction of second 
generation AEDs.   
3. To demonstrate the outcome of epilepsy in relation to several demographic (age 
and gender) , pharmacological and clinical aspects. 
4. To investigate and compare the efficacy among: Individual AEDs, older AEDs, 
modern AEDs, generations of AEDs, gender, age groups, years of referral and 
epilepsy type. 
5. To investigate and compare the tolerability among: Individual AEDs, established 
AEDs, modern AEDs, generations of AEDs, gender, age groups, years of referral 
and epilepsy type. 
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6. To define the term of refractory epilepsy giving the number of treatment regimens 
applied that need to be failed before a patient can be considered as having 
refractory epilepsy.   
1.2.12. Pharmacogenetics of AEDs 
Pharmacological intervention is considered as the main tool for the treatment of epilepsy. 
The response to AEDs has demonstrated a wide range of variation among these patients. 
Accordingly, individual variation in the response to these drugs among patients is 
becoming an important clinical issue. Hartl and Orel (1992) have shown that genetic 
factors play a major role in the variability of drug response (Hartl and Orel, 1992). The 
variability in drug response based on genetic basis is known as “pharmacogenetics” 
(Vogel, 1959). It ranges from resistance to treatment to adverse drug reactions and drug-
drug interactions. Therefore, further research on pharmacogenetics can provide an 
opportunity to tailor drugs selection and dosage based on both clinical and genetic factors 
(Kruglyak, 1999).  
At least 33 chromosome regions have been linked to epilepsy (Prasad et al., 1999). Several 
syndromes of idiopathic generalised epilepsy have been linked to genetic variation in ion 
channels. For instance, generalised epilepsy with febrile seizures plus (GEFS+) is linked to 
a variation in the sodium channel subunit (Ceulemans et al., 2004;Kamiya et al., 2004). 
Four groups of genes have been identified to play a major role in controlling epilepsy and 
its AED treatment response.  
1. Genes responsible for characterisation of epilepsy subclass. 
2. Genes that encode pharmacokinetic related proteins associated with AED efficacy. 
3. Genes that are associated with AED toxicity. 
4. Genes responsible for ion channel and AED receptors (Spear, 2001).  
Therefore, any individual variation among these genes can influence the response to AED 
treatment (Clancy and Kass, 2003;Holmes, 2002;Ma et al., 2004;Ramachandran and 
Shorvon, 2003;Spear, 2001).  
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Pharmacogenetics can play a role in the pharmacodynamics of AEDs. AED targets such as 
ion channels and receptors might be altered by the changes in their genetic transcription. 
These changes can lead to variation in drug response or even drug non-responsiveness 
(Ramachandran and Shorvon, 2003). Sometimes, seizures can induce modifications in 
AED targets leading to a change in the sensitivity to these drugs (Remy and Beck, 2006).  
In terms of the effects of pharmacogenetics on the pharmacokinetic properties of AEDs, a 
limited number of studies have explored the association between drug transporter protein 
gene polymorphisms and the response to AED treatment (Hung et al., 2005;Siddiqui et al., 
2003;Tan et al., 2004). ABCB1 gene is responsible for encoding the efflux transporter, P-
gp. P-gp is used in the transport of several AEDs (Potschka et al., 2002). Over expression 
of P-gp has been identified in the brain tissues of patients with refractory epilepsy that 
raised its likely role in the development of intractable seizures (Marchi et al., 2004). 
Therefore, variability in the expression of P-gp can result in individual variation in AED 
response.  
1.2.13. Pharmaco-resistance to AEDs (refractory epilepsy) 
Although, the majority of patients with epilepsy end up having well-controlled seizures, 
around 30% of epilepsy patients do not achieve remission despite using several options of 
AED/s combinations (Cockerell et al., 1995;Kwan and Brodie, 2000a).  This leads to 
negative physical, psychological and social consequences in this group of patients 
associated with increased drug load and sudden unexpected death (Kwan and Brodie, 
2002).  In the presence of treatment options other than pharmacotherapy, particularly 
epilepsy surgery, there is no doubt that early identification of patients with refractory 
epilepsy will be accompanied by considerable saving of time, effort and economic costs 
through offering this alternative option to suitable patients.  Certain epilepsy syndromes 
are known to have a low response rate to medical treatment but can be cured through 
surgical intervention (Engel and Shewmon, 1993).  One of these is mesial temporal lobe 
epilepsy in which surgical treatment can offer a 70 – 80% chance of a cure (Wieser et al., 
1993). According to a US study that investigated the total life time treatment cost in 
patients with epilepsy, this was $4272 US for a patient in remission while the treatment 
cost in a patient with refractory epilepsy was $138,602 US (Begley et al., 1994).  
Refractory epilepsy can be considered as the main reason for the continued search for new 
AEDs (Jallon, 1997b).  
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Obviously, not all patients with persistant seizures despite AED treatment can be labeled as 
having refractory epilepsy.  In some cases, the epilepsy appears to be uncontrolled because 
it has not been adequately treated leading to a “pseudo-resistance” or false resistance to 
treatment (Perucca, 1998).  Pseudo-resistance to AED treatment can be due to: poor 
compliance of the patients, inappropriate drug selection for a particular seizure type, 
inadequate dosage of drugs, inappropriate life style (e.g. high alcohol intake, sleep 
deprivation and exposure to excessive stress) and inappropriate assessment of response e.g. 
development of pseudoseizures (psychogenic seizures) as a substitute for epileptic seizures 
and being treated without effect with the eventual misdiagnosis of pharmacoresistant 
epilepsy.  
As a self-explanatory term “pharmacoresistant epilepsy” might be defined as the 
persistence of seizures despite using the most appropriate AEDs and reaching the 
maximally tolerated doses of these drugs.  Although, it seems a straight forward definition, 
it is associated with multiple uncertainties such as: individual differences, the tolerated 
dose for each drug adjusted for each patient, the number of drugs that needs to be 
prescribed before a patient can be considered as resistant to treatment and whether they 
should be on monotherapy or combined therapy.  
Despite the usefulness of such a definition, we lack a consensus of how this concept can be 
applied in both daily clinical practice and in the research field (French, 2006). This is 
evident since “refractory epilepsy” or “pharmacoresistant epilepsy” has been given a 
variety of definitions by different investigators based on several factors e.g. seizure 
frequency, seizure severity, drug concentration and life style. Table 12 shows some of 
these definitions.  In addition, other investigators have developed scoring systems to 
distribute patients in groups based on the presence of certain criteria.  For instance, Perucca 
(1997) has graded patients with pharmacoresistant epilepsy into three grades taking into 
account the number of drugs that failed at maximally tolerated dosage and the probability 
of achieving seizure freedom consequently at each grade (Perucca, 1997).  Instead of three 
grades, Schmidt (1986) has applied six grades for these patients in which the first four 
grades were related to pseudoresistant epilepsy while the fifth and sixth grades were linked 
to the number of drugs that failed (Schmidt, 1986). Alving (1995) added a seventh grade 
that represented the failure to achieve remission using AED combinations, an aspect that 
was not addressed in the previous two scoring systems (Alving, 1995).  
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Absence of a uniform definition of refractory epilepsy leads to significant differences in 
the outcome of clinical studies recruiting this group of patients because they would 
represent a mixture of underlying definitions of pharmacoresistant epilepsy (e.g. seizure 
type, severity and number of regimens applied).  Such differences in outcome can even be 
observed in studies using the same AED e.g. a difference in responder rates to lamotrigine 
from 13% to 67% in two double blind add-on studies using comparable doses (Fitton and 
Goa, 1995;Goa et al., 1993).  It will also lead to inaccurate selection of patients to be 
considered suitable candidates for surgery.  
 
Reference Definition 
(Leppik, 1992) 
Occurrence of seizures with an anti-convulsant drug 
concentration of at least 1 standard medication, the 
usually effective range at the time of the seizures.  
(Schachter, 1993) 
Inability to live a life-style consistent with personal 
capabilities because of seizures, adverse effects of 
anticonvulsants and/or psychosocial problems.  
(Wolf, 1994) 
Persistence of seizures even at the highest dosage of 
anti-convulsant drug tolerated without unacceptable 
adverse effects.  
(Berg et al., 1996) 
Uncontrolled seizures with an average frequency of at 
least 1 per month for at least 2 years despite trials of at 
least 3 anticonvulsants.  
Table 12. Some definitions of pharmacoresistant epilepsy proposed by various 
investigators.  
 
 
Once a unified definition of pharmacoresistant epilepsy has been achieved, it will be 
beneficial for people of various professions.  These include: clinicians providing medical 
care for epilepsy patients, researchers interested in conducting clinical trials of AEDs and 
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comparing their results, epilepsy patients themselves and their caretakers, health 
administrators, legislators, insurers, educators, lawyers and employers.  
Based on this essential need, a definition of drug resistant epilepsy has recently been 
proposed as “failure of adequate trials of two tolerated and appropriately chosen and used 
AED schedules (whether as monotherapies or in combination) to achieve sustained seizure 
freedom” (Kwan et al., 2009).   
Intractability of seizures might be predicted by the presence of a number of factors.  The 
predictors might be broadly divided into three groups; disease related, genetic and drug 
related factors.  Disease related factors include early onset of seizures (Camfield et al., 
1993;Casetta et al., 1999), the long duration between first seizure and onset of treatment, 
high frequency of seizures before starting treatment (Arts et al., 1999;Beghi and Tognoni, 
1988), type of seizures and epilepsy syndrome (Aikia et al., 1999;Mattson et al., 1996), 
persistence of seizures despite continuing proper treatment, occurrence of status 
epilepticus, the number of frequently failed drugs at appropriate doses, family history of 
epilepsy (Berg et al., 2001;Elwes et al., 1984), presence and severity of brain damage and 
the presence of certain structural lesions in the brain such as cortical dysplasia and 
hippocampal sclerosis(Brorson and Wranne, 1987;Hauser et al., 1996). The relation 
between intractable seizures and some of these factors is still a controversial issue (Regesta 
and Tanganelli, 1999).  The initial response to AED treatment can also be an important 
factor for predicting drug resistant epilepsy (Camfield and Camfield, 1996;Dlugos et al., 
2001;Kwan and Brodie, 2000a) and patients with failure of two consecutive AED 
treatment regimens are unlikely to develop seizure freedom afterwards.  
Regarding genetic predictors, two hypotheses have been proposed.  One of the possible 
mechanisms underlying refractory epilepsy is the multi-drug transporter hypothesis. There 
are certain substances (transporters) present in the endothelial cells of the blood brain 
barrier; these play a major role in the outward efflux of many molecules including drugs 
which is considered as a defense mechanism to prevent drug accumulation within the 
brain.  Consequently, these transporters lead to the regulation of the pharmacological 
behavior of many drugs through affecting their absorption, distribution and elimination.  
They are also involved in “multidrug resistance” (MDR) development that represents the 
failure of treatments in several diseases such as tumours, infections and epilepsy because 
of their role in limiting the ability of drugs to reach target tissues and expediting the 
elimination of these treatments (Loscher and Potschka, 2002).  P-glycoprotein (PGP) is one 
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of these transporters; it is the encoded product of the human multi-drug resistance -1 
(MDR-1) gene or ABCB1 gene.  PGP is of particular importance due to the wide range of 
substrates it can act on including many drugs (Fromm, 2004).  
There is accumulating evidence correlating the multi-drug transporter hypothesis to 
refractoriness of epilepsy, as first proposed by Tishler and colleagues (1995) who reported 
an over-expression of MDR-1 encoding the multidrug transporter PGP in humans in the 
majority of patients with drug resistant epilepsy when studying their brain tissues (Tishler 
et al., 1995).  
 
Another hypothesis that has been raised as a possible mechanism contributing to drug 
resistant epilepsy is the drug target hypothesis in which certain changes are assumed to 
take place in one of the targets of AEDs such as ion channels, neurotransmitter receptors, 
transporters and enzymes involved in drug pharmacokinetics.  Several studies have 
confirmed either loss or complete absence of anticonvulsant activity exerted by AEDs on 
certain drug targets in patients with refractory epilepsy.  For, instance, Vreugdenhil and 
Wadman (1999) have reported a reduction by half of the carbamazepine response of 
sodium channels of CA1 neurons isolated from the epileptic focus of fully kindled rats 
compared with control rats (Vreugdenhil and Wadman, 1999).  There are two points that 
need to be considered in this hypothesis, the limited ability to demonstrate it clinically in 
humans because patients responding to treatment do not generally undergo surgery making 
it difficult to obtain tissue samples.  Also, since patients with refractory epilepsy do not 
respond to a wide range of AEDs acting through various mechanisms makes the drug 
target hypothesis of limited value to contribute to refractory epilepsy as it is usually based 
on one AED rather than multiple drugs. 
In terms of drug related factors that might contribute to refractory epilepsy, development of 
tolerance to the antiepileptic activity of drugs is an important issue.  In such situations, the 
anticonvulsant effect of AEDs will decrease following prolonged use (Bogg et al., 2000).  
The same pattern is observed with side effects of AEDs in which their severity has been 
shown to reduce after prolonged exposure to AEDs (Frey et al., 1986).  Other factors are 
the ineffectiveness of the current mechanisms of antiepileptic action of the available AEDs 
to treat intractable seizures.  In addition, several types of epilepsy such as temporal lobe 
epilepsy lead to physiological and morphological changes in the neural circuits of brain 
regions e.g. the hippocampus (Elger, 2003), lowering the sensitivity to AEDs as seen in 
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mesial temporal lobe epilepsy (the most common type of epilepsy treated surgically) in 
which the rate of treatment failure reaches 75% (Spencer, 2002).   
Patients with pharmacoresistant epilepsy can be grouped into three patterns based on the 
timing of developing the intractable seizures.  It might present initially (de novo) in some 
patients even before starting their AED treatment as evident in their poor response to the 
first AED prescribed; this group represents most patients with pharmacoresistant epilepsy 
as only few patients who fail on their first AED treatment will develop remission 
eventually (Kwan and Brodie, 2000a).  In other cases, refractory epilepsy might develop 
later, a condition that might be due to progression of the disease or certain accompanying 
changes within the brain.  A third group of patients with refractory epilepsy might show a 
fluctuating pattern of response to AED treatment ranging between periods of frequent 
seizures and intervals of complete seizure control.  
In an attempt to correlate the patterns of drug resistant epilepsy discussed earlier in this 
section with the current understanding of mechanisms contributing to this refractoriness, 
the multi-drug transporter and drug-target hypotheses might be applied to explain at least 
partially, two patterns.  The first pattern i.e. initial (de novo) AED resistance can be 
assumed to be either intrinsic or acquired.  Acquired initial resistance, even before starting 
treatment and based on results from animal studies might be explained as frequent seizures 
before starting treatment that lead to over-expression or upregulation of multi-drug 
transporters and drug-target alterations in epileptogenic brain tissues, which consequently 
results in AED resistance.  High seizure frequency before commencing treatment is one of 
the factors associated with intractability (Sillanpaa, 1993).  In other cases, alterations of 
multi-drug transporters of drug-targets might be of an intrinsic nature due to genetic 
polymorphisms which will also leads to de novo AEDs resistance eventually.  
The second pattern of AED resistance (i.e. recurrence of seizures after initial remission) 
occurs despite AED treatment and is due to alterations in drug-targets in the brain 
associated with progression of epilepsy, as has been shown by certain investigations 
(sensitive imaging techniques and histological examination) that recurrent seizures and a 
long duration of epilepsy are associated with changes in the brain such as volume reduction 
and neuronal loss in the hippocampus (Liu et al., 2001;Mathern et al., 2002).  Recurrence 
of seizures will be followed by over-expression of multi-drug transporters leading to AED 
resistance.
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2.1. Study population 
This is a large-scale retrospective observational study involving patients with newly 
diagnosed epilepsy.  Patients were first diagnosed and commenced treatment with 
antiepileptic drugs (AEDs) at the Epilepsy Unit of the Western Infirmary Hospital, 
Glasgow, Scotland.  They were seen between the period from July 1982 to December 
2005.  As the Unit is not only a tertiary referral service, patients are referred to the Unit 
either by general practitioners or accident and emergency department physicians.  
It is essential for patients enrolled in this study to be diagnosed with epilepsy at the 
epilepsy unit by qualified doctors not by general practitioners or accidents and emergency 
physicians. This is due to: 
• Epilepsy can be easily misdiagnosed as the differential diagnosis of seizures 
includes several conditions (Table 3). 
• To ensure the correct diagnosis of epilepsy, it is advisable to allow a period of 
observation for further events instead of introducing treatment immediately after 
the first seizure.  
• Patients with provoked seizures and those with widely separated seizures are not 
usually prescribed treatment, as avoidance of the precipitating factors can be 
sufficient.  
• To create patient awareness regarding the implications and consequences of this 
diagnosis e.g. driving, employment and life style.  
• Accepting the need for treatment obtained from qualified professional epilepsy staff 
is likely to maximise the compliance of patients with AED therapy.  
• The choice of AED to be prescribed to these patients depends on several factors 
such as seizure type, number of seizures and the tolerability profile of that 
particular AED.    
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• Common side effects of AED treatment along with the risk of teratogenesis in 
females with childbearing age and advice on contraception should be provided to 
the patients.  
Also, patients recruited should be started on their first ever AED treatment at the epilepsy 
unit. This is because epilepsy clinics accept both newly diagnosed patients and those with 
refractory epilepsy in which seizure freedom rate is usually low.  Consequently, 
performing studies in populations including refractory epilepsy will yield results which do 
not reflect accurately findings in the general population.  Therefore, using newly diagnosed 
epilepsy patients with their AED treatment first started at the Epilepsy Unit will be 
associated with more accurate findings and more reliable assessment of AEDs treatment.  
2.2. Managing patients at the epilepsy unit 
The Epilepsy Unit of the Western Infirmary Hospital, Glasgow provides clinical services 
for patients with established and suspected seizure disorders, conducts research related to 
aetiology and pharmacological intervention of epilepsy and trains a range of health 
professionals.  
The outpatient service operates on Tuesday and Wednesday from 1.30 PM to 4.30 PM 
every week.  The Tuesday clinic is confined to patients who have already embarked on 
their AED treatment, while the Wednesday clinic usually deals with patients following 
their first seizure, those with untreated epilepsy and those with whom the diagnosis of 
epilepsy has not yet been confirmed.  It is managed by two epilepsy nurse specialists and at 
least two qualified doctors specialising in epilepsy.  Also many patients are reviewed 
throughout the week in the Epilepsy Unit in particular urgent referrals of treated and 
untreated epilepsy.  Usually, patients suspected of having epilepsy are referred to the first 
seizure clinic by general practitioners or accidents and emergency physicians. 
In the clinic, a detailed history is obtained from the patient and witnesses.  This includes 
demographic data, risk factors of epilepsy, medical conditions, regular medications and a 
detailed description and frequency of episodes that have already occurred.  
This is followed by investigations i.e. electroencephalography (EEG) and brain imaging 
i.e. computed tomography (CT) scan and magnetic resonance imaging (MRI) that are 
carried out as clinically indicated in order to confirm the diagnosis of epilepsy and to help 
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in identifying the seizure type which will subsequently aid in the selection of AED 
appropriate for that specific seizure type.  Some of these investigations are used to 
determine the presence of any brain lesion that could be the focus of seizures with the 
possibility of subsequent surgical intervention.  
Once the diagnosis of epilepsy has been confirmed, treatment of these patients with the 
most appropriate AEDs commences.  
2.3. Treatment schedules 
Patients in whom the diagnosis of epilepsy has been confirmed start their first ever AED. 
The first treatment regimen is usually monotherapy.  Subsequent appointments are 
arranged to follow up patients regarding their response to treatment.  Treatment schedules 
are modified in the following circumstances: 
• Persistence of seizures despite reaching the maximum tolerated dose and good 
patient compliance. 
• Development of intolerable side effects. 
• Risk of teratogenic effects in female patients of childbearing potential. 
• Risk of toxicity identified by high serum anticonvulsant concentration.  
Modification of treatment schedules is either by dosage adjustments, substitution of the 
current AED or offering combined therapy.  These steps are followed until the final goal of 
complete seizure control is achieved.  When poor compliance with epilepsy treatment is 
suspected, it can be assessed either by direct questioning and/or measurement of serum 
drug concentration in the blood (for certain AEDs). Measurement of serum anticonvulsant 
concentration can also be used as a guide to dosage adjustments and drug toxicity.  
Carbamazepine and sodium valproate are prescribed either in the regular release form or a 
sustained release form that is usually associated with a lower risk of side effects and 
prolonged serum concentration.  Sustained release forms are usually selected to minimise 
the frequency of drug administration and lower the risk of side effects with subsequent 
improvement in patient compliance.  In this study, both regular release and sustained 
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release forms are considered as the original regular form since this project is mainly 
concerned with the pharmacodynamics of AEDs (the mechanisms by which these agents 
act) rather than their pharmacokinetics properties (the ways by which body systems handle 
the drug).   
2.4. Filing system at the epilepsy unit 
The patients’ folders are kept in the epilepsy research unit in appropriate cabinets; these 
folders are arranged in chronological order starting from 1982, the year at which the 
Epilepsy Unit was established.  Folders of deceased patients are kept in two separate 
cabinets.  Access to folders of the Epilepsy Research Unit is only allowed to authorised 
unit staff.  The patients’ folders usually contain demographic data, details of each visit to 
the epilepsy clinic along with investigations carried out and details of treatment regimens.  
Prior to each clinic, folders of appointed patients are collected from cabinets and 
transferred to the epilepsy clinic in the out patient department.  After the clinic, these 
folders are taken back to the epilepsy research unit where all details and consultations 
between doctor and patient during the visit are typed by the administrative staff on a letter 
to the referring physician; eventually the letter is filed in the folder which is stored in the 
appropriate cabinet.  
2.5. Data collection 
Based on the inclusion criteria of this project, patients were identified, their case records 
were obtained and the required patient information extracted by detailed review of the case 
notes and recorded on a prepared worksheet using software Microsoft® Access 2000 
(9.0.3821 SR-1).    
As data collection for this study required a long time to be collated, there was a long 
interval between the data collection for the first patient in the study and that of the last 
patient.  During this interval, changes in treatment details of patients could have taken 
place and even inclusion criteria could have changed.  Therefore, to ensure the accuracy of 
data obtained, a second patient review was performed to pick up any such changes.    
Ethical approval of such type of study was not required beside the measures taken to keep 
data collected as confidential as possible e.g. limited access to authorized staff and deleting 
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patients names from the database. In addition, data obtained from patients’ records were 
recorded and stored in adherence with the Data Protection Act 1998.  
Patient data were recorded according to the following categories: 
• Demographic data: name, folder number, gender, date of birth, intellectual status, 
date of referral and date of last clinic visit. 
• Clinical history: family history of epilepsy, birth injury, febrile seizures, other 
medical conditions, alcohol abuse, drug abuse and any neurological deficit with the 
cause. 
• Investigations: findings from EEG, brain CT scan, brain MRI, any other imaging 
procedures and also the results of serum anticonvulsant concentrations obtained.  
• Seizure details: seizure type, epilepsy type, syndrome (if known), date of first ever 
seizure and whether patient was seen after first seizure by medical staff.  
• Treatment details (including each AED/ AED combination): starting date of 
treatment, starting dose, serum concentration on starting dose (if available), 
maximum dose, serum concentration on maximum dose (if available), side effects, 
maximum tolerated dose, response on maximum tolerated dose and any comments 
on that particular treatment regimen.  
• Outcome: analysis of the outcome of epilepsy by the end of 2 years, 5 years, 10 
years and 15 years of patient follow up.  Each section includes: number of 
treatment regimens applied, current type of treatment (monotherapy or combined 
therapy), current AED/s, seizure status and any comments till that point of follow 
up. 
There were two types of outcomes of epilepsy in this study.  These were ultimate and 
partial outcomes.  The ultimate outcome of epilepsy represents the final response on the 
maximum tolerated dose of the last AED/ AED combination prescribed to each patient in 
this study on the last follow up appointment.  The ultimate outcome of epilepsy is 
categorised into three groups: 
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1. Patients in remission: these are the patients who had a seizure free period 
for at least the last 12 months of follow up (duration of remission recorded). 
2. Relapsed patients: these are the patients who experienced ongoing 
uncontrolled seizures after at least a 12 months period of initial control.  A 
seizure following a missed dose of treatment after a year of seizure freedom 
period was not considered as a relapse if control was established again.  
3. Patients with refractory epilepsy:  these represent the patients who have 
never been seizure free.  Patients who developed complete seizure control 
following surgery were considered as refractory because this study is 
mainly targeted at outcome due to pharmacological intervention.  By the 
time of database lock, every patient who had less than 12 months seizure 
freedom period was also considered as refractory since they had a period of 
treatment within the Unit of at least 12 months.  
Partial outcome of epilepsy constitutes the response to each AED/ AED combination given 
to the patients using the maximum tolerated dose on the last follow up appointment on that 
particular agent (s).  
Dynamic data as in this study requires a cut-off point to define the end of follow up of 
patients. All the information included in the database up to that point was analysed 
regardless of any future changes in these data sets after the end of data collection.  It was 
decided to end following up the study population (lock database) on the first of April 2008; 
the last patient followed up at the last day of data collection (31st of March 2008) had a 
minimum period of 27 months (2 years and 3 months) of follow up.  
Following up the patients for the purpose of this study started from the visit at which AED 
treatment was commenced.  AED/AED combination and dose modifications prescribed on 
the last visit of a patient to the Unit were not included in the study due to the difficulty of 
assessing the efficacy and tolerability of these agents after the end of patient follow up.  
Microsoft® Word 2000 (9.0.3821 SR-1) was applied for writing up this thesis and 
Microsoft® Excel 2000 (9.0.3821 SR-1) for constructing various figures and curves.  
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2.6. Seizure classification 
Classification of seizure types and epilepsy syndromes was performed using guidelines of 
the International League Against Epilepsy ILAE (Commission, 1981; Commission, 1989).  
In this study, epilepsy will be broadly classified into two groups based on seizures types:  
Focal (localisation related) epilepsy: this group is characterised by the presence of partial 
seizures (either simple or complex) with or without secondary generalisation.  It can be 
further subdivided into: 
• Symptomatic epilepsy in which there is an underlying pathology in the brain 
(evident by brain imaging techniques) that contributes to the development of 
seizures e.g. infections, tumours, cerebrovascular disease (cerebral infarction or 
cerebral hemorrhage), mesial temporal sclerosis and cortical dysplasia.  
• Cryptogenic epilepsy in which it is assumed that there is an underlying brain lesion 
but it is unidentified.  
Idiopathic generalised epilepsy: this group includes several subtypes such as primary 
generalised tonic clonic seizures, myoclonic jerks and absence seizures and syndromes e.g. 
benign neonatal familial convulsions, juvenile absence epilepsy and juvenile myoclonic 
epilepsy. Idiopathic epilepsy is presumed to posses a genetic origin.   
2.7. Analysis of database 
In order for the database to be able to answer the research questions of this study, the 
following calculations had to be performed: 
2.7.1. Outcome of epilepsy  
This section investigates the ultimate outcome of epilepsy in relation to several 
demographic, clinical and pharmacological aspects.  As mentioned earlier in the section of 
data collection, the ultimate outcome of epilepsy represents the final response on the 
maximum tolerated dose of the last AED/ AED combination on the last follow up 
appointment. It is classified into three groups that include remission, refractory and 
relapsed.  Patients who relapsed and those who continued to have seizures despite 
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treatment were considered as non-responders, while patients with remission represented 
the responder group.  The aspects investigated in relation to outcome of epilepsy were:  
• Outcome by year of referral 
• Outcome by age groups  
• Outcome by gender 
• Outcome by type of treatment regimen (monotherapy or combined therapy) 
• Outcome by type of epilepsy 
• Outcome by mechanism of action 
• Outcome by generations of AED 
For some of those aspects, the ultimate outcome of epilepsy was calculated based on the 
last treatment schedule e.g. outcome by mechanism of action of the last AED prescribed. 
In contrast, other aspects were analyzed in relation to the ultimate outcome of epilepsy 
using the first treatment regimen e.g. outcome by age groups.   
2.7.2. Effectiveness of AEDs  
Two parameters were considered, the efficacy and tolerability of AEDs.  Both were also 
analysed in relation to several demographic, clinical and pharmacological aspects in order 
to investigate any significant influence of any of these aspects on the effectiveness of 
AEDs and consequently the ultimate outcome of epilepsy.  
2.7.2.1. Efficacy of AEDs 
Efficacy of AEDs in this project was measured based on the percentage of patients 
achieving seizure freedom for a minimum period of 12 months at last recorded follow up. 
It was calculated using the parameter “Response on maximum tolerated dose of that 
particular regimen” available in the therapy section of the database.  This parameter was 
categorised as follows: seizure freedom (of at least 12 months on that particular AED/AED 
combination), ongoing seizures, discontinued due to side effects, relapsed (after a period of 
Chapter 2. Methods.  85 
at least 12 months of seizure freedom).  Efficacy of each AED/AED combination 
represents the rate of patients who achieved seizure freedom among the total number of 
patients on that particular agent(s).  Efficacy was calculated with regard to the following 
aspects:  
• Efficacy among individual AEDs 
• Efficacy among generations of AEDs 
• Efficacy among gender 
• Efficacy among combinations of AEDs  
• Efficacy among epilepsy type 
• Efficacy among age groups  
2.7.2.2. Tolerability of AEDs   
To demonstrate the tolerability of AEDs applied in this study, withdrawal due to side 
effects was employed as an indicator. All side effects attributable to AED/AED 
combination treatment were recorded in the database including idiosyncratic reactions 
bearing in mind that only side effects that remain were recorded while those that resolved 
after some time from starting treatment were ignored. AEDs tolerability was calculated as 
the rate of patients who discontinued a certain AED/ AED combination due to side effects 
among the total number of patients on that particular agent/ combination.  The high 
percentage of withdrawal due to side effects among patients on a particular AED indicated 
a low tolerability profile for that agent and vice versa.  Tolerability was calculated in 
relation to the following factors:  
• Tolerability among individual AEDs 
• Tolerability among generations of AEDs 
• Tolerability among gender 
• Tolerability among epilepsy type  
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• Tolerability among age groups  
2.7.3. Potential applications of database 
One of the main advantages of Microsoft Access software used for database construction is 
its ability to analyze the data included to answer questions of interest to this study.  Further 
details on the benefits of this software are discussed in other sections of this chapter.  In 
addition to defining the efficacy and tolerability of AEDs and examining the relationships 
of outcome of epilepsy with different demographic, pharmacological and clinical issues, 
this database can be employed for other applications such as:  
• Demonstrating the response rate of a particular AED after failure of response to 
another AED working by the same primary mechanism of action. 
• Identifying the response rate of the two generations of AEDs in patients with a 
particular type of epilepsy (localisation-related or idiopathic generalised). 
• Identifying the response rate of different classes of AEDs (grouped according to the 
primary mechanism of action) in patients with a particular type of epilepsy. 
• Defining the frequency of prescription and response rate of a particular AED 
combination in comparison with another combination. 
2.8. Mechanism of action of AEDs 
In this study, mechanisms of action of AEDs were analysed in relation to the ultimate 
outcome of epilepsy and effectiveness of these drugs.  
AEDs prescribed were divided into groups based on the mechanism of action.  As it is well 
known that most AEDs tend to have multiple mechanisms of action in order to exert their 
effects, this project focused on the primary mechanism of action of each drug.  Agents with 
multiple mechanisms of action without an identifiable primary mechanism were included 
in one group. Those drugs that have never been applied in this study population or were 
prescribed rarely or those that have been withdrawn from the market for various reasons or 
unidentified AEDs (as in the case of clinical trials) were not considered in the 
classification. The main mechanism of action was defined based on the observations of 
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Kwan and colleagues that ranked all the mechanisms of action of each AED (Kwan et al., 
2001).  
2.9. Defining refractory epilepsy 
Another aspect of this study is to define refractory epilepsy by identification of the number 
of treatment regimens needed to be deemed unsuccessful after which, the term of 
“refractory epilepsy” can be applied.  Failure of AEDs was considered either due to poor 
tolerability or lack of efficacy.  Initially, calculations were made based on 50% of WHO’s 
defined daily dose of each AED (World Health Organization, 2008). Therefore, below that 
level, failure would be due to poor tolerability while above which, failure would be due to 
lack of efficacy.  In order to detect any difference that might take place, this study also 
considered 25% and 75% of the daily defined dose.  Table 13 demonstrates the doses of 
AEDs after manipulation into the three categories (25%, 50% and 75%).  Again, patients 
with rarely prescribed AEDs or those with unidentified agents (in clinical trials) were 
excluded from this analysis.  
Defining refractory epilepsy using the two types of treatment failures i.e. due to lack of 
efficacy and poor tolerability was performed through comparing the prognosis of epilepsy 
following each of these types of failures.  
The aim of this analysis is to demonstrate the number of patients who might develop a state 
of seizure freedom after each failure of a treatment regimen due to the lack of efficacy.  
The lower the number of patients with seizure freedom indicates a more likely chance of 
having refractory epilepsy.  This analysis included the first, second, third and forth 
treatment regimens.  The prognosis of these regimens was demonstrated by comparison of 
both types of failures i.e. due to lack of efficacy or poor tolerability.  
2.10. Statistical analysis 
Analysis was undertaken in consultation with Professor John Norrie, Director of Robertson 
centre for Biostatistics, University of Glasgow. Univariate analysis employed Student’s t-
test for continuous or numerical data (Mann-Whitney test where data is not normally 
distributed) and Chi-square test for categorical data. Statistical significance was inferred, 
after appropriate correction for multiple comparisons, for p-value of less than 0.05. 
Multivariate analysis was performed under expert supervision.  
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AED DDD (WHO) 
25 % of 
DDD 
50 % of 
DDD 
75 % of 
DDD 
CARBAMAZEPINE 1 g 250 mg or less 
500 mg or 
less 
750 mg or 
less 
SODIUM VALPROATE 1.5 g 375 mg or less 
750 mg or 
less 
1125 mg 
or less  
LAMOTRIGINE 0.3 g 75 mg or less  
150 mg or 
less 
225 mg or 
less 
PHENYTOIN 0.3 g 75 mg or less  
150 mg or 
less 
225 mg or 
less 
OXCARBAZEPINE 1 g 250 mg or less 
500 mg or 
less 
750 mg or 
less 
TOPIRAMATE 0.3 g 75 mg or less  
150 mg or 
less 
225 mg or 
less 
GABAPENTIN 1.8 g 450 mg or less 
900 mg or 
less 
1350 mg 
or less 
LEVETIRACETAM 1.5 g 375 mg or less 
750 mg or 
less 
1125 mg 
or less  
PREGABALIN 0.3 g 75 mg or less  
150 mg or 
less 
225 mg or 
less 
ZONISAMIDE 0.2 g 50 mg or less 
100 mg or 
less 
150 mg or 
less 
VIGABATRIN 2 g 500 mg or less 
1 g or less 1500 mg 
or less 
TIAGABINE 30mg 7.5 mg or less 
15 mg or 
less 
22.5 mg or 
less 
PHENOBARBITAL 0.1 g 25 mg or less 
50 mg or 
less 
75 mg or 
less 
PRIMIDONE 1.25 g 312.5 mg or less 
625 mg or 
less 
937.5 mg 
or less 
CLOBAZAM 20 mg 5 mg or less 10 mg or less 
15 mg or 
less 
ACETAZOLAMIDE 0.75 g 187.5 mg or less 
375 mg or 
less 
562.5 mg 
or less 
Table 13. Recommendations of the WHO for the daily defined dose (DDD) of AEDs along 
with 25%, 50% and 75% of the doses. 
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2.11. Limitations 
This study includes the following limitations: 
• As this study recruited all newly diagnosed patients who were referred to the 
Epilepsy Unit at the Western Infirmary, Glasgow and who started AED treatment 
between 1982 and 2005, there was no randomisation of the study population. 
• Patients included in the study were prescribed different AEDs to manage a 
particular seizure type.  This is due to the wide range of physicians in the Epilepsy 
Unit during the long period of study i.e. almost 26 years with different experiences 
and opinions in the diagnosis and management of this disease, and also due to the 
different criteria of the patients themselves. 
• Using seizure frequency is not a hundred percent reliable as it depends on the 
patient’s memory to record their seizures especially after a long period between 
clinic appointments that might reach up to 6 months. To make these recordings as 
accurate as possible, the patients were supplied with seizure description charts to 
record the number of seizures they develop along with the timing and description of 
these seizures.  Also it is advised that patients bring a witness of the seizure with 
them to the clinic.  Despite all these precautions, they are not successful at all times 
as the patients may forget to bring these charts at the clinic appointment or there 
was no witness when the seizure occurred.    
• It is not appropriate to compare the annual outcome of epilepsy of seven years of 
using older AEDs (before the introduction of new AEDs i.e. 1982 - 1988) to that of 
19 years (1989-2008) of using both older and modern AEDs since the Epilepsy 
Unit of Western Infirmary was established in 1982. However, the current project 
showed to be able to identify any changes that took place in the annual outcome of 
epilepsy before and after the introduction of second generation AEDs.  
• The exclusion of patients with poor compliance in order to make the study as 
accurate as possible has taken away many patients, which indicates that poor 
compliance is a characteristic of the normal population and therefore, excluding 
these patients does not make the study population actually represent the general 
population.   
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2.12. Inclusion / exclusion criteria 
2.12.1. Inclusion criteria 
• Only patients with confirmed diagnosis of epilepsy were included in this project.  
• This study included all newly diagnosed epilepsy patients. 
• These patients first started treatment with AEDs and were followed up at the 
Epilepsy Unit of the Western Infirmary, Glasgow. 
• Patients included in the study were those who were referred to the epilepsy clinic in 
the period from the 1st of July 1982 until the 30th December 2005.    
• Patients recruited had their treatment started in the Epilepsy Unit within the period 
from the 1st July 1982 until the 5th April 2006.  
2.12.2. Exclusion criteria 
• Patients with significant exposure to AEDs (other than rescue medication) prior to 
referral to the Epilepsy Unit were excluded. 
• Newly diagnosed patients who were started on AEDs at the unit before July 1982 
or after 5th April 2006 were not included in the study. 
• Patients known to be persistently non-compliant with treatment were excluded from 
the study. 
• Exclusion criteria included patients with pseudoseizures and those with dubious 
diagnosis.  
• Patients who were immediate responders on the last treatment regimen 
(monotherapy or polypharmacy) but the database was locked before completion of 
the 12 months period of seizure freedom were excluded form the study.  
• Deceased patients with a period of treatment less than 12 months.  
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• Patients who moved to another area during the period of follow up or were referred 
to another hospital for ease of transport (according to their wishes) were excluded 
because of the difficulty to assess their response to treatment once they are away if 
they have not been seen regularly in the clinic especially in case of seizures 
recurrence.   
2.13. Database construction 
Databases are created to be useful; they enable us to store, retrieve, analyse and summarise 
data.  Subsequently, results of any query can be obtained and presented. As mentioned 
earlier, the database applied in this study was built using Microsoft Access software, which 
employs relational databases in which the data stored are related and can be brought 
together whenever needed.  There are four main components of the Access databases:   
1. Tables: these are considered to be the building blocks of databases; they are used to 
store data and subsequently are employed for extraction of information required to 
achieve data analysis.  Therefore, caution should be taken when constructing these 
tables in order to ensure ease of data entry and accuracy of data analysis afterwards.  
All databases either contain one or more tables.  
2. Queries: the main benefits of using databases are the capability of answering 
questions and performing tasks on request, a function of the queries section. 
Queries can retrieve essential data from multiple tables and analyse them based on 
the design of a query in order to answer the question raised.  
3. Forms: these are used to control data entry and data views.  Sometimes, the tables 
used are large, thereby making it difficult to detect a small piece of information, 
therefore, using forms will allow the study to focus on what is really needed when 
entering or viewing data e.g. instead of showing the data obtained from all patients 
in one table, the forms section of the software can be used to show the required data 
of each patient individually.  Privacy can also be ensured when designing forms by 
selecting which fields can be viewed by other users. 
4. Reports: these are used to summarise and print data of the database.  
All the data obtained in this study were distributed into six different tables:  
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1. “Demography” table: this table was designed to collect demographic data of the 
patients, clinical history, investigations and relapse details (Table 14).   
2. “Outcome” table: in which details were collected regarding the progress of patient 
treatment after 2, 5, 10 and 15 years of follow up.  This information includes: 
number of treatment regimens applied, current type of treatment (monotherapy or 
combined therapy), current AED/ AED combination used and seizure status (Table 
15).  
3. “Therapy” table: this table is concerned with all the details of each AED/ AED 
combination prescribed.  These details include: type of treatment (monotherapy or 
combined therapy), date of starting treatment, AED/ AED combination applied, 
starting dose, serum concentration after starting dose, maximum dose, serum 
concentration after maximum dose, side effects, response on maximum tolerated 
dose and any comments on that particular treatment regimen.  These details were 
collected in each treatment regimen applied to the patients. The maximum number 
of regimens applied in this study was nine (Table 16).   
4. “Last regimen” table: that includes details on the last AED/ AED combination 
applied to the whole study population along with the generation to which they 
belong and the ultimate outcome of epilepsy (Table 17).  
5. “Daily defined doses” table: this table contains all the required information on the 
doses of AEDs applied by all the recruited patients in all treatment regimens.  In 
those patients with ongoing seizures, failure of treatment was categorised into 
either, a lack of efficacy or poor tolerability.  These calculations were performed at 
25%, 50% and 75% of the daily defined doses based of the WHO recommendations 
(Table 18).  
6. “Length to seizure freedom” table: this table in only concerned with patients who 
achieved complete seizure control as an ultimate outcome of epilepsy by the end of 
study.  It includes details on the duration (in months) required by this group of 
patients to reach seizure freedom. These include: date of starting treatment, date of 
starting seizure freedom, the period (in months) required to reach seizure freedom, 
date of last visit, the period (in months) between starting seizure freedom and last 
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clinic visit and responder classification (immediate or delayed responders) (Table 
19).    
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Name 
File number 
Date of birth 
Gender 
Intellectual status 
Referral date 
Demographic data 
Date of last visit 
 
Alcohol abuse 
Drug abuse 
Birth injury 
Family history of epilepsy 
Febrile seizures 
Other medical problems 
History 
Neurological deficit & cause 
 
Electroencephalography (EEG) 
Magnetic resonance imaging (MRI) 
Brain computed tomography (Brain CT scan) 
Investigations 
Other Imaging  
 
Date of first seizure 
Epilepsy classification 
Epilepsy syndrome 
Seizure type 
Multiple seizure types 
Seizure free period 
Date of starting reseizure (if relapsed) 
Action before relapse 
Action after relapse 
Seizure details 
Remission again? 
Table 14. Data collected in the "demography table" of the database. 
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Unit number 
Referral date 
Date of starting treatment 
Date of last visit 
Months required to reach first 
seizure freedom period  
Months required to reach second 
seizure freedom period   
Months required to reach third 
seizure freedom period   
Months required to reach forth 
seizure freedom period   
General information 
Months required to reach fifth 
seizure freedom period   
 
Number of regimens applied 
Current regimen type (monotherapy 
or combined therapy)   
AED/ AEDs combination  
Outcome at 2 years 
Seizure status 
Number of regimens applied 
Current regimen type (monotherapy 
or combined therapy)  
AED/ AEDs combination 
Outcome at 5 years 
Seizure status 
Number of regimens applied 
Current regimen type (monotherapy 
or combined therapy)  
AED/ AEDs combination 
Outcome at 10 
years 
Seizure status 
Number of regimens applied 
Current regimen type (monotherapy 
or combined therapy)  
AED/ AEDs combination 
Outcome 
Outcome at 15 
years 
Seizure status  
Table 15. Data collected in the "outcome table" of the database. 
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Unit number 
Outcome 
Number of regimens applied 
General information  
Type of treatment among all 
regimens applied (monotherapy or 
polypharmacy)  
 
Existing AED/ AEDs combination  
New AED/ AEDs combination  
Type of treatment (monotherapy or 
polypharmacy) 
Date of starting new treatment 
Starting dose 
Serum level (on starting dose) 
Maximum dose 
Serum level (on maximum dose) 
Maximum tolerated dose   
Response on maximum tolerated dose  
Treatment regimen 
(starting from first 
until ninth regimen) 
Side effects 
Table 16. Data collected in the "therapy table" of the database. 
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Unit number 
Outcome General information 
Number of regimens 
 
Last regimen type 
Last regimen AED/s 
combination 
Last treatment regimen 
details 
Generation of last regimen 
AED/s combination  
Table 17. Date collected in the "last regimen table" of the database. 
 
 
 
Unit number 
General information 
Outcome 
 
AED 
Maximum tolerated dose 
Response on maximum tolerated dose  
Type of treatment failure on 25% of DDD 
(LOE or PT)  
Type of treatment failure on 25% of DDD 
(LOE or PT)  
Treatment regimen 
(starting from first until 
ninth regimen) 
Type of treatment failure on 25% of DDD 
(LOE or PT)  
Table 18. Data collected in the "daily defined doses (%) table" of the database; DDD: daily 
defined dose, LOE: lack of efficacy, PT: poor tolerability.  
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Unit number 
Date of birth 
Sex 
Age 
General information 
Responders classification 
 
Date of starting treatment  
Date of last visit 
Comments on patients details on 
last clinic visit 
Period (in months) between 
starting seizure freedom and last 
clinic visit 
Date of starting seizure freedom 
Details on length to seizure 
freedom 
Months required until starting 
seizure freedom 
Table 19. Data collected in the "length to seizure freedom table” of the database.  
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3.1. General Overview 
3.1.1. Demography 
Among 1502 patients referred to the Epilepsy Unit during the period from July 1982 till 
December 2005, 1098 patients (73%) met the inclusion criteria and were recruited in the 
study. The remaining 404 (27%) were excluded mainly due to either poor compliance (n = 
107) or because treatment was started before referral to the unit (n = 95) or there was not 
enough details in the case records on the treatment given to patients (n = 68). Patients 
recruited had a minimum period of follow up of two years and 26 years as the maximum 
(median 8 years, IQR 5 to 12). The ages of study population were between 9 and 93 years 
old when started their treatment at the Unit (median 32 years, IQR was from 20 to 51). 575 
of the study population were males (52 %) and 523 were females (48 %).  
3.1.2. AED regimens 
Based on the regimens of AEDs taken by the patients of study population, Table 20 and 
Flow Chart 1 were constructed showing the flow of patients throughout the study from one 
regimen to the next according to their response to that regimen (percentage outcome on 
each regimen). In table 20, (n) represents number of patients with ongoing seizures or 
relapses who went on to treatment with a new regimen after failure of the previous regimen 
either due to lack of efficacy or poor tolerability, except in the first regimen in which (n) 
represents the total number of patients recruited in the study. For a number of reasons, 
some patients who were not controlled on a particular regimen did not proceed to a further 
treatment option. Therefore, the number of patients who started a new regimen was always 
lower than those who did not respond to AED/ AED combination treatment on the 
previous regimen. Table 20 also demonstrates the percentage developing seizure freedom 
on each particular treatment regimen; patients in their first ever AED treatment had the 
highest rate of achieving complete seizure control compared to the subsequent schedules. 
Information on patients on monotherapy and polypharmacy (combined therapy) along with 
their response in each treatment regimen is shown in the flow chart (Flow Chart 1).    
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Regimen n 
Responders  
(%) 
Non-responders 
First 1098 544 (50%) 554 
Second 398 146 (37%) 252 
Third 168 41 (24%) 127 
Fourth 68 11 (16%) 57 
Fifth 32 4 (13%) 28 
Sixth 16 2 (13%) 14 
Seventh 9 2 (22%) 7 
Eighth 3 0 3 
Ninth 2 0 2 
Table 20. Flow of patients throughout the study regarding treatment regimens applied along 
with rates of seizure freedom in each regimen.  
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Flow Chart 1. Patients’ response to AEDs treatment regimens including monotherapy 
(mono) and polypharmacy (poly). 
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The chance to develop complete seizure freedom on the first ever treatment with AEDs 
was also the highest when I compared the rates of response to AEDs based on outcome of 
each individual regimen independent of other regimens i.e. those patients who continued 
with their particular AED treatment regimen until either reaching complete seizure control 
or continuing seizures that necessitated moving to the subsequent regimen (Table 21 and 
Figure 2). The highest response in the first regimen was followed by a gradual reduction in 
response rate with the subsequent treatment regimens.  
 
 
Regimens n 
Responders 
(%)  
Non-responders 
Patients in first regimen only  700 544 (78%) 156 
Patients in second regimen only 230 146 (63%) 84 
Patients in third regimen only 100 41 (41%) 59 
Patients in fourth regimen only 36 11 (31%) 25 
Patients in fifth regimen only  16 4 (25%) 12 
Patients in sixth regimen only 7 2 (29%) 5 
Patients in seventh regimen only 6 2 (33%) 4 
Patients in eighth regimen only 1 0 1 
Patients in ninth regimen only  2 0 2 
Total 1098 750 348 
Table 21. Response of patients to each treatment regimen individually. 
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Figure 3. Response of patients to each treatment regimen individually.   
 
 
3.1.3. The first AED 
Of the 1098 patients recruited, 544 (50%) reached a state of seizure freedom on the first 
ever AED applied. In the first ever AED treatment, drugs with the highest prescription rate 
were lamotrigine (n = 372) followed by sodium valproate (n = 274) and carbamazepine (n 
= 224) with similar rates of response (53%, 53% and 51%, respectively); there was 
insignificant difference between these three drugs in terms of efficacy. Among these three 
agents, side effects leading to withdrawal of treatment were marginally more frequent with 
carbamazepine (13%) compared to sodium valproate (12%) and lamotrigine (10%), but 
statistical analysis did not show any significant difference regarding tolerability between 
these drugs.   
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 CBZ VPA LTG Others Total 
n 224 274 372 228 1098 
Responders 
on first 
regimen (%) 
115 (51%) 146 (53%) 196 (53%) 87(38%) 544 
Withdrawal 
rate due to 
side effects on 
first regimen 
(%) 
29 (13%) 34 (12%) 39 (10%) 55(24%) 157 
Table 22. Response to treatment with AEDs in the first regimen.  
 
 
3.1.4. Patterns of response 
Based on the response to AEDs of patients in this study, the analysis demonstrated three 
different patterns of response.  
1. Patients who managed to achieve complete seizure control by the end of study after 
having continuous ongoing seizures. They constituted 66% of the total study 
population (728). This group of patients had been prescribed either single AED 
treatment regimen or tried multiple regimens with either monotherapy or combined 
therapy until remission was obtained.  
2. Patients with intractable (continuing) seizures despite the application of multiple 
AED regimens as monotherapy or combined therapy. These patients were never 
able to achieve seizure freedom. They were 272 (25%).  
3. Patients with fluctuation of response to AED treatment. Sometimes, they have a 
period of seizure freedom that might reach up to 12 months or even longer then 
suddenly develop relapse with reappearance of seizures that last for a period of 
Chapter 3. Results.  106 
time, eventually, they either become seizure free again or continue with seizures. 
The situation will be different in other patients who have a period of ongoing 
seizures that might last up to several years despite using multiple treatment 
regimens and then develop a state of seizure freedom that lasts for at least 12 
months period. They either continue seizure free or relapse. In some cases, the 
patients might have multiple relapses after multiple periods of seizure freedom 
states. These patients constituted 98 (9%) of the total study population. 
3.1.5. Immediate responders 
Among patients who responded to the first AED treatment (544), a group developed 
seizure freedom immediately after starting treatment. This group constituted 24% (261 
patients) of the whole study population. As mentioned earlier in section 3.1.3, lamotrigine, 
sodium valproate and carbamazepine were prescribed more frequently in comparison to 
other agents (Figure 4). The response rate of these three drugs in the immediate responders 
showed lamotrigine to be associated with the highest efficacy (33%) followed by sodium 
valproate (28%) and carbamazepine (22%) with a significant difference noted (p-value = 
0.02).   
Among immediate responders with idiopathic generalised epilepsy (n = 74), sodium 
valproate was associated with the highest response rate (41%) followed by lamotrigine 
(35%) and carbamazepine (9%) (p-value < 0.001). In terms of immediate responders with 
focal epilepsy (n = 187), lamotrigine had the highest efficacy (32%) followed by 
carbamazepine (27%) and sodium valproate (22%) without any significant difference (p-
value = 0.1). Males had a higher immediate response rate than females on sodium 
valproate and carbamazepine while females demonstrated a higher response than males 
which treated with lamotrigine (Table 23).  
This group of patients was maintained on relatively moderate doses of AEDs. Ages of 
these patients were between 10 and 93 years with a median of 32. This group of patients 
had a median period of follow up 8 years.    
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 LTG VPA CBZ Others Total 
Immediate 
responders on 
first regimen (%) 
86 (33%) 72 (28%) 58 (22%) 45 261  
Idiopathic 26 (35%) 30 (41%) 7 (9%) 11 74 
Focal 60 (32%) 42 (22%) 51 (27%) 34 187 
Male / Female 34 / 52 54 / 18 35 / 23 29 / 16 152 / 109 
Dosing median 
(mg/day)  
150           
(25–200) 
1000        
(300–1500) 
400       
(100–1000) 
- - 
Median age 
(range) on 
starting 
treatment (years) 
32 (10 – 93)  
Median period 
(range) of follow 
up (years) 
 8 (2 – 25) 
Table 23. Characteristics of immediate responders (n = 261).   
 
 
  
33%
22%
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6%
3%
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0.70%
0.30%
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Oxc (n=11)
Tpm (n=8)
Tgb (n=2)
Pht (n=1)
 
Figure 4. AEDs taken by immediate responders (n = 261).         
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3.2. Factors with potential to influence the outcome of 
epilepsy 
The number of patients who achieved complete seizure freedom (responders) by the end of 
study was 750 (68%) while the non-responders (relapsed patients and those with refractory 
seizures) were 348 (32 %) (Table 24).   
 
 
The study 
population  
(n= 1098) 
Responders 
(n= 750) 
Non-responders  
(n= 348)  
Demographic description 
Male / Female  575 / 523 411 / 339 164 / 184 
Median age on starting 
treatment (years) 
32  
(range 9 - 93) 
32  
(range 9 - 93) 
33  
(range 12 – 81) 
Median period of follow up 
(years) 
8  
(range 2 – 26) 
8  
(range 2 - 26) 
8  
(range 2 - 24) 
Epilepsy classification 
Idiopathic 251 182 69 
Cryptogenic 400 286 114 
Symptomatic 447 282 165 
Treatment details 
Median number of regimens 
1  
(range 1 – 9) 
1  
(range 1 – 7) 
 2  
(range 1 – 9) 
Monotherapy / 
Polypharmacy 
913 / 185 680 / 70 233 / 115 
Table 24. Comparison between responder and non-responder patients regarding several 
aspects. 
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The outcome of epilepsy was analysed in relation to two categories of factors: 
pharmacological and non-pharmacological.   
3.2.1. Non-pharmacological factors 
3.2.1.1. Gender 
Among all male patients of the study population (575), 411 (71%) developed complete 
seizure freedom by the end of study. The figure was lower in females in whom responders 
to AEDs were 339 (65%) against 184 (35%) non-responders (Figure 5). In terms of 
statistical analysis, a significant difference was noticed between males and females 
regarding the outcome of epilepsy (p-value = 0.018).   
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Figure 5. Outcome of epilepsy vs. gender.  
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3.2.1.2. Age groups 
Dividing the study population according to the age of patients on starting treatment with 
AEDs resulted in eight groups. The response rate to AED treatment was relatively high in 
patients aged less than 20 years old (72%); this was followed by a gradual decline in 
response rate until it reaches the minimum in patients with age between 40 and 49 years 
(52%), after which, the response rate shows a gradual elevation again until it reaches the 
highest rate in patients with age 80 years or older (96%) (Table 25 and Figure 6).   
 
 
 
Age group  
(years) 
N 
Responders  
(%) 
Non-responders 
(%)  
< 20 241 173 (72 %) 68 (28 %) 
20 – 29 243 169 (70 %) 74 (30 %) 
30 – 39 176 112 (64 %) 64 (36 %) 
40 – 49 144 75 (52 %) 69 (48 %) 
50 – 59 118 77 (65 %) 41 (35 %) 
60 – 69 86 63 (73 %) 23 (27 %) 
70 – 79 67 59 (88 %) 8 (12 %) 
≥ 80 23 22 (96 %) 1 (4 %) 
Total 1098 750 348 
Table 25. Outcome of epilepsy vs. age groups of patients.  
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Figure 6. Outcome of epilepsy vs. age groups of patients.
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In the group of patients (≥ 65 years old), there were 122 patients aged between 65 and 93 
years old. Among these, 106 patients developed complete seizure freedom (87%) by the 
end of study while 16 did not. Out of the responders (106), 75 patients (61%) achieved 
seizure freedom state while on the first AED treatment regimen. In terms of epilepsy 
classification, 118 (97%) of this age group patients had focal epilepsy compared to 4 
patients (3%) with idiopathic generalised epilepsy. Responders to monotherapy were 101 
(95%) compared to only 5 patients (5%) who developed complete seizure control on 
combined therapy.    
3.2.1.3. Years of referral 
By distributing the patients included in this study according to their years of referral to the 
Epilepsy Unit, 24 groups of patients were developed, representing the period from 1982 
until 2005 (Table 26). In general, the number of patients referred to the unit showed a 
pattern of gradual elevation from 1982 (4 patients) until 2005 (77 patients). Obviously, the 
duration of follow up is decreased as the years of referral become more recent. In terms of 
the percentage achieving a complete seizure control, this ranged between 59% and 90% 
except for those years characterized by very low numbers of patients referred.   
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Year of 
referral 
N 
Responders 
(%)  
Non-
responders 
1982 4 4 (100 %) 0 
1983 2 2 (100 %) 0 
1984 6 4 (67 %) 2 
1985 14 9 (64 %) 5 
1986 11 7 (64 %) 4 
1987 2 2 (100 %) 0 
1988 10 9 (90 %) 1 
1989 14 11 (79 %) 3 
1990 31 22 (71 %) 9 
1991 24 19 (79 %) 5 
1992 30 21 (70 %) 9 
1993 30 24 (80 %) 6 
1994 51 32 (63 %) 19 
1995 69 46 (67 %) 23 
1996 73 50 (68 %) 23 
1997 46 32 (70 %) 14 
1998 58 34 (59 %) 24 
1999 66 48 (73 %) 18 
2000 87 67 (77 %) 20 
2001 89 59 (66 %) 30 
2002 83 58 (70 %) 25 
2003 122 84 (69 %) 38 
2004 99 63 (64 %) 36 
2005 77 43 (56 %) 34 
Total  1098 750 (68 %) 348 
Table 26. Outcome of epilepsy vs. years of patients' referral. 
 
 
The whole study population was subsequently divided based on years of referral into three 
groups with similar numbers of patients. The first group comprised patients referred to the 
Epilepsy Unit in the period from 1982 to 1996, the second group had patients referred 
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between 1997 and 2001. Those patients referred between 2002 and 2005 represented the 
third group (Table 27 and Figure 7).   
 
Period of 
referral 
n 
Responders 
(%) 
Non-
responders 
1982 - 1996 371 262 (71 %) 109 
1997 - 2001 346 240 (69 %) 106 
2002 - 2005 381 248 (65 %) 133 
Total  1098 750  348 
Table 27. Outcome of epilepsy vs. periods of referral. 
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Figure 7. Outcome of epilepsy vs. periods of referral.   
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The group with the most recent range of referral years had the lowest remission rate (65%) 
compared to the group that constituted the oldest range of years of referral (Table 27 and 
Figure 7). There was insignificant difference between the three groups regarding remission 
rate (p-value = 0.2).   
3.2.1.4. Type of epilepsy 
Based on the aetiology of epilepsy, patients were divided into two groups i.e. idiopathic 
and focal epilepsy. Focal (localization related) epilepsy was further subdivided into 
cryptogenic and symptomatic epilepsy. Patients with symptomatic epilepsy had the lowest 
rate of developing complete seizure freedom after treatment with AEDs (63%). Rate of 
achieving complete seizure control was similar in the other two groups i.e. idiopathic and 
cryptogenic epilepsy (73% and 72 % respectively) and higher than symptomatic epilepsy. 
There was a statistically significant difference between these three groups in terms of 
achieving seizure freedom (p-value = 0.008). By distributing the patients into the two 
major groups i.e. idiopathic and focal epilepsy, focal epilepsy showed a lower response 
rate to AEDs (67%) compared to idiopathic epilepsy (73%). Insignificant statistical 
difference was detected between these two major groups of epilepsy regarding developing 
complete seizure control state (p-value = 0.1).   
3.2.2. Pharmacological factors 
3.2.2.1. Type of treatment with AEDs 
With regard to type of treatment with AEDs i.e. monotherapy or polypharmacy (combined 
therapy), 50% of responders to AEDs were on monotherapy in the first treatment regimen. 
There was a gradual decline in the rate of developing seizure freedom in the subsequent 
treatment schedules (Table 28). Statistical analysis showed a significant difference 
between these groups of treatment regimens with regard to developing seizure freedom (p-
value = 0.03).   
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Treatment 
regimens 
N 
Responders on 
monotherapy (%) 
Non-responders 
on monotherapy 
First  1098 544 (50%) 554 
Second 254 101 (40%) 153 
Third 64 26 (41%) 38 
Fourth 17 6 (35%) 11 
Fifth 3 1 (33%) 2 
Sixth 3 1 (33%) 2 
Seventh 2 1 (50%) 1 
Eighth 0 0 0 
Ninth 1 0 1 
Table 28. Response to sequential monotherapies. 
 
Patients on polypharmacy had a similar pattern of response with a 31% response rate in the 
second regimen followed by a dramatic reduction until the last regimen (Table 29). A 
statistical difference was noticed between these schedules of combined therapy and rate of 
seizure freedom (p-value = 0.0006). This might indicate that in some patients, treatment 
with polypharmacy was better than sequential monotherapy.  
Treatment 
regimens 
N 
Responders on 
polypharmacy (%) 
Non-responders on 
polypharmacy 
First  - - - 
Second 144 45 (31%) 99 
Third 104 15 (14%) 89 
Fourth 51 5 (10%) 46 
Fifth 29 3 (10%) 26 
Sixth 13 1 (8%) 12 
Seventh 7 1 (14%) 6 
Eighth 3 0  3 
Ninth 1 0  1 
Table 29. Response to sequential polypharmacies. 
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3.2.2.2. Mechanism of action of AEDs 
In an attempt to detect any possible correlation that might exist between the rate of 
developing seizure freedom in epilepsy patients and the mechanisms of actions by which 
AEDs work, AEDs applied by patients in this study in their last monotherapy regimen 
were initially divided into five groups based on their primary mechanisms of action i.e. 
blockade of sodium channels, blockade of calcium channels, potentiation of potassium 
channels, potentiation of GABA inhibitory mechanism and inhibition of glutamate 
excitatory mechanism. Subsequently, based on the number of patients taking each AED in 
their last monotherapy regimen of the study, these groups were reduced to two: blockade 
of sodium channels and potentiation of GABA inhibitory mechanism. Other mechanisms 
were not included in the analysis as they were represented by a small number of patients 
taking AEDs working primarily by other mechanisms of action. AEDs with primary action 
on sodium channels include carbamazepine, phenytoin, lamotrigine and oxcarbazepine. On 
the other hand, AEDs that act mainly through the potentiation of GABA inhibitory effect 
are clobazam, phenobarbital, tiagabine, sodium valproate and vigabatrin.  
74% of patients developed seizure freedom while being on AEDs acting mainly by 
blockade of sodium channels against 76% for those on drugs mainly acting by potentiation 
of GABA inhibitory mechanism without any statistical significant difference between them 
with regard to the ultimate outcome of epilepsy (p-value = 0.4) (Fig 8).   
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Figure 8. Outcome of epilepsy vs. mechanisms of action of AEDs. 
 
 
It is believed that AEDs working by the same primary mechanism of action will lead to the 
same drug response regardless of the number of times they have been prescribed to a 
particular patient i.e. changing the AED but the main mechanism of action remains the 
same. The following analysis was performed on AEDs working by blockade of sodium 
channels as the main mechanism of action (carbamazepine, lamotrigine, oxcarbazepine and 
phenytoin) using treatment regimen failure on 50% of the daily-defined dose due to lack of 
efficacy as an indicator. There were 31 attempts to use sodium channels blockers after 
failure initially using another agents working primarily by the same mechanism of action. 
Out of these 31 attempts, seizure freedom was achieved in 12 cases while 15 cases failed 
that regimen again due to lack of efficacy. The remaining 4 cases had failure of treatment 
due to poor tolerability. AEDs acting primarily by potentiation of GABA (sodium 
valproate, vigabatrin, tiagabine, phenobarbital and clobazam) were used 10 times after they 
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have been applied initially with unsuccessful results. Out of these, seizure freedom was 
achieved in 6 cases while the regimen failed due to lack of efficacy in 4 cases.   
3.2.2.3. Generations of AEDs 
Among the total study population of this project (n =1098), 913 patients were taking AED 
monotherapy at the last clinic visit and out of these, 680 patients (61.9%) reached a state of 
complete seizure control. In order to detect any significant correlation between generations 
of AEDs and the ultimate outcome of epilepsy, these monotherapy patients were divided in 
two groups according to the generation of AEDs they were using on their last visit and then 
were subsequently further categorized in two further subgroups based on the outcome of 
epilepsy. The remission rates of patients on first and second generations AEDs were found 
to be exactly the same i.e. 31% of the population in each subgroup.   
185 patients were on combined therapy (polypharmacy) on their last clinic appointment. 
Out of these, 70 patients (6.4%) achieved seizure freedom. In order to demonstrate any 
significant difference between first and second generations AEDs in terms of the outcome 
of epilepsy, patients on combined therapy were divided in three groups based on 
generations of AEDs included in each combination of AEDs i.e. a combination of first 
generation drugs, a combination of second generation drugs and a combination of both first 
and second generations AEDs. Analysis showed a response rate of 25% among those 
patients who had a combination of first generation drugs in their last visit to the epilepsy 
clinic (n = 4). In those patients with a combination of second generation agents, the 
response rate was 28% (n = 54) while those with a combination of both generations had the 
highest remission rate of 43% (n = 127) (Flow Chart 2). Unfortunately, the low number of 
patients on combination of first generation agents (n = 4) has limited the ability to compare 
with the other two groups. This kind of analysis was not possible in patients in their first 
treatment regimen as all epilepsy patients on their first treatment regimen are prescribed 
AED treatment on monotherapy basis.    
Adding responder patients on monotherapy on the last clinic visit with those responders on 
combined therapy resulting in a total remission rate of 750 patients (68.3%) in this study.   
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Flow Chart 2. Response rate to type of treatment at the last clinic visit among the two 
generations of AEDs.    
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3.3. Factors with potential to influence the effectiveness 
of AEDs 
This section examines any potential correlation between the response (efficacy and 
tolerability) of individual AEDs included in the study in relation to various 
pharmacological and non-pharmacological issues.  
3.3.1. Effectiveness among individual AEDs and generations 
Among all the patients recruited to this study, 750 developed complete seizure freedom. Of 
these, 680 (62%) had remission using a single AED treatment (monotherapy). In total, 
there were 1442 attempts to use AEDs as monotherapy in patients in this study, of which 
680 were successful. Among individual AEDs, agents with the highest prescription rate 
were identified and their efficacy calculated. These included (in descending order of 
efficacy): levetiracetam (65%), topiramate (53%), carbamazepine (50%), sodium valproate 
(49%), lamotrigine (49%) and oxcarbazepine (43%). The remaining AEDs were taken by 
only a small number of patients. Among these agents, a significant statistical difference 
was observed in terms of their efficacy to eliminate seizures (p-value < 0.001) (Table 30 
and Figure 9). Focusing on the three most commonly prescribed agents, these included 
lamotrigine, sodium valproate and carbamazepine.  
By dividing AEDs applied in this study into two groups based on their generation, first and 
second generation AEDs showed almost the same total cumulative efficacy (49% and 50%, 
respectively) excluding unknown AEDs (in clinical trials) and rarely prescribed agents. 
Statistically, results showed insignificant difference between the first and second 
generations AEDs in terms of total cumulative efficacy (p-value = 0.6) (Table 30 and 
Figure 10).  
 
 
 
 
Chapter 3. Results.  123 
 
 
Regimens AED 1 2 3 4 5 6 7 8 9 Total Efficacy 
CBZ 115  (224) 
21  
(47) 
3  
(11) 
2  
(2) 0 0 0 0 0 
141 
(284) 50 % 
VPA 146  (274) 
47  
(115) 
3  
(12) 
1 
(3) 
0 
(1) 
1  
(1) 0 0 0 
198 
(406) 49 % 
PHT 4  (7) 
1  
(4) 
0 
(1) 0 0 0 0 0 0 
5 
(12) 42 % 
LTG 196  (372) 
21  
(59) 
8  
(18) 
0  
(6) 
1 
(1) 0 0 0 
0  
(1) 
226 
(457) 49 % 
GBP 14  (19) 
1  
(6) 
1 
(2) 0 0 
0 
(1) 0 0 0 
16 
(28) 57 % 
LEV 26  (42) 
0  
(1) 
6  
(7) 0 0 0 
1  
(1) 0 0 
33 
(51) 65 % 
TPM 24  (42) 
4  
(10) 
2  
(5) 
1  
(2) 0 0 0 0 0 
31 
(59) 53 % 
OXC 13  (31) 
6  
(12) 
3  
(8) 
2  
(4) 0 0 
0  
(1) 0 0 
24 
(56) 43 % 
TGB 5  (14) 0  0 0 0 0 0 0 0 
5 
(14) 36 % 
VGB 0 0 0 0 0 (1) 0 0 0 0 
0 
(1) 0 
ZNS 0 0 0 0 0 0 (1) 0 0 0 
0 
(1) 0 
Others 1  (73) 0  0 0 0 0 0 0 0 
1 
(73) 1 % 
Total of 
responders on 
monotherapy  
544 101 26 6 1 1 1 0 0 680 - 
Total of non-
responders on 
monotherapy 
554 153 38 11 2 2 1 0 1 - - 
n 1098 254 64 17 3 3 2 0 1 - - 
Table 30. Efficacy of AEDs in patients on monotherapy.  
Shaded rows represent first generation AEDs.  
 
 
In terms of the tolerability profile of AEDs, lamotrigine demonstrated the best tolerability 
with the lowest rate of withdrawal due to side effects of 11%, it was followed by 
carbamazepine and sodium valproate (13%), levetiracetam (14%) while topiramate and 
oxcarbazepine showed the worst tolerability profile with a rate of withdrawal of 20% 
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excluding AEDs taken by a small number of patients (Table 31 and Figure 9). There was 
not any significant difference between these AEDs and tolerability profile (p-value = 0.2).  
In order to detect any difference in the tolerability profile of AEDs among the two 
generations of these agents, the total cumulative tolerability of AEDs of each generation 
was calculated.  First and second generations had the same overall tolerability (13%) - 
excluding unknown AEDs (in clinical trials) and rarely prescribed agents - without any 
significant difference between them (Table 31 and Figure 10).    
 
 
Regimens AED 1 2 3 4 5 6 7 8 9 Total 
Rate of 
withdrawal  
CBZ 29 (224) 
8 
(47) 
1 
(11) 
0 
(2) 0 0 0 0 0 
38 
(284) 13% 
VPA 34 (274) 
17 
(115) 
1 
(12) 
0 
(3) 
0 
(1) 
0 
(1) 0 0 0 
52 
(406) 13% 
PHT 1  (7) 
1  
(4) 
0 
(1) 0 0 0 0 0 0 
2 
(12) 17 % 
LTG 39 (372) 
10 
(59) 
0 
(18) 
0 
(6) 
0 
(1) 0 0 0 
0 
(1) 
49 
(457) 11% 
GBP 2  (19) 
2  
(6) 
0 
(2) 0 0 
0 
(1) 0 0 0 
4 
(28) 14 % 
LEV 6  (42) 
1  
(1) 
0  
(7) 0 0 0 
0  
(1) 0 0 
7 
(51) 14 % 
TPM 9  (42) 
2  
(10) 
0  
(5) 
1  
(2) 0 0 0 0 0 
12 
(59) 20 % 
OXC 9  (31) 
1  
(12) 
1  
(8) 
0  
(4) 0 0 
0  
(1) 0 0 
11 
(56) 20 % 
TGB 3  (14) 0  0 0 0 0 0 0 0 
3 
(14) 21 % 
VGB 0 0 0 0 1 (1) 0 0 0 0 
1 
(1) 100 % 
ZNS 0 0 0 0 0 1 (1) 0 0 0 
1 
(1) 100 % 
Others 25  (73) 0  0 0 0 0 0 0 0 
25 
(73) 34 % 
Table 31. Withdrawal rate of AEDs due to side effects in patients on monotherapy.  
Shaded rows represent first generation AEDs.   
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Figure 9. Effectiveness of AEDs
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Figure 10. Effectiveness of AEDs among generations.  
 
 
 
 
3.3.2. Efficacy among AED combinations 
In the 1098 patients of this study, 356 attempts at AED combinations utilizing various 
agents were made. Out of these, 70 attempts were successful in bringing patients into a 
state of complete seizure freedom, 6.4% of the whole study population. Most of the 
combinations (311) comprised two AEDs. There were 311 attempts at double therapy and 
67 of these were successful (6.1% of the total study population). 37 attempts used 
combinations of three agents with two successful attempts, a remission rate of 0.2%.  
Quadruple therapy comprising 4 agents was attempted on 8 occassions and one was 
successful (remission rate of 0.1%) (Appendix 1).   
In terms of specific AED combinations, the combination with the highest prescription rate 
was valproate and lamotrigine (81 patients) with an efficacy of 40%, this was followed by 
lamotrigine and levetiracetam combination with a prescription rate of 27 patients and 
efficacy of 11%, then lamotrigine and topiramate combination (23 patients) with an 
efficacy of 26% (Table 32).  
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AED Combinations n Responders 
(%)  
Duo therapy 
VPA + LTG 81 32 (40%) 
LEV + 1AED 64 13 (20%) 
TPM + 1AED 46 11 (24%) 
CBZ + 1 AED 50 7 (14%) 
Other duo therapies 70 4 (6%) 
Triple therapy 
CBZ + GBP + TPM 5 1 (20%) 
VPA + TPM + LEV  1 1 (100%) 
Other triple therapy  31 0  
Quadruple therapy 
VPA + LTG + TPM + LEV 2 1 (50%) 
Other quadruple therapy  6 0 
Total  356 70 
Table 32. Efficacy among AEDs combinations. 
 
 
3.3.3. Effectiveness among age groups 
For all AEDs (monotherapy) applied in the first treatment regimen among various age 
groups of patients recruited in the study, there were minimal differences in the efficacy in 
age groups less than 60 years. After 60 years, there is a pattern of gradual elevation of the 
efficacy profile of AEDs as patients’ age increases until it reaches the maximum in patients 
with ages of 80 years or older. In terms of tolerability of AEDs in the first treatment 
regimen, similar values were noticed among all age groups, ranging from 9% to 17%. It 
was difficult to calculate the efficacy in the subsequent treatment regimens, as the timing 
of starting these regimens varied among patients (Table 33 and Figure 11). Insignificant 
statistical differences were noted in terms of efficacy and tolerability of AEDs regarding 
various age groups (p-value = 0.1 and 0.6, respectively).    
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Age groups (years) n Efficacy (%) Rate of 
withdrawal (%) 
< 20  241 119 (49%) 31 (13%) 
20 – 29 243 123 (51%) 38 (16%) 
30 – 39 176 82 (47%) 28 (16%) 
40 – 49 144 66 (46%) 13 (9%) 
50 – 59 118 53 (45%) 18 (15%) 
60 – 69 86 42 (49%) 15 (17%) 
70 – 79 67 43 (64%) 10 (15%) 
≥ 80 23 16 (70%) 4 (17%) 
Total  1098 544 157 
Table 33. Effectiveness of AEDs among age groups of patients in the first treatment 
regimen.  
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Figure 11. Effectiveness of AEDs among age groups of patients in the first treatment regimen.
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Out of the group of patients aged over 64 years (n = 122), 101 patients developed complete 
seizure freedom while on monotherapy compared to 5 patients on combined therapy. 
Among patients on monotherapy, carbamazepine (n = 40), sodium valproate (n = 35) and 
lamotrigine (n = 48) were the highest prescribed AEDs. Among these three agents, sodium 
valproate was the drug with the highest efficacy (77%) compared to carbamazepine (75%) 
and lamotrigine (69%) (Table 34). Statistical significant difference in efficacy could not be 
identified for these drugs (p-value = 0.6). Also in this group of patients, it was shown that 
first generation AEDs were more efficacious (77%) than second generation agents (56%) 
with a significant statistical difference (p-value = 0.007) (Table 34).  
With respect to the tolerability profile of AEDs in elderly patients and among the three 
most commonly prescribed agents i.e. sodium valproate, carbamazepine and lamotrigine, 
sodium valproate was the best tolerated drug with the lowest rate of withdrawal due to side 
effects (9%) followed by carbamazepine and lamotrigine (both 13%) (Table 35) without 
any significant difference (p-value = 0.8). A small difference in rate of withdrawal due to 
side effects between the first and second generations of AEDs was observed (13% and 
15%, respectively) without any significant difference (p-value = 0.7) (Table 35).  
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Regimens AED 1 2 3 4 5 6 7 8 9 Total Efficacy 
CBZ 24  (33) 
5 
(6) 0 
1 
(1) 0 0 0 0 0 
30 
(40) 75 % 
VPA 18  (24) 
8 
(10) 
1 
(1) 0 0 0 0 0 0 
27 
(35) 77 % 
PHT 2  (2) 0 0 0 0 0 0 0 0 
2 
(2) 100 % 
LTG 24  (39) 
8 
(8) 
1 
(1) 0 0 0 0 0 0 
33 
(48) 69 % 
GBP 1  (1) 0 
1 
(1) 0 0 0 0 0 0 
2 
(2) 100 % 
LEV 2  (3) 0 0 0 0 0 0 0 0 
2 
(3) 67 % 
TPM 2  (4) 0 0 0 0 0 0 0 0 
2 
(4) 50 % 
OXC 2  (9) 
0 
(1) 
1 
(1) 0 0 0 0 0 0 
3 
(11) 27 % 
Others 0  (7) 0  0 0 0 0 0 0 0 
0 
(7) 0 % 
Total of 
responders 
on 
monotherapy  
75 21 4 1 0 0 0 0 0 101 - 
Total of non-
responders 
on 
monotherapy 
47 4 0 0 0 0 0 0 0 - - 
n 122 25 4 1 0 0 0 0 0 - - 
Table 34. Efficacy of AEDs in elderly patients (≥ 65 years old) on monotherapy. 
Shaded rows represent first generation AEDs. 
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Regimens AED 1 2 3 4 5 6 7 8 9 Total 
Rate of 
withdrawal  
CBZ 5  (33) 
0 
(6) 0 
0 
(1) 0 0 0 0 0 
5 
(40) 13% 
VPA 3  (24) 
0 
(10) 
0 
(1) 0 0 0 0 0 0 
3 
(35) 9% 
PHT 0  (2) 0 0 0 0 0 0 0 0 
2 
(2) 100 % 
LTG 6  (39) 
0 
(8) 
0 
(1) 0 0 0 0 0 
0 
(1) 
6 
(48) 13% 
GBP 0  (1) 0 
0 
(1) 0 0 0 0 0 0 
0 
(2) 0 % 
LEV 0  (3) 0 0 0 0 0 0 0 0 
0 
(3) 0 % 
TPM 2  (4) 0 0 0 0 0 0 0 0 
2 
(4) 50 % 
OXC 3  (9) 
0 
(1) 
0 
(1) 0 0 0 0 0 0 
3 
(11) 27 % 
Others 0  (7) 0  0 0 0 0 0 0 0 
0 
(7) 0 % 
Table 35. Withdrawal rate of AEDs due to side effects in elderly patients (≥ 65 years old) on 
monotherapy.  
Shaded rows represent first generation AEDs. 
 
 
 
 
3.3.4. Effectiveness among gender 
Efficacy of all AEDs given as monotherapy was examined in relation to gender. In most 
AEDs used, the efficacy in males was found to be higher than in females although there 
was variability regarding the rate of AED prescription i.e. carbamazepine, sodium 
valproate, phenytoin and tiagabine showed a higher prescription rate in males in 
comparison to lamotrigine, topiramate, gabapentin and levetiracetam in which the females 
had a higher prescription rate. Males and females had the same prescription rate for 
oxcarbazepine (Table 36 and Figure 12). Among the three most commonly prescribed 
AEDs i.e. carbamazepine, sodium valproate and lamotrigine, sodium valproate showed a 
statistically significant gender-related difference of efficacy (p-value = 0.006). 
Calculations of the total cumulative efficacy of AEDs in this study in males and females 
showed a higher total efficacy in males (55%) in comparison to females (44%) with a 
significant statistical difference (p-value < 0.001).   
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In case of tolerability profiles, male patients tolerated AEDs better than females. For 
instance, out of 164 attempts of carbamazepine application in males, the rate of withdrawal 
due to side effects was 10% compared to 18% with females in which there were 120 
attempts. Rate of sodium valproate prescription was higher than for carbamazepine, it was 
applied in 243 male patients with a withdrawal rate due to side effects of 9%. Similar to 
carbamazepine, female patients on sodium valproate (n = 163) had a higher rate of 
withdrawal than males i.e. 18%. The same pattern was noticed with lamotrigine in which 
males had a rate of withdrawal due to side effects of 8% (n = 166) compared to 12% in 
case of females (n = 291) (Table 37 and Figure 13). Carbamazepine and sodium valproate 
showed statistically significant gender differences in tolerability (p-value = 0.03 and 0.006, 
respectively).  Based on cumulative tolerability males tolerated AEDs (9%) better than 
females (17%) with a statistically significant difference (p-value < 0.001).   
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Regi
men 
Gender CBZ VPA LTG OXC TPM PHT GBP LEV TGB VGB ZNS 
N 224 274 372 31 42 7 19 42 14 0 0 
Males 70 (135) 
102 
(178) 
81 
(143) 
9 
(15) 
16 
(23) 
2 
(5) 
4 
(7) 
17 
(23) 
4 
(8) 0 0 1st 
Females 45 (89) 
44 
(96) 
115 
(229) 
4 
(16) 
8 
(19) 
2 
(2) 
10 
(12) 
9 
(19) 
1 
(6) 0 0 
N 47 115 59 12 10 4 6 1 0 0 0 
Males 13 (27) 
26 
(60) 
10 
(18) 
4 
(7) 
1 
(1) 
1 
(2) 0 0 0 0 0 2nd 
Females 8 (20) 
21 
(55) 
11 
(41) 
2 
(5) 
3 
(9) 
0 
(2) 
1 
(6) 
0 
(1) 0 0 0 
N 11 12 18 8 5 1 2 7 0 0 0 
Males 0 (2) 
3 
(4) 
1 
(4) 
3 
(4) 
2 
(3) 0 0 
1 
(1) 0 0 0 3rd 
Females 3 (9) 
0 
(8) 
7 
(14) 
0 
(4) 
0 
(2) 
0 
(1) 
1 
(2) 
5 
(6) 0 0 0 
N 2 3 6 4 2 0 0 0 0 0 0 
Males 0 1 (1) 
0 
(1) 
0 
(1) 0 0 0 0 0 0 0 4th 
Females 2 (2) 
0 
(2) 
0 
(5) 
2 
(3) 
1 
(2) 0 0 0 0 0 0 
N 0 1 1 0 0 0 0 0 0 1 0 
Males 0 0 0 0 0 0 0 0 0 0 0 5th 
Females 0 0 (1) 
1 
(1) 0 0 0 0 0 0 
0 
(1) 0 
N 0 1 0 0 0 0 1 0 0 0 1 
Males 0 0 0 0 0 0 0 0 0 0 0 (1) 6th 
Females 0 1 (1) 0 0 0 0 
0 
(1) 0 0 0 0 
N 0 0 0 1 0 0 0 1 0 0 0 
Males 0 0 0 0 (1) 0 0 0 
1 
(1) 0 0 0 7
th
 
Females 0 0 0 0 0 0 0 0 0 0 0 
N 0 0 0 0 0 0 0 0 0 0 0 
Males 0 0 0 0 0 0 0 0 0 0 0 8th 
Females 0 0 0 0 0 0 0 0 0 0 0 
N 0 0 1 0 0 0 0 0 0 0 0 
Males 0 0 0 0 0 0 0 0 0 0 0 9th 
Females 0 0 0 (1) 0 0 0 0 0 0 0 0 
Males 
(Efficacy) 
83 
(164) 
51% 
132 
(243) 
54% 
92 
(166) 
55% 
16 
(28) 
57% 
19 
(27) 
70% 
3 
(7) 
43% 
4 
(7) 
57% 
19 
(25) 
76% 
4 
(8) 
50% 
0 
0 
(1) 
0% Total 
Females  
(Efficacy) 
58 
(120) 
48% 
66 
(163) 
40% 
134 
(291) 
46% 
8 
(28) 
29% 
12 
(32) 
38% 
2 
(5) 
40% 
12 
(21) 
57% 
14 
(26) 
54% 
1 
(6) 
17% 
0 
(1) 
0% 
0 
Table 36. Differences between gender in efficacy of all AEDs in all regimens.  
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Figure 12. Efficacy of AEDs vs. gender.
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Regi
men 
Gender CBZ VPA LTG OXC TPM PHT GBP LEV TGB VGB ZNS 
N 224 274 372 31 42 7 19 42 14 0 0 
Males 13 (135) 
16 
(178) 
12 
(143) 
2 
(15) 
3 
(23) 
1 
(5) 
1 
(7) 
2 
(23) 
1 
(8) 0 0 1st 
Females 16 (89) 
18 
(96) 
27 
(229) 
7 
(16) 
6 
(19) 
0 
(2) 
1 
(12) 
4 
(19) 
2 
(6) 0 0 
N 47 115 59 12 10 4 6 1 0 0 0 
Males 3 (27) 
6 
(60) 
2 
(18) 
0 
(7) 
0 
(1) 
0 
(2) 0 0 0 0 0 2nd 
Females 5 (20) 
11 
(55) 
8 
(41) 
1 
(5) 
2 
(9) 
1 
(2) 
2 
(6) 
1 
(1) 0 0 0 
N 11 12 18 8 5 1 2 7 0 0 0 
Males 0 (2) 
0 
(4) 
0 
(4) 
0 
(4) 
0 
(3) 0 0 
0 
(1) 0 0 0 3rd 
Females 1 (9) 
1 
(8) 
0 
(14) 
1 
(4) 
0 
(2) 
0 
(1) 
0 
(2) 
0 
(6) 0 0 0 
N 2 3 6 4 2 0 0 0 0 0 0 
Males 0 0 (1) 
0 
(1) 
0 
(1) 0 0 0 0 0 0 0 4th 
Females 0 (2) 
0 
(2) 
0 
(5) 
0 
(3) 
1 
(2) 0 0 0 0 0 0 
N 0 1 1 0 0 0 0 0 0 1 0 
Males 0 0 0 0 0 0 0 0 0 0 0 5th 
Females 0 0 (1) 
0 
(1) 0 0 0 0 0 0 
1 
(1) 0 
N 0 1 0 0 0 0 1 0 0 0 1 
Males 0 0 0 0 0 0 0 0 0 0 1 (1) 6th 
Females 0 0 (1) 0 0 0 0 
0 
(1) 0 0 0 0 
N 0 0 0 1 0 0 0 1 0 0 0 
Males 0 0 0 0 (1) 0 0 0 
0 
(1) 0 0 0 7
th
 
Females 0 0 0 0 0 0 0 0 0 0 0 
N 0 0 0 0 0 0 0 0 0 0 0 
Males 0 0 0 0 0 0 0 0 0 0 0 8th 
Females 0 0 0 0 0 0 0 0 0 0 0 
N 0 0 1 0 0 0 0 0 0 0 0 
Males 0 0 0 0 0 0 0 0 0 0 0 9th 
Females 0 0 0 (1) 0 0 0 0 0 0 0 0 
Males 
(Tolerability) 
16 
(164) 
10% 
22 
(243) 
9% 
14 
(166) 
8% 
2 
(28) 
7% 
3 
(27) 
11% 
1 
(7) 
14% 
1 
(7) 
14% 
2 
(25) 
8% 
1 
(8) 
13% 
0 
1 
(1) 
100
% Total 
Females  
(Tolerability) 
22 
(120) 
18% 
30 
(163) 
18% 
35 
(291) 
12% 
9 
(28) 
32% 
9 
(32) 
28% 
1 
(5) 
20% 
3 
(21) 
14% 
5 
(26) 
19% 
2 
(6) 
33% 
1 
(1) 
100% 
0 
Table 37. Differences between gender in tolerability of all AEDs in all regimens. 
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Figure 13. Tolerability of AEDs vs. gender.
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3.3.5. Effectiveness in idiopathic generalised epilepsy 
Patients recruited with idiopathic generalised epilepsy were 251, 182 of these became 
seizure free by the end of study while the remaining (69 patients) did not (Table 24). 164 
patients achieved remission while being on monotherapy and 18 were on polypharmacy.  
Analyzing the effectiveness of AEDs among patients with idiopathic generalised epilepsy, 
first generation AEDs showed a total cumulative efficacy of 58% in comparison to second 
generation agents that had a total efficacy of 48% excluding unknown AEDs (in clinical 
trials) and rarely prescribed agents. Insignificant statistical difference existed between first 
and second generation AEDs in terms of the total efficacy (p-value = 0.07). With respect to 
individual drugs, sodium valproate was the AED with the highest prescription and 
response rate as well among all first and second generations agents (59%) excluding AEDs 
applied by a small number of patients (Table 38 and Figure 14). Statistical investigation 
among the two commonly prescribed agents in this group of patients i.e. sodium valproate 
and lamotrigine showed a significant difference (p-value = 0.03).  
In patients with idiopathic generalised epilepsy, sodium valproate also demonstrated the 
best tolerability profile with the lowest rate of drug withdrawal due to side effects (9%) 
compared to 13% in case of lamotrigine without any significant statistical difference 
between them (p-value = 0.3). In addition, first generation AEDs had a total cumulative 
tolerability profile slightly better than second generation AEDs with a rate of withdrawal 
due to side effects of 10% compared to 15% in case of modern agents with a non- 
significant difference (p-value = 0.2) (Table 39 and Figure 14).   
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Idiopathic epilepsy (n=164) AED 1 2 3 4 5 6 7 8 9 Total Efficacy 
CBZ 12 (26) 
4 
(6) - 
1 
(1) - - - - - 
17 
(33) 52% 
VPA 55 (89) 
15 
(28) 
0 
(1) 
0 
(1) - - - - - 
70 
(119) 59% 
PHT 1 (1) 
1 
(1) - - - - - - - 
2 
(2) 100% 
LTG 49 (102) 
3 
(13) 
2 
(4) - - - - - - 
54 
(119) 45% 
GBP 1 (1) 
0 
(1) - - - - - - - 
1 
(2) 50% 
LEV 4 (5) 
0 
(1) 
4 
(5) - - - - - - 
8 
(11) 73% 
TPM 2 (4) 
1 
(4) - 
1 
(1) - - - - - 
4 
(9) 44% 
OXC 6 (8) 
0 
(1) 
1 
(1) - - - - - - 
7 
(10) 70% 
TGB 1 (6) - - - - - - - - 
1 
(6) 17% 
Others 0 (9) - - - - - - - - 
0 
(9) 0 
Total of 
responders 131 24 7 2 0 0 0 0 0 164 - 
n 251 55 11 3 0 0 0 0 0 - - 
Table 38. Efficacy of AEDs used as monotherapy among patients with idiopathic 
generalised epilepsy. 
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Idiopathic epilepsy (n=164) AED 1 2 3 4 5 6 7 8 9 Total 
Rate of 
withdrawal 
CBZ 4 (26) 
1 
(6) 0 
0 
(1) 0 0 0 0 0 
5 
(33) 15% 
VPA 9 (89) 
2 
(28) 
0 
(1) 
0 
(1) 0 0 0 0 0 
11 
(119) 9% 
PHT 0 (1) 
0 
(1) 0 0 0 0 0 0 0 
0 
(2) 0% 
LTG 14 (102) 
2 
(13) 
0 
(4) 0 0 0 0 0 0 
16 
(119) 13% 
GBP 0 (1) 
0 
(1) 0 0 0 0 0 0 0 
0 
(2) 0% 
LEV 1 (5) 
1 
(1) 
0 
(5) 0 0 0 0 0 0 
2 
(11) 18% 
TPM 2 (4) 
1 
(4) 0 
0 
(1) 0 0 0 0 0 
3 
(9) 33% 
OXC 1 (8) 
1 
(1) 
0 
(1) 0 0 0 0 0 0 
2 
(10) 20% 
TGB 1 (6) 0 0 0 0 0 0 0 0 
1 
(6) 17% 
Others 0 (9) - - - - - - - - 
0 
(9) 0% 
Table 39. Withdrawal rate due to side effects of AEDs used as monotherapy among patients 
with idiopathic generalised epilepsy. 
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Figure 14. Effectiveness of AEDs among patients with idiopathic generalised epilepsy.  
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3.3.6. Effectiveness in focal epilepsy 
There were 847 patients with focal epilepsy included in this study, 400 of whom had 
cryptogenic epilepsy (unknown aetiology) and 447 had symptomatic epilepsy with a 
defined aetiology.  Responders to AEDs among the two groups (cryptogenic and 
symptomatic epilepsy) comprised 568 patients, 279 did not achieve seizure freedom by the 
end of study (Table 24). Out of the 568, 516 patients achieved remission while being on 
monotherapy while the remaining (52) were on polypharmacy.   
Table 40 shows that 47% of patients with focal epilepsy achieved remission using older 
AEDs compared to 51% who were prescribed second generation AEDs - excluding 
unknown AEDs (in clinical trials) and rarely prescribed agents - with a non significant 
difference (p-value = 0.1). Lamotrigine was the AED with the highest prescription and 
response rates (51%) among all other AEDs (first and second generations) followed by 
carbamazepine (49%) and sodium valproate (45%), excluding AEDs taken by a small 
number of patients.  Statistical analysis showed insignificant difference between these 
three agents in terms of efficacy (p-value = 0.2) (Table 40 and Figure 15).  
The AED with the best tolerability profile was also lamotrigine with a rate of withdrawal 
due to side effects of 10% followed by carbamazepine (13%) and sodium valproate (14%) 
excluding AEDs taken by a small number of patients; there was insignificant difference 
between these drugs in terms of tolerability. A similar total cumulative tolerability profile 
was noted when the first and second generations of AEDs were compared (14% and 13% 
respectively) with an insignificant difference (p-value = 0.5) (Table 41 and Figure 15).  
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Focal epilepsy (n=516) 
AED 
1 2 3 4 5 6 7 8 9 
Total Efficacy 
CBZ 
103 
(198) 
17 
(41) 
3 
(11) 
1 
(1) 
- - - - - 
124 
(251) 
49% 
VPA 
91 
(185) 
32 
(87) 
3 
(11) 
1 
(2) 
0 
(1) 
1 
(1) 
- - - 
128 
(287) 
45% 
PHT 
3 
(6) 
0 
(3) 
0 
(1) 
- - - - - - 
3 
(10) 30% 
LTG 
147 
(270) 
18 
(46) 
6 
(14) 
0 
(6) 
1 
(1) - - - 
0 
(1) 
172 
(338) 51% 
GBP 
13 
(18) 
1 
(5) 
1 
(2) 
- - 
0 
(1) 
- - - 
15 
(26) 58% 
LEV 
22 
(37) 
- 
2 
(2) 
- - - 
1 
(1) 
- - 
25 
(40) 63% 
TPM 
22 
(38) 
3 
(6) 
2 
(5) 
0 
(1) 
- - - - - 
27 
(50) 54% 
OXC 
7 
(23) 
6 
(11) 
2 
(7) 
2 
(4) 
- - 
0 
(1) 
- - 
17 
(46) 
37% 
TGB 
4 
(8) 
- - - - - - - - 
4 
(8) 
50% 
VGB - - - - 
0 
(1) 
- - - - 
0 
(1) 
0% 
ZNS - - - - - 
0 
(1) 
- - - 
0 
(1) 0% 
Others 
1 
(64) 
- - - - - - - - 
1 
(64) 2% 
Total of 
responders 
413 77 19 4 1 1 1 0 0 516 - 
n 847 199 53 14 3 3 2 0 1 - - 
Table 40. Efficacy of AEDs used as monotherapy among patients with focal epilepsy. 
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Focal epilepsy (n=516) 
AED 
1 2 3 4 5 6 7 8 9 
Total 
Rate of 
withdrawal 
CBZ 
25 
(198) 
7 
(41) 
1 
(11) 
0 
(1) 
0 0 0 0 0 
33 
(251) 
13% 
VPA 
25 
(185) 
15 
(87) 
1 
(11) 
0 
(2) 
0 
(1) 
0 
(1) 
0 0 0 
41 
(287) 
14% 
PHT 
1 
(6) 
1 
(3) 
0 
(1) 
0 0 0 0 0 0 
2 
(10) 20% 
LTG 
25 
(270) 
8 
(46) 
0 
(14) 
0 
(6) 
0 
(1) 0 0 0 
0 
(1) 
33 
(338) 10% 
GBP 
2 
(18) 
2 
(5) 
0 
(2) 
0 0 
0 
(1) 
0 0 0 
4 
(26) 15% 
LEV 
5 
(37) 
0 
0 
(2) 
0 0 0 
0 
(1) 
0 0 
5 
(40) 13% 
TPM 
7 
(38) 
1 
(6) 
0 
(5) 
1 
(1) 
0 0 0 0 0 
9 
(50) 18% 
OXC 
8 
(23) 
0 
(11) 
1 
(7) 
0 
(4) 
0 0 
0 
(1) 
0 0 
9 
(46) 
20% 
TGB 
2 
(8) 
0 0 0 0 0 0 0 0 
2 
(8) 
25% 
VGB 0 0 0 0 
1 
(1) 
0 0 0 0 
1 
(1) 
100% 
ZNS 0 0 0 0 0 
1 
(1) 
0 0 0 
1 
(1) 100% 
Others 
22 
(64) 
0 0 0 0 0 0 0 0 
22 
(64) 34% 
Table 41. Withdrawal rate due to side effects of AEDs used as monotherapy among patients 
with focal epilepsy. 
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Figure 15. Effectiveness of AEDs among patients with focal epilepsy.   
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3.3.7. Effectiveness among various treatment regimens 
(sequence of prescription) 
Based on the calculations of individual AED efficacy and tolerability in various treatment 
regimens, it seems that the response to AEDs is a dynamic matter rather than constant 
because it varies based on the sequence of treatment regimen in which a particular AED 
has been applied. For instance, efficacy of carbamazepine when applied in the first 
treatment regimen (51%) was different from its efficacy in the remaining regimens (43%) 
(Table 42). The same issue was also noted for tolerability profiles e.g. tolerability to 
lamotrigine when prescribed in the first treatment regimen (10%) was different from its 
tolerability in the remaining regimens (12%) (Table 42). This variation in effectiveness of 
AEDs has been observed in most of the AEDs used in this study, the extent of variation 
tended to be bigger in case of efficacy in comparison with tolerability.   
 
 
 Efficacy  Tolerability 
AED 
First 
regimen 
Remaining 
regimens  
Total  
 First 
regimen 
Remaining 
regimens  
Total  
CBZ 51% 43% 50%  13% 15% 13% 
VPA 53% 39% 49%  12% 14% 13% 
LTG 53%
 
35%
 
49%
 
 10%
 
12%
 
11%
 
TPM 57% 41% 53%  21% 18% 20% 
OXC 42% 44% 43%  29% 8% 20% 
LEV 62%
 
78%
 
65%
 
 14%
 
11%
 
14%
 
Table 42. A comparison of efficacy and tolerability of AEDs among various treatment 
regimens. 
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3.3.8. Effectiveness of AEDs among dose ranges 
Recruited patients were categorized according to the last AED applied. AEDs with the 
highest prescription rate were selected which constituted six groups of patients using six 
AEDs; these included (in descending order) lamotrigine (n = 457), sodium valproate (n = 
406), carbamazepine (n = 284), topiramate (n = 59), oxcarbazepine (n = 56) and 
levetiracetam (n = 51). In responders, doses were categorized. Eventually, efficacy 
(cumulative percentages of patients with seizure freedom) was calculated for all doses 
categories for all six AEDs. In terms of tolerability of these AEDs, the common side 
effects leading to withdrawal of these agents were identified (Table 43) along with the 
doses at which most of the patients discontinued these drugs.  
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AED n Common side effects 
Lamotrigine 
49 
(457) 
Rash (43%), 
GI disturbance (22%),  
Irritability (13%),  
Headache (11%),  
Tiredness (11%). 
Sodium valproate  
52 
(406) 
Weight gain (31%), 
Tiredness (27%),  
Tremor (23%),  
GI disturbance (17%). 
Carbamazepine 
38 
(284) 
Rash (55%), 
Tiredness (29%),  
GI disturbance (11%). 
Topiramate 
12 
(59) 
Paraesthesia (67%),  
GI disturbance (50%), 
Word finding difficulty (25%), 
Weight loss (25%). 
Oxcarbazepine  
11 
(56) 
Tiredness (45%),  
Rash (36%), 
GI disturbance (18%). 
Levetiracetam 
7 
(51) 
Behavioral problems (57%),  
Headache (29%), 
Tiredness (29%).  
Table 43. Withdrawals from AEDs due to side effects along with the common side effects. 
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3.3.8.1. Lamotrigine 
Of patients who achieved seizure freedom while on monotherapy with lamotrigine (n = 
226), 94% developed remission while taking around two thirds or less (≤ 400 mg/day) of 
the maximum dose required for all the patients to reach a state of complete seizure control 
(≤ 600 mg/day). Among patients who discontinued lamotrigine due to side effects (n = 49), 
94% of these patients were found to be taking a dose of ≤ 300 mg/day, the daily defined 
dose of lamotrigine based on WHO recommendations (Figure 16).  
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Figure 16. Seizure freedom achieved on lamotrigine (n=226) and its rate of withdrawal due to 
side effects (n=49) among various dose ranges. 
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3.3.8.2. Sodium Valproate 
In case of sodium valproate, efficacy and tolerability followed an almost identical pattern 
in relation to dose ranges. 90% of the patients who developed complete seizure control on 
this drug (n =198) were taking around half or less (≤ 1500 mg/day) of the maximum dose 
required for all the patients on this drug to achieve remission (≤ 3000 mg/day). In terms of 
tolerability, 92% of patients who discontinued this AED due to side effects (n = 52) were 
also taking a dose of ≤ 1500 mg/day that is the recommended daily dose (Figure 17).   
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Figure 17. Seizure freedom achieved on sodium valproate (n=198) and its rate of withdrawal 
due to side effects (n=52) among various dose ranges.  
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 3.3.8.3. Carbamazepine 
Among patients who achieved remission while on monotherapy with carbamazepine (n = 
141), 92% were taking half or less than the maximum dose needed for all the patients on 
this drug to obtain seizure control i.e. ≤ 800 mg/day. Among patients who withdrew from 
carbamazepine due to side effects (n = 38), 97% of these patients were on a dose of 600 
mg/day or less which is around half of the WHO recommended daily defined dose 
(1000mg/day) (Figure 18).   
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Figure 18. Seizure freedom achieved on carbamazepine (n=141) and its rate of withdrawal 
due to side effects (n=38) among various dose ranges.   
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3.3.8.4. Topiramate 
In patients who achieved remission while on topiramate (n = 31), 600 mg/day was the 
maximum dose at which all responders had seizure freedom. 97% of this group of patients 
managed to obtain complete seizure control while on a dose as low as one third or less than 
that maximum dose i.e. ≤ 200 mg/day. All the patients (100%) who discontinued 
topiramate due to side effects (n = 12) were on a dose of ≤ 200 mg/day that is two thirds of 
the daily defined dose (300 mg/day) (Figure 19).   
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Figure 19. Seizure freedom achieved on topiramate (n=31) and its rate of withdrawal due to 
side effects (n=12) among various dose ranges.   
. 
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3.3.8.5. Oxcarbazepine 
The maximum dose of oxcarbazepine required for all patients to obtain remission was 
1500 mg/day. 96% of these patients were able to achieve seizure freedom while being 
applying three fourths or lower than that maximum dose i.e. ≤ 1200 mg/day. In terms of 
tolerability of oxcarbazepine, 91% of patients who discontinued this agent (n = 11) were 
taking a dose of ≤ 900 mg/day that is slightly lower than the recommended daily defined 
dose (1000 mg/day) (Figure 20).  
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Figure 20. Seizure freedom achieved on oxcarbazepine (n=24) and its rate of withdrawal due 
to side effects (n=11) among various dose ranges.   
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3.3.8.6. Levetiracetam 
Among patients who achieved remission while being on levetiracetam (n = 33), 91% of 
these patients were on a dose of ≤ 2000 mg/day that is two thirds of the maximum dose 
required for all patients on this drug to reach a state of complete seizure control. Among 
patients who discontinued levetiracetam due to side effects (n = 7), 86% were on a dose of 
≤ 1000 mg/day which is two thirds of the recommended daily defined dose (1500 mg/day) 
(Figure 21).  
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Figure 21. Seizure freedom achieved on levetiracetam (n=33) and its rate of withdrawal due 
to side effects (n=7) among various dose ranges.    
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3.4. Defining refractory epilepsy 
This study used a cut off point as 50% of the daily defined dose to be the limit below 
which the failure of treatment will be due to poor tolerability while above that level, failure 
would be due to lack of efficacy of the drug.  
After failure of the first treatment regimen with monotherapy due to lack of efficacy (n = 
347), the number of responders among those who applied the second regimen (n = 223) 
constituted 31% (n = 69). Patients in whom treatment had failed in the first regimen due to 
poor tolerability were 135, 104 of whom were started on the second regimen with a 
response rate of 45% (n = 47) (Table 44 and Flow Chart 3).  
In patients who failed of the first and second treatment regimens due to lack of efficacy 
and started on the third schedule (n = 70), the response rate was 19% (n = 13) compared 
20% (n = 6) in those who failed the first regimen due to lack of efficacy and second due to 
poor tolerability and then were started on their third schedule (n = 30).   
Failure of the first and second treatment regimens due to poor tolerability and starting on 
the third schedule (n = 12) was associated with a response rate of 25% (n = 3). In contrast, 
failure of the first regimen due to poor tolerability and the second due to lack of efficacy 
with starting the third schedule subsequently (n = 29) has resulted in a response rate of 
41% (n = 12) (Table 44 and Flow Chart 3).   
Unfortunately, the lower number of patients following the third treatment regimen has 
limited the capability to compare between the two different types of treatment failures.  
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Table 44. Failure of treatment despite reaching 50% of the daily defined dose.  
RES: responders, LOE: failure of treatment due to lack of efficacy, PT: failure of treatment 
due to poor tolerability. 
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Flow Chart 3. Failures of treatment due to lack of efficacy (LOE) and poor tolerability (PT) 
based on 50% of the daily defined dose.  
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Changing the cut off point to 25% of the daily defined dose resulted in an increase in the 
number of patients with failure of treatment regimens due to lack of efficacy while failure 
due to poor tolerability became lower compared to the 50% daily dose threshold.  
Analysis showed 41% of patients had failure of the first regimens due to lack of efficacy 
with a response rate in the second regimen of 34%, failure of the first regimen due to poor 
tolerability comprised 3% of the study population with a response rate in this group of 
patients of 50% (Table 45 and Flow Chart 4). 
The response rate of patients who failed two regimens due to lack of efficacy was 25% 
compared to 0% (nil) in those who failed two regimens due to poor tolerability. There were 
no patients who developed seizure freedom after treatment failures in the first regimen due 
to lack of efficacy and second regimen due to poor tolerability while on the opposite i.e. 
failure of the first regimen due to poor tolerability and second schedule due to lack of 
efficacy was associated with a response rate of 33% (Table 45 and Flow Chart 4).   
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Table 45. Failure of treatment despite reaching 25% of the daily defined dose.  
RES: responders, LOE: failure of treatment due to lack of efficacy, PT: failure of treatment 
due to poor tolerability. 
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Flow Chart 4. Failures of treatment due to lack of efficacy (LOE) and poor tolerability (PT) 
based on 25% of the daily defined dose.   
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When the cut off point was moved to 75% of the daily defined dose, there was a wider 
dose range of poor tolerability and consequently higher number of patients with failure of 
treatment due to poor tolerability. On the other hand, number of patients with failure of 
treatment due to lack of efficacy was lower than that in case when cut off is 50% of the 
daily defined dose.  
After failure of the first treatment schedule due to lack of efficacy (21%), the response rate 
in the second schedule was 29% compared to 42% response rate in the second regimen in 
case of failure of the first schedule due to poor tolerability (23%) (Table 46 and Flow Chart 
5).  
 Patients with failure of two treatment regimens due to lack of efficacy had a response rate 
of 13% in comparison to 39% response rate in case of patients with failure of two 
schedules due to poor tolerability. In case of failure of the first regimen due to lack of 
efficacy and second schedule due to poor tolerability, the response rate was 12% while it 
was 33% in the opposite sequence i.e. failure of the first regimen due to poor tolerability 
and second schedule due to lack of efficacy (Table 46 and Flow Chart 5).  
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Table 46. Failure of treatment despite reaching 75% of the daily defined dose.   
RES: responders,   LOE: failure of treatment due to lack of efficacy, PT: failure of treatment 
due to poor tolerability.  
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Flow Chart 5. Failures of treatment due to lack of efficacy (LOE) and poor tolerability (PT) 
based on 75% of the daily defined dose
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In this chapter, discussion focused initially on special populations i.e. age groups, gender, 
idiopathic generalised epilepsy and focal epilepsy, followed by consideration of the whole 
study population with regard to the ultimate outcome of epilepsy, AED response, dosage, 
mechanism of action, generations of AEDs and definition of drug resistant epilepsy.   
4.1. Age groups 
Calculation of the remission rate among various age groups of patients recruited in this 
study was performed at the end of the study based on age on starting AED treatment.  
Patients in the age group less than 20 years had a high remission rate followed by a gradual 
decline till it reached the minimum at age group (40-49). After the age of 50, there was an 
elevation of response rate as the age of epilepsy patients increases till it reached the highest 
in patients ≥ 80 years old.  Therefore, epilepsy patients in age groups older than 50 years 
tended to have a higher rate of seizure freedom compared to adults with age groups 
between 20 and 49 years old. Similar results were noticed by Brodie and Kwan who 
reported a dramatic elevation in the remission rate after the age of 50 years (Figure 22) 
(Brodie and Kwan, 2005).   
In order to be able to compare these results with other relevant studies, patients of this 
investigation have been redistributed into three major groups based on their age; 
adolescents (< 20 years old) with median follow up of 9 years, adults (between 20 and 64 
years old with median follow up of 8 years) and elderly patients (≥ 65 years old with 
median follow up of 9 years) (Table 47).   
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Patients 
groups 
Age 
(years) n 
Median 
follow up 
(years) 
Responders 
(%) 
Non-
responders  
(%) 
Adolescents < 20 241 9 173 (72 %) 68 (28 %) 
Adults 20 - 64 735 8 471 (64%) 264 (36%) 
Elderly ≥ 65  122 9 106 (87%) 16 (13%) 
Total  1098  750 348 
Table 47. Outcome of epilepsy among the three major age groups. 
 
 
Findings in table 47 are consistent with those of Mohanraj and Brodie from the same 
Epilepsy Unit but on a smaller population with shorter duration of follow up; patients were 
diagnosed with epilepsy and started their first ever AED treatment between July 1982 and 
May 2001 (Mohanraj and Brodie, 2006). They observed the same pattern of remission rate 
that is initially high in adolescents group of patients, with a drop in adults’ age group then 
an elevation again in elderly patients to reach its highest rate (Figure 23).  
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Figure 22. Remission rates among age groups (Brodie and Kwan, 2005).  
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Figure 23. A comparison of remission rates between A (Mohanraj and Brodie, 2006) and B 
(this study).  
 
 
The higher response rate in elderly patients might be explained by the low epileptogenicity 
of underlying cerebral lesions in these patients and the low risk of genetic predisposition 
for recurrent seizure activity or better compliance. Unfortunately, few randomized clinical 
trials are available to evaluate the efficacy and tolerability of individual AEDs in elderly 
patients with newly diagnosed epilepsy although it is an age group with amongst the 
highest incidence of epilepsy (Stephen and Brodie, 2000).   
When calculating the efficacy and tolerability of AEDs among age groups, only the first 
treatment regimen was employed because of the difficulty of performing these calculations 
in the subsequent regimens due to individual differences of starting each regimen among 
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patients. Also, as adolescent patients move toward adulthood and adults become elderly, 
this leads to overlapping results.  
 In the first treatment regimen of this study among the three age groups, adolescents and 
adults had similar total cumulative efficacy of drugs (49% and 48%, respectively) while - 
as in the case of the ultimate outcome of epilepsy - elderly patients with epilepsy showed 
the highest total cumulative efficacy of AEDs in the first schedule (61%) (Table 48). The 
variation in efficacy between these three age groups resulted in a significant statistical 
difference (p-value = 0.01). Minimal differences were observed in total cumulative 
tolerability of AEDs among the three age groups. Elderly patients showed a slightly lower 
tolerability (higher rate of withdrawal due to side effects) compared to the other two 
groups with insignificant difference (p-value = 0.7).   
The highest total cumulative efficacy of AEDs in elderly patients may be due to the same 
factors assumed to be responsible for the higher remission rate observed by the end of 
study in this group. These factors include better compliance, the low risk of genetic 
predisposition for recurrent seizures and the low epileptogenecity of underlying cerebral 
lesions.  
 
 
Patients 
groups 
Age 
(years) n 
Efficacy in first 
regimen (%) 
Tolerability in 
first regimen (%) 
Adolescents < 20 241 119 (49%) 31 (13%) 
Adults 20 – 64 735 350 (48%) 106 (14%) 
Elderly ≥ 65  122 75 (61%) 19 (16%) 
Total  1098 544 157 
Table 48. Effictiveness of all AEDs in the first regimen among the three major age groups. 
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Stephen and colleagues - defining remission as developing a minimum period of seizure 
freedom of at least 12 months - showed total cumulative efficacy of AEDs of 63% in the 
first AED treatment regimen in elderly patients with newly diagnosed focal epilepsy 
referred between 1982 and 2003, a value exactly the same as in this report (63%) (Stephen 
et al., 2006). They also showed a total cumulative tolerability of 12% in the first schedule 
compared to 16% in this study. AEDs with the highest prescription rate were the same in 
both studies; these included carbamazepine, sodium valproate and lamotrigine (Table 49) 
(Stephen et al., 2006). Based on the findings of Stephen et al., there was a total remission 
rate of 79% by the end of study, 93% of these had seizure freedom while on monotherapy 
and 7% on polypharmacy. This analysis showed a remission rate of 87% by the end of 
study, 96% of these patients developed seizure freedom on monotherapy and 4% on 
combined therapy.   
The higher total remission rate of this study (around 26 years of follow up) compared to 
Stephen and colleagues (2006) observations (with follow up of 24 years approximately) 
might indicate that the longer duration of patients follow up with consecutive AED 
treatment regimens will be associated with the higher chances of developing seizure 
freedom eventually even in terms of individual AEDs (Table 49).    
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AED A B 
Carbamazepine 
N 39 33 
Efficacy (%) 26 (67%) 24 (73%) 
Tolerability (%) 5 (13%) 5 (15%)  
Sodium valproate 
N 23 23 
Efficacy (%) 15 (65%) 17 (74%) 
Tolerability (%) 2 (9%) 3 (13%) 
Lamotrigine 
N 35 30 
Efficacy (%) 22 (63%) 20 (67%) 
Tolerability (%) 6 (17%) 5 (17%) 
Table 49. Effectiveness of the three commonly prescribed AEDs in the first regimen in 
elderly patients with focal epilepsy, comparison between A (Stephen et al., 2006) and B (this 
study). 
 
 
Among adolescent patients of this study with age less than 20 years old (n = 241), 
remission rate at the end of study was 72% with a seizure freedom rate of 49% following 
the first treatment regimen. Carbamazepine, sodium valproate and lamotrigine constituted 
the drugs with the highest prescription rate in the first regimen (40, 63 and 101, 
respectively). Efficacy among these three agents was 58% for carbamazepine followed by 
sodium valproate (54%) and lamotrigine (50%) without any significant difference (p-value 
= 0.6). Carbamazepine also showed the best tolerability profile in the first regimen with the 
lowest withdrawal rate due to side effects of (8%) followed by sodium valproate (11%) and 
lamotrigine (12%) but without any statistical difference between them (p-value = 0.7).   
Adult patients in the age group between 20 and 64 years old (n = 735) had 64% as a total 
remission rate over the course of the study and 48% after the first treatment regimen. In the 
first regimen, AEDs with the highest prescription rate were lamotrigine (n =232), sodium 
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valproate (n =187) and carbamazepine (n =151) with lamotrigine as the most efficacious 
agent (53%) and also best tolerability (9%). There was insignificant difference observed 
between these three AEDs in terms of efficacy (p-value = 0.3) and tolerability (p-value = 
0.2).   
Elderly patients ≥ 65 years old (n = 122) had a seizure freedom rate of 87% at the end of 
study and 61% following the first treatment regimen. During the first regimen, AEDs with 
the highest prescription rate were lamotrigine (n = 39) followed by carbamazepine (n = 33) 
and sodium valproate (n = 24). Sodium valproate had the highest efficacy (75%) followed 
by carbamazepine (73%) and lamotrigine (62%) with insignificant statistical difference (p-
value = 0.4), while sodium valproate was also the best tolerated (13%) followed by 
carbamazepine (15%) and lamotrigine (18%) without any statistical difference (p-value = 
0.9). Similar effects were observed by Morgan and colleagues who noted an increased rate 
of continuation on sodium valproate treatment in the first regimen associated with 
increasing age i.e. from 71% in those under 5 years of age to 84% in cases of ≥ 75 years 
old (Morgan et al., 2004).   
Elderly patients tend to be more susceptible to side effects of AEDs compared to younger 
populations (Arroyo and Kramer, 2001). In the current investigation, elderly patients had 
the highest rate of AED withdrawal due to side effects compared to adults and adolescents 
(Table 48) particularly in the case of second generation AEDs (Table 50). This increased 
susceptibility to development of side effects in elderly patients might be due to the lower 
performance of various body systems and the physiological changes that are characteristics 
of this age group. Lamotrigine has significantly better tolerability compared with 
carbamazepine but with similar efficacy (time to first seizure) (Brodie et al., 1999). 
Lamotrigine is better tolerated in terms of withdrawal due to side effects compared with 
gabapentin and carbamazepine without significant difference in rates of seizure freedom 
during the first 12 months of treatment (Rowan et al., 2005). This was not the case in our 
study in which lamotrigine and carbamazepine showed a similar tolerability profile (15%) 
(Table 50), while in terms of efficacy, carbamazepine was more superior (73%) to 
lamotrigine (62%) in patients with aged ≥ 65 years old (Table 51).     
There was a noticeable variation between the age groups in the efficacy of first and second 
generations on AEDs in the first treatment regimen (Table 51). Adolescents patients with 
epilepsy in this study showed a higher total cumulative efficacy of first generation agents 
i.e. carbamazepine, sodium valproate and phenytoin (55%) compared to second generation 
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drugs (lamotrigine, gabapentin, levetiracetam, topiramate, oxcarbazepine and tiagabine) 
(48%) with insignificant statistical difference (p-value = 0.2). The opposite was the case in 
adult patients in whom the total cumulative efficacy of older drugs (48%) was lower than 
the newer drugs (55%) associated with insignificant statistical difference (p-value = 0.05). 
There was a big variation between the total cumulative efficacy of the two generations 
drugs in elderly patients. The efficacy of first generation AEDs (75%) was much higher 
than second generation drugs (55%) with a significant statistical difference noticed (p-
value = 0.03).    
Tolerability of different generations of AEDs among age groups in the first treatment 
schedule was also analyzed in this study with small differences observed between the first 
and second generations drugs in the adolescent (3% variation with p-value  = 0.3) and 
adult groups (1% variation and p-value = 0.4). Again, the elderly patients in this study 
showed a relatively bigger difference between the total cumulative tolerability of the two 
generations AEDs in comparison to other age groups. This group of patients tolerated older 
drugs with a cumulative rate of withdrawal due to side effects of 14% compared with 
newer drugs in which the cumulative rate of withdrawal due to side effects was 20% 
(Table 50) lacking any significant statistical difference (p-value = 0.3).   
Among elderly patients on monotherapy in the last treatment regimen (n = 113), those with 
focal epilepsy comprised 109 patients. Remission rate of elderly patients with focal 
epilepsy on sodium channels blocking AEDs was 89% compared to 90% in those on AEDs 
working mainly by potentiation of GABA inhibitory effect with insignificant difference 
noticed (p-value = 0.8). Only 4 elderly patients with idiopathic generalised epilepsy were 
identified limiting the ability to perform an accurate analysis with regard to the correlation 
between the ultimate outcome of epilepsy and the mechanism of action of AEDs on the last 
treatment schedule.  
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AED  
Adolescents 
(< 20 years)  
(n=241) 
Adults 
(20 – 64) 
(n=735) 
Elderly 
(> 64 years) 
(n=122)  
CBZ 
3 (8%) 
(40) 
21 (14%) 
(151) 
5 (15%) 
(33) 
VPA 
7 (11%) 
(63) 
24 (13%) 
(187) 
3 (13%) 
(24) 
PHT 
0 
(0) 
1 (20%) 
(5) 
0  
(2) 
LTG 
12 (12%) 
(101) 
20 (9%) 
(232) 
6 (15%) 
(39) 
GBP 
0 
(3) 
2 (13%) 
(15) 
0  
(1) 
LEV 
1 (17%) 
(6) 
5 (15%) 
(33) 
0  
(3) 
TPM 
3 (50%) 
(6) 
4 (13%) 
(32) 
2 (50%) 
(4) 
OXC 
1 (20%) 
(5) 
5 (29%) 
(17) 
3 (33%) 
(9) 
TGB 
0 
(6) 
3 (38%) 
(8) 
0 
(0) 
Generation of AEDs 
First 10% 13% 14% 
Second 13% 12% 20% 
Table 50. Tolerability (%) of individual and generations of AEDs among various age groups 
in the first treatment regimen (monotherapy).  
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AED  
Adolescents 
(< 20 years)  
(n=241) 
Adults 
(20 – 64) 
(n=735) 
Elderly 
(> 64 years) 
(n=122)  
CBZ 
23 (58%) 
(40) 
68 (45%) 
(151) 
24 (73%) 
(33) 
VPA 
34 (54%) 
(63) 
94 (50%) 
(187) 
18 (75%) 
(24) 
PHT 
0 
(0) 
2 (40%) 
(5) 
2 (100%) 
(2) 
LTG 
50 (50%) 
(101) 
122 (53%) 
(232) 
24 (62%) 
(39) 
GBP 
1 (33%) 
(3) 
12 (80%) 
(15) 
1 (100%) 
(1) 
LEV 
3 (50%) 
(6) 
21 (64%) 
(33) 
2 (67%) 
(3) 
TPM 
3 (50%) 
(6) 
19 (59%) 
(32) 
2 (50%) 
(4) 
OXC 
3 (60%) 
(5) 
8 (47%) 
(17) 
2 (22%) 
(9) 
TGB 
1 (17%) 
(6) 
4 (50%) 
(8) 
0 
(0) 
Generation of AEDs  
First 55% 48% 75% 
Second 48% 55% 55% 
Table 51. Efficacy (%) of individual and generations of AEDs among various age groups in 
the first treatment regimen (monotherapy). 
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To sum up, among the three age groups of epilepsy patients i.e. adolescents, adults and 
elderly, elderly patients had the highest remission rate by the end of study and also the 
highest total cumulative efficacy of AEDs in the first schedule. A longer duration of follow 
up of epilepsy patients with various AED treatment regimens was associated with a higher 
chance of developing remission eventually.  
The total cumulative efficacy of the two generations of AEDs demonstrated a higher 
efficacy of the first generation AEDs compared to second generation agents (p-value = 0.2) 
among adolescents patients. Adult patients with epilepsy had an opposite pattern with a 
lower efficacy of older drugs than newer agents (p-value = 0.05). Among elderly group of 
patients, first generation agents were significantly more efficacious than newer drugs (p-
value = 0.03). In terms of total cumulative tolerability, minimal differences were noticed 
between the two generations of AEDs in case of adolescents and adults patients. Elderly 
patients had a bigger difference between the two generations of AEDs in favour of older 
drugs with insignificant difference.   
4.2. Gender 
According to (Kotsopoulos et al., 2002), epilepsy is more common in males than females 
probably as a result of the more likely exposure to risk factors of epilepsy in  males than 
females e.g. head trauma and CNS infections. Following treatment, my study was able to 
detect a statistical significant difference in the outcome of epilepsy between males and 
females (p-value = 0.018). Male patients with epilepsy showed a rate of complete seizure 
freedom of 71% compared to female patients who had a lower rate of developing remission 
(65%). This might be because epilepsy tends to raise more medical issues in females than 
males with a consequent withdrawal of AEDs treatment in females (Morrell, 1996). Some 
of these issues include: cosmetic reasons as some AEDs can lead to weight gain, risk of 
teratogenecity in pregnant and child bearing age women, disturbances in bone health, 
fertility, menstruation and ovulation and failure of hormonal contraception.  
For most of the AEDs prescribed in this study i.e. carbamazepine, sodium valproate, 
lamotrigine, oxcarbazepine, topiramate, phenytoin, levetiracetam and tiagabine, the 
efficacy of drugs was higher in males than females except for gabapentin where efficacy 
was similar. Carbamazepine, sodium valproate, lamotrigine were the AEDs with the 
highest prescription rate; among these, sodium valproate exhibited a significant statistical 
difference of efficacy between males and females patients (p-value = 0.006) (Table 52). 
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The total cumulative efficacy of all AEDs prescribed in this study in males (55%) was also 
higher than that in females (44%) with a significant statistical difference (p-value < 0.001). 
With regard to generations of AEDs, males showed a higher significant efficacy than 
females to both first (p-value = 0.02) and second generation AEDs (p-value < 0.001) 
(Table 53).  
 
Efficacy  Tolerability 
 
males females  males females 
Carbamazepine  
51% 
(n=164) 
48% 
(n=120) 
 
10% 
(n=164) 
18% 
(n=120) 
Sodium valproate 
54% 
(n=243) 
40% 
(n=163) 
 
9% 
(n=243) 
18% 
(n=163) 
Lamotrigine 
55% 
(n=166) 
46% 
(n=291) 
 
8% 
(n=166) 
12% 
(n=291) 
Table 52. Gender differences of efficacy and tolerability among the three commonly 
prescribed AEDs. 
 
 
 
Gender 
Efficacy among 
first generation 
AEDs (%) 
Efficacy among 
second generation 
AEDs (%) 
Males 53% 59% 
Females 44% 45% 
Table 53. Gender differences of efficacy among generations of AEDs. 
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Tolerability profile of AEDs used in this study indicated a better tolerability in males than 
females for most of the drugs prescribed i.e. carbamazepine, sodium valproate, 
lamotrigine, oxcarbazepine, topiramate, phenytoin, levetiracetam and tiagabine. Also, as 
for efficacy, gabapentin was the only drug with the same tolerability in males and females. 
Lower body weight of females may be the reason that makes males more readily tolerate 
these drugs than females as lower body weight leads to a high serum concentration more 
rapidly which will consequently raise the risk of developing side effects in females. 
Among the three commonly prescribed agents i.e. carbamazepine, sodium valproate and 
lamotrigine, tolerability differences between males and females were statistically 
significant for carbamazepine (p-value = 0.03) and sodium valproate (p-value = 0.006) 
(Table 52). Male patients with epilepsy tolerated AEDs better with a lower rate of side 
effects (9%) than females (17%) with a significant statistical difference (p-value < 0.001). 
Gender differences in tolerability among generations of AEDs showed that male patients 
tolerated drugs better than females for both first (p-value = 0.001) and second generation 
agents (p-value = 0.01) (Table 54).  
 
Gender 
Tolerability among 
first generation 
AEDs (%) 
Tolerability among 
second generation 
AEDs (%) 
Males 9% 9% 
Females 18% 16% 
Table 54. Gender differences of tolerability among generations of AEDs. 
 
 
Although insignificant difference in the efficacy of lamotrigine by gender in patients with 
partial seizures has been reported (Glaxo, 1996), this study was able to demonstrate a 
significant difference (p-value = 0.03) between gender in patients with partial seizures on 
lamotrigine where 58% of male patients on this drug developed complete seizure control 
compared to 46% of females. The application of a different measure of efficacy of drugs 
i.e. 50% or more reduction in seizure frequency and median seizure reduction might be in 
part the reason behind the observed differences between the two studies. The same 
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scenario was also noticed by (Pledger et al., 1995) when topiramate was applied as add-on 
therapy in patients with partial-onset seizures; an insignificant difference was observed 
between males and females in terms of efficacy of the drug. When this project focused 
only on patients with partial seizures on topiramate, a statistical significant difference was 
demonstrated in the efficacy between males (70%) and females (41%) (p-value = 0.04) 
taking into consideration that this analysis was performed only on monotherapy.   
In terms of AEDs prescription rate for older compared to newer drugs, Falip et al., found 
that 8% of men and 21% of women were treated with second generation AEDs as 
monotherapy (n= 496) (Falip et al., 2005). This study also demonstrated that females had a 
higher rate of second generation AEDs prescription (62%) than males (41%) in the first 
treatment schedule. Morgan and colleagues observed a significantly higher prescription 
rate for lamotrigine in females (57%) in comparison with males (23%) (Morgan et al., 
2004). Increased rate of second generation AEDs prescription in females may be explained 
by the more frequent side effects of older agents in females such as teratogenicity, 
interference with contraception and weight gain. This analysis was only performed on the 
first treatment regimen because there is an overlap with first generation drugs as these 
drugs might be used in the second treatment regimen in case of failure of achieving 
complete seizure freedom in the first regimen in some patients.  
When analyzed in terms of generations of AEDs, male patients with epilepsy in this study 
showed a lower total cumulative efficacy with first generation AEDs i.e. carbamazepine, 
sodium valproate and phenytoin (55%) compared with second generation agents i.e. 
lamotrigine, oxcarbazepine, topiramate, gabapentin, levetiracetam, tiagabine, vigabatrin 
and zonisamide (60%) with insignificant statistical difference (p-value = 0.2). The analysis 
showed almost the same difference between the two generations of drugs whether 
conducted in the first treatment schedule (p-value = 0.2) or on the total attempts of using 
these drugs at the end of study (p-value = 0.1) (Table 55). In contrast, female patients had 
the same total cumulative efficacy in the two generations (49%) in the first treatment 
regimen and similar findings were noted in terms of the total attempts at AEDs prescribtion 
(Table 55).  
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Generation of 
AEDs 
First treatment 
regimen 
Total 
regimens 
First 55% 53% Efficacy in 
males Second 60% 59% 
 
First 49% 44% Efficacy in 
females Second 49% 45% 
Table 55. Efficacy of first and second generation AEDs according to gender. 
 
Only a minimal difference was observed in male patients between the total cumulative 
tolerability of older AEDs (9%) and newer drugs (10%) in the first treatment regimen. In 
the case of the total attempts of AEDs application, the total cumulative tolerability was 
exactly the same (9%) for the two generations of AEDs in males (Table 56). Similarly, 
total cumulative tolerability of the two generations of AEDs among females showed a very 
small difference (2%) in the first treatment regimen and in the total attempts of AEDs 
application (Table 56).   
 
 
Generation of 
AEDs 
First treatment 
regimen 
Total 
regimens 
First 9% 9% Tolerability 
in males Second 10% 9% 
 
First 18% 18% Tolerability  
in females Second 16% 16% 
Table 56. Tolerability of first and second generation AEDs according to gender.  
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Among patients with idiopathic generalised epilepsy, male patients on monotherapy in the 
last treatment schedule showed a higher remission rate (79%) with AEDs acting primarily 
by blockage of sodium channels than females (69%) with insignificant difference (p-value 
= 0.2). In case of AEDs working mainly by potentiation of GABA inhibitory effect as 
monotherapy in the last regimen, males also demonstrated a higher remission rate (90%) 
compared to females (69%) with a significant statistical difference observed (p-value = 
0.01). This difference might be because sodium valproate which is the AED with the 
highest prescription rate and highest efficacy against IGE patients belongs to this group. It 
is more commonly used by males than females because of its side effects are related more 
to females, such as the risk of teratogenicity in women of childbearing age and weight 
gain.  
Among patients with focal epilepsy on monotherapy in the last AED regimen, remission 
rate was similar for male and female patients (75% and 73%, respectively) on AEDs acting 
mainly by blockage of sodium channels (p-value = 0.6). Also similar values were observed 
for males (70%) and females (74%) regarding the remission rate on AEDs acting primarily 
by potentiation of GABA inhibitory effect applied in the last regimen as monotherapy (p-
value = 0.6).   
In summary, this study demonstrated a highly significant difference for remission rate in 
male patients with epilepsy than in females following AEDs treatment. Efficacy analysis of 
the commonly prescribed AEDs demonstrated that sodium valproate had a significantly 
higher efficacy in males than females; also the total cumulative efficacy of all AEDs was 
significantly higher in males than females. The efficacy of first and second generation 
AEDs were also shown to be significantly higher in male patients than in females. Among 
the three commonly prescribed AEDs, carbamazepine and sodium valproate showed a 
significant difference between males and females in favour of males regarding tolerability. 
In terms of the total cumulative tolerability profiles, male patients with epilepsy were 
found to tolerate AEDs significantly better than females. Also males had a better 
tolerability to both first and second generations of AEDs than females. Second generation 
AEDs were found to be more frequently prescribed to female patients with epilepsy 
compared to males.  
Among male patients, the total cumulative efficacy was lower with older drugs than newer 
agents with a very small difference in case of total cumulative tolerability. A minimal 
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difference was observed in the total cumulative efficacy and tolerability between first and 
second generation AEDs among female patients in this study.   
The main mechanism of action of AEDs applied as monotherapy in the last treatment 
schedule in both types of epilepsy (idiopathic and focal) was associated with insignificant 
small differences except in IGE patients receiving AEDs acting primarily by potentiation 
of GABA inhibitory effect in which males had a significantly higher remission rate in 
comparison to females.   
4.3. Idiopathic generalised epilepsy (IGE) 
Among the total population of this study, 251 patients with idiopathic generalised epilepsy 
were identified with a total remission rate of 73% that is similar to findings of other 
investigators (Perucca, 2001b;Reutens and Berkovic, 1995) who showed the rate of 
developing complete seizure control in patients with IGE ranged from 80% to 90%. In 
terms of response to the first ever treatment with AEDs in idiopathic generalised epilepsy, 
Mohanraj and Brodie showed a similar rate (50%) compared to 52% in this project but 
with slightly lower total remission rate (64% versus 73%) (Mohanraj and Brodie, 2007). 
Patients with IGE tend to have a better prognosis possibly due to the presumed genetic 
origin of this type of epilepsy that is usually accompanied by an epileptogenic process 
remission either with AED treatment or even without treatment in some cases i.e. 
spontaneous remission (Kwan and Sander, 2004).  
Idiopathic generalised epilepsy includes several syndromes; it is essential to use the most 
appropriate AED therapy for the treatment of IGE syndromes. Among older AEDs, sodium 
valproate is considered as the drug of choice for treatment of multiple IGE syndromes, it 
can be used in juvenile myoclonic epilepsy and absence seizures with a rate of seizure 
freedom of more than 80% (Bourgeois et al., 1987;Calleja et al., 2001;Covanis et al., 1982) 
while other agents such as carbamazepine and phenytoin were associated with poor 
outcome, exacerbation of seizures and subsequent categorization of these patients as 
having refractory epilepsy (Benbadis et al., 2003). For instance, carbamazepine was found 
to exacerbate absence seizures and juvenile myoclonic epilepsy in this group of patients 
(Thomas et al., 2006).  Of the second generation agents, lamotrigine, levetiracetam, 
topiramate and zonisamide are becoming more known for efficacy against IGE (Karceski 
et al., 2005) but they are less commonly prescribed in this type of epilepsy, as they are not 
officially approved for use (Table 57). That explains the findings of this analysis in which 
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sodium valproate and lamotrigine were the drugs with the highest prescription rate in 
patients with idiopathic generalised epilepsy (n = 119 for each) with sodium valproate as 
the most efficacious AED (59%) compared to lamotrigine (45%) with a statistical 
significant difference between them (p-value = 0.03). Similar findings were reported by 
other investigators who showed sodium valproate to be the most effective drug against 
idiopathic generalised epilepsy (68%) followed by lamotrigine (45%) (Mohanraj and 
Brodie, 2005b).  In addition, the Standard And New Antiepileptic Drugs (SANAD) study, 
found that sodium valproate is the most effective AED in this group of patients and 
recommended its remaining as the first line treatment for such patients (Marson et al., 
2007b). 
 
 
 
 
Epilepsy syndrome  First-line AEDs Second-line AEDs 
Childhood absence  Lamotrigine 
Levetiracetam 
Topiramate 
Juvenile absence Lamotrigine 
Levetiracetam 
Topiramate 
Juvenile myoclonic 
epilepsy 
Lamotrigine 
Clobazam 
Levetiracetam 
Topiramate 
Generalised tonic–clonic 
seizures only 
Lamotrigine 
Topiramate 
Levetiracetam 
Table 57. NICE guidelines for newer AEDs treatment by idiopathic generalised epilepsy 
syndrome (NICE, 2004). 
 
 
 
Unfortunately, data collection on patients with idiopathic generalised epilepsy in this study 
only focused on the major classification of epilepsy (i.e. idiopathic and focal) with their 
responses to AEDs treatment without looking for specific individual syndromes of each 
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subgroup. Therefore, detecting the details of AEDs applied in each syndrome cannot be 
performed in this analysis.  
In terms of tolerability of AEDs applied in patients with idiopathic generalised epilepsy, 
sodium valproate was also the drug associated with the highest tolerability as its rate of 
withdrawal due to side effects was the lowest (9%) compared with 13% for lamotrigine 
with insignificant deference noted (p-value = 0.3). Also, a similar sequence was observed 
in another study that reported sodium valproate as the best tolerated drug (5%) followed by 
lamotrigine (6%) (Mohanraj and Brodie, 2005b), an observation also reported by the 
SANAD study (Marson et al., 2007b). Based on the findings of other investigators, sodium 
valproate had the highest rate of continuation on treatment in comparison to 
carbamazepine, lamotrigine and phenytoin (Morgan et al., 2004).    
In order to detect any correlation between the generations of AEDs used in this study and 
patients with idiopathic generalised epilepsy, an analysis demonstrated a higher response 
rate to the first generation AEDs than second generation agents in this group of patients. 
The total cumulative efficacy in the older AEDs of this study (carbamazepine, sodium 
valproate and phenytoin) in the first treatment regimen was 59% compared to 50% in case 
of modern drugs (lamotrigine, gabapentin, levetiracetam, topiramate, oxcarbazepine and 
tiagabine) with insignificant difference noted (p-value = 0.1).  The pattern was similar 
when the analysis was performed using the total attempts of AEDs applications at the end 
of study with 58% total cumulative efficacy in the older agents in comparison to 48% in 
case of newer AEDs lacking any significant statistical difference (p-value = 0.07) (Table 
58). On the other hand, the difference observed between the first and second generation 
AEDs in terms of the total cumulative tolerability was smaller than that noticed in case of 
efficacy. Total cumulative tolerability of the first generation drugs was 11% compared to 
15% in the newer agents in the first treatment schedule with insignificant difference (p-
value = 0.3). Regarding the total attempts of AEDs applications, total cumulative 
tolerability was 10% in older drugs compared to 15% in newer agents also lacking any 
statistical significant difference (p-value = 0.2) (Table 58).  
Among idiopathic generalised epilepsy patients on monotherapy in the last treatment 
schedule (n = 212), those on AEDs acting by sodium channels blockage (carbamazepine, 
phenytoin, lamotrigine and oxcarbazepine) as the primary mechanism of action (n = 110) 
had a remission rate of 73% in comparison to 82% for those on AEDs acting by 
potentiation of GABA inhibitory effect (clobazam, phenobarbital, tiagabine, sodium 
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valproate and vigabatrin). Insignificant statistical difference was noted between these two 
groups (p-value = 0.1).  
 
 
 
 
 
Generation of 
AEDs 
First treatment 
regimen 
Total 
regimens 
First 59% 58% 
Efficacy 
Second 50% 48% 
 
First 11% 10% 
Tolerability   
Second 15% 15% 
Table 58. Total cumulative effectiveness of first and second generation AEDs among 
patients with idiopathic generalised epilepsy. 
 
 
 
In summary, patients with idiopathic generalised epilepsy in this analysis demonstrated a 
high rate of developing complete seizure control. In terms of individual AEDs, sodium 
valproate and lamotrigine were the drugs with the highest prescription rate in this group of 
patients with sodium valproate as the drug with the highest efficacy and best tolerability. 
First generation AEDs showed a higher response rate in patients with IGE than modern 
drugs without any significant difference. In terms of tolerability, older AEDs showed a 
slightly better tolerability than newer drug with insignificant difference. Analysis of the 
mechanism of action of the last AED monotherapy applied to idiopathic generalised 
epilepsy patients demonstrated a higher response rate to AEDs acting by potentiation of 
GABA inhibitory effect than sodium channels blocking AEDs with insignificant 
difference. 
4.4. Focal (localization-related) epilepsy 
847 patients with focal epilepsy were recruited in this study, more than three times the 
number of patients with idiopathic generalised epilepsy (n = 251). Analysis in this study 
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demonstrated that a lower number of patients with focal (localization-related) epilepsy 
achieved remission using AEDs treatment (67%) than idiopathic generalised epilepsy 
patients (73%) with a non-significant difference between the two groups (p-value = 0.1), a 
finding also been reported by other studies (Aikia et al., 1999;Kwan and Brodie, 
2000a;Mattson et al., 1996;Perucca, 2001b;Reutens and Berkovic, 1995). The same pattern 
of response according to type of epilepsy was reported by Kwan and Brodie who observed 
a lower remission rate for patients with focal epilepsy (60%) in comparison to 74% in case 
of idiopathic generalised epilepsy patients (Kwan and Brodie, 2000a). The 67% remission 
rate in focal epilepsy patients in this project was close to that reported by (Mohanraj and 
Brodie, 2005a) who showed a remission rate by 57% of patients with this type of epilepsy. 
The lower opportunity of developing complete seizure control in focal epilepsy in 
comparison to idiopathic generalised epilepsy might be due to the presence of underlying 
cerebral pathology such as gross structural brain lesion or congenital neurological deficit 
(Sander, 2003).  
In terms of efficacy of AEDs, carbamazepine or lamotrigine are usually the treatments of 
choice to start with in case of epilepsy with localized onset in the brain (Marson et al., 
2007a). According to Marson and colleagues (SANAD study) lamotrigine has efficacy 
similar to that of carbamazepine for the treatment of partial seizures while gabapentin and 
topiramate are inferior to carbamazepine in this group; these findings were obtained based 
on the efficacy measure “time to 12 months remission” (Marson et al., 2007a). In contrast, 
this analysis showed that among the three commonly prescribed AEDs, lamotrigine was 
the drug with both the highest prescription and highest response rate (51%) while 
carbamazepine had a remission rate of 49% followed by sodium valproate (45%) with non-
significant difference (p-value = 0.2). Based on the findings of other investigators, there is 
a consensus based on 43 opinion leaders in the field of epilepsy that carbamazepine is the 
treatment of choice for simple partial, complex partial and secondary generalized seizures 
(Karceski et al., 2005). According to that analysis, three agents had the highest scores for 
the treatment of localization-related epilepsy; carbamazepine, lamotrigine and 
oxcarbazepine. A similar conclusion was reached from this analysis with respect to 
carbamazepine and lamotrigine but with sodium valproate instead of oxcarbazepine.   
Focusing the analysis on the first treatment regimen for patients with focal epilepsy, 
carbamazepine, sodium valproate and lamotrigine were also the three most commonly 
prescribed AEDs. There were small differences in efficacy between these agents. 
Lamotrigine had the highest efficacy (54%) followed by carbamazepine (52%) and sodium 
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valproate (49%) (p-value = 0.5). Another study found a similar pattern of response of these 
three drugs in the first treatment schedule in patients with focal epilepsy reporting that 
these three agents were the more commonly prescribed and that lamotrigine was more 
likely to provide seizure control (63%)  followed by carbamazepine (45%) and sodium 
valproate (42%) (Mohanraj and Brodie, 2005b).  
Lamotrigine was also according to our analysis the best tolerated AED with a rate of 
withdrawal due to side effects of 10% followed by carbamazepine and sodium valproate 
(13% and 14%, respectively) (p-value = 0.2). These findings are consistent with (Marson 
et al., 2007a) in which lamotrigine was the agent with the least number of patients 
reporting side effects.  
It seems there is not a big difference between the efficacy of the first and second 
generation AEDs when applied in the treatment of patients with localization-related 
epilepsy. Findings for both two generations were identified and compared (Table 59) 
showing a slightly lower total cumulative efficacy of older AEDs than modern agents, this 
difference (4%) is same whether in the first regimen or total attempts of AEDs applications 
at the end of study in patients with focal epilepsy (p-value = 0.2 and 0.1, respectively).  For 
tolerability of AEDs in patients with focal epilepsy, both generations had similar values 
whether in the first treatment schedule or total attempts of using these agents (p-value = 
0.7 and 0.5, respectively) (Table 59). 
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Generation of 
AEDs 
First treatment 
regimen 
Total attempts 
First 51% 47% 
Efficacy 
Second 55% 51% 
 
First 13% 14% 
Tolerability 
Second 12% 13% 
Table 59. Total cumulative effectiveness of first and second generation AEDs among 
patients with focal epilepsy.   
 
 
701 patients with focal epilepsy on monotherapy in the last treatment regimen were 
identified. Among these, 428 were found to be taking sodium channels blocking agents 
(carbamazepine, phenytoin, lamotrigine and oxcarbazepine) as AEDs compared to 185 
patients on AEDs acting primarily by potentiation of GABA inhibitory effect (clobazam, 
phenobarbital, tiagabine, sodium valproate and vigabatrin). Remission rate was similar in 
the two groups (74% and 71%, respectively) with insignificant difference noted (p-value = 
0.5).   
To sum up, in contrast to patients with idiopathic generalised epilepsy, focal epilepsy 
patients demonstrated a lower remission rate. The three commonly prescribed AEDs in 
patients with focal epilepsy were lamotrigine, carbamazepine and sodium valproate. 
Among these, lamotrigine was the drug with the highest prescription rate, highest efficacy 
and best tolerability profile. Second generation AEDs demonstrated a slightly higher 
efficacy than first generation agents with insignificant difference while in terms of 
tolerability, similar values were noticed for older and newer AEDs. Minor differences were 
observed in the remission rate among the primary mechanisms of action of AEDs applied 
in the last treatment regimen as monotherapy (sodium channels blockage and potentiation 
of GABA inhibitory effect) in patients with focal epilepsy.  
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4.5. Improved outcome of epilepsy 
Total remission rate of patients recruited in this study was 68.3%. This value was 
attributable to 61.9% seizure freedom in patients while on monotherapy at their last clinic 
visit and 6.4% in those on combined therapy (polypharmacy).  
To detect any improvement in the outcome of epilepsy, it was essential to compare the 
findings of this current study with another one preferably with the same conditions. 
Fortunately, a study has been conducted previously at the same department (the Epilepsy 
Unit of the Western Infirmary); it was similar to this study but with shorter duration of 
patient follow up and smaller study population and was conducted on the newly diagnosed 
patients from 1982 until 1997 with 470 patients recruited (Kwan and Brodie, 2000a). In 
contrast, this current investigation followed 1098 newly diagnosed epilepsy patients 
referred to the Unit between 1982 and 2005.   
The comparison demonstrated around 4% elevation in the total remission rate; this value 
was obtained through an increase in remission using treatment with monotherapy (around 
1% compared with the first cohort) and treatment with polypharmacy (around 3% from the 
first cohort) (Table 60).   
 
 
 
 
 
Recruitment  n Monotherapy 
Combined 
therapy 
Total 
Remission rate  
  
1982 – 1997 470 61 % 3.0 % 64.0 % 
1982 – 2005  1098 61.9 % 6.4 % 68.3 % 
Table 60. Seizure freedom rates in an expanded cohort of patients with newly diagnosed 
epilepsy.  
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When the study population of Kwan and Brodie (2000) (n = 470) was followed up for a 
longer duration until 2008 instead of 1997 i.e. 26 years of follow up (11 years longer), 417 
patients were found to be still under active follow up. Analysis to 2008 demonstrated the 
total remission rate was increased by around 6% (around 3% remission on monotherapy 
and 3% on combined therapy (Table 61).   
This finding suggested an elevation in the rate of achieving seizure freedom as the period 
of patients follow up was increased. An eleven years longer duration of follow up of 
patients referred between 1982 and 1997 resulted in around 6% increase in the chance of 
achieving seizure freedom state in these patients (Figure 24). Analysis of the outcome of 
epilepsy based on years of referral (Table 27) indicates a decline in remission rate in the 
recent years where duration of patient follow up is short compared to the high rate of 
complete seizure control in patients referred to the Epilepsy Unit with long duration of 
follow up. Camfield and Camfield have also reported that the longer the period of follow 
up of patients, the greater the proportion of those who develop complete seizure control 
subsequently (Camfield and Camfield, 1996).  
 
Recruitment  
Date of 
analysis 
n Monotherapy 
Combined 
therapy 
Total 
Remission rate  
  
1982 – 1997 1997 470 61 % 3.0 % 64.0 % 
1982 – 1997 2008 417 64.5 % 6 % 70.5 % 
Table 61. Recalculation of seizure freedom rates of data of (Kwan and Brodie, 2000a) study 
based on analysis performed on 2008 (after 26 years of follow up) compared with initial 
analysis on 1997.  
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Figure 24. Seizure freedom on AEDs treatment (monotherapy and combined therapy) of this 
study compared to Kwan and Brodie (Kwan and Brodie, 2000a).  
  
 
This improvement in the outcome of epilepsy was related to the longer duration of follow 
up of these patients. The development and introduction of new AEDs for epilepsy is a 
continuous process and as time passes, more new agents are available in the market for 
clinical practice. Therefore, the improvement in the outcome of epilepsy following longer 
duration of patients’ follow up might be linked to the increasing options of second 
generation AEDs available to treat this disease.   
There is an increasing rate of prescription of second generation AEDs as these agents are 
becoming more widely accepted and prescribed by clinicians in the last decade (NICE, 
2004). To identify the AEDs that those 417 patients who continued treatment after 1997, a 
further analysis was performed on patients referred to the epilepsy unit after 1997 i.e. from 
1998 until 2005 (n = 681) as treatment would be expected to be similar to those 417 
patients referred before 1998 in terms of choice of AEDs selection. This analysis 
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demonstrated that the rate of second generation AEDs prescription in patients on 
monotherapy referred after 1997 was 60% compared to 40% in case of first generation 
agents. On the other hand, these figures were completely opposite for patients referred 
before 1998 in which the rate of second generation AEDs prescription (34%) was lower 
than first generation agents (66%) (Table 62).  
Dividing the study population into three groups based on years of referral with the first 
group representing the population of Kwan and Brodie (2000) with referral period between 
1982 and 1997 while the other two groups represent the more recent years of referral to the 
Epilepsy Unit, (Figure 25) demonstrates a gap between the first group and the other two 
groups. According to this analysis, patients of the two more recent groups needed a shorter 
duration of treatment to achieve seizure freedom compared with the first group keeping in 
mind that during the period of referral of the two recent groups (1998 – 2005) more options 
of second generation AEDs were available.  
 
 
 
 
Drug use  
before 1998  
(A; n = 470) 
Drug use  
before 1998  
(B; n = 417) 
Drug use  
after 1997 onwards 
(B; n = 681) 
Monotherapy 423 349 564 
Older AEDs (%) 289 (68%) 232 (66%) 224 (40%) 
Newer AEDs (%) 134 (32%) 117 (34%) 340 (60%) 
Table 62. A comparison of monotherapy drug use on the last clinic visit of patients 
commenced on treatment before 1998 and after 1997 onwards with seizure freedom rates,   
A (Kwan and Brodie, 2000a) and B (this study).  
 
 
 
Another way of determining the rate of second generation AED prescription since their 
introduction was by identifying these agents during the three periods of referral adjusted to 
make the number of patients in each group as equal as possible. This analysis showed a 
gradual elevation in the rate of prescription of modern drugs over the years of referral at 
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the expense of old drugs; 28% in patients referred to the Epilepsy Unit between 1982 and 
1996, and 38% between 1997 and 2001. In the most recent group (referred between 2002 
and 2005), the prescription rate of second generation agents reached 59%. Increasing the 
rate of newer drugs prescription was associated with a gradual elevation in the response 
rate. This was accompanied by a gradual reduction in the prescription rate of first 
generation AEDs from 58% in the earliest referral group, then 39% in the next group and 
27% in the most recent group of referral. Accordingly, a gradual reduction in response rate 
of these older agents was noticed (Table 63).   
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Figure 25. Outcome of epilepsy by duration of treatment during three periods of referral to the epilepsy unit. 
Chapter 4. Discussion.  195 
 
 
 
 
Generation of 
AEDs 
n (%) Responders  
First 216 (58%) 165 (76%) (1982 – 1996) 
(n = 371) Second  103 (28%)  82 (80%) 
 
First 136 (39%)  99 (73%) (1997 – 2001) 
(n = 346) Second  131 (38%)  102 (78%)  
 
First 104 (27%)  81 (78%)  (2002 – 2005) 
(n = 381) Second  223 (59%)  151 (68%)  
Table 63. A comparison between the rate of first and second generations AEDs prescription 
on the last clinic visit and their response rates according to the periods of referral in 
patients on monotherapy.   
 
  
 
When the second generation AEDs started to be prescribed clinically, most were usually 
given to epilepsy patients as add-on medications (polypharmacy). Table 64 shows the type 
of treatment (monotherapy or polypharmacy) given to patients on their last clinic visit 
among the three periods of referral. It demonstrates the highest rate of combined therapy 
prescription in the second group of years of referral (1997 - 2001) 23% compared to the 
first (1982 - 1996) 14% and third group (2002 - 2005) 14%. In the first period of referral, 
rate of combined therapy prescription was low as the second generation AEDs were just 
entering the market with limited clinical trial data and lack of awareness of their 
effectiveness by the clinicians. The higher prescription of combined therapy in the second 
group compared with the first period may be because second generation drugs had been 
shown to have good efficacy with lower side effects profiles that made them more widely 
accepted and prescribed by physicians. Similar to the first period of referral, the third 
group was characterised by a lower polypharmacy prescription rate in comparison to the 
second period possibly because further research had shown similar efficacy of second 
generation AEDs compared to first generation agents minimizing their prescriptions as 
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add-on therapy. Remission rate was also the highest in the second group (16%) compared 
to the first (6%) and third group (6%) (Table 64 and Figure 26).  
 
 
Period of 
referral 
n 
Monotherapy 
on last 
regimen 
Responders 
on 
monotherapy 
(%) 
Polypharmacy 
on last  
regimen 
Responders  
on 
polypharmacy 
(%) 1982 - 1996 371 319 (86%) 247 (94%) 52 (14%) 15 (6%) 
1997 - 2001 346 267 (77%) 201 (84%) 79 (23%) 39 (16%) 
2002 - 2005 381 327 (86%) 232 (94%) 54 (14%) 16 (6%) 
Total  1098 913 680 185 70 
Table 64. Type of treatment on last regimen (monotherapy or polypharmacy) with response 
rate during periods of referral.  
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Figure 26. Type of treatment on last regimen (monotherapy or polypharmacy) during year of 
referral in seizure freedom patients.    
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Therefore, it might be concluded that the longer duration of follow up of epilepsy patients 
is associated with more opportunities to select one of the wide range of second generation 
AEDs (with variable mechanisms of actions) with a consequent better chances of achieving 
seizure control in these patients.  
Another element associated with increasing the duration of follow up is the number of 
treatment regimens applied. Patients who fail to show complete seizure control on a certain 
treatment regimen (whether monotherapy or polypharmacy) will eventually be moved to 
another regimen either through substitution or combining with another AED.  
The chance of achieving seizure freedom is highest with the first treatment schedule and 
declines with subsequent regimens whether the AED treatment is applied as monotherapy 
or combined therapy. Based on this study, complete seizure control was achieved 
progressively until the seventh treatment schedule (Table 65). Patients who developed 
complete seizure freedom on the first treatment regimen constituted 50% of the whole 
study population compared to 13% in case of responders to the second treatment schedule 
(whether monotherapy or polypharmacy). On the other hand, patients with remission on all 
subsequent regimens together (i.e. third, fourth, fifth, sixth and seventh treatment 
schedules) constituted only 5% of the whole study population (Figure 27). Therefore, 
responders on the first two regimens contributed to 63% of the remission rate of the whole 
study population. Failure to achieve remission on the first two treatment regimens was 
associated with a low chance of achieving seizure freedom on the subsequent schedules 
(Figure 28). These findings support other studies that suggested the definition of refractory 
epilepsy should follow the failure of two appropriately selected and adequately tried AEDs 
based on their observations of remission rate of 47% following the first treatment regimen, 
13% following the second and only 4% on the subsequent regimens (Arts et al., 2004; 
Kwan and Brodie, 2000a). The hope for achieving a state of complete seizure control is 
always there although small as in the work of Sillanpaa who demonstrated that remission 
of seizures can be achieved after a period of as long as 30 - 35 years after the diagnosis 
(Sillanpaa, 1993). By modification of AED therapy demonstrated a remission rate of 3% of 
the patients each year after a 20 year history of intractable seizures (Callaghan et al., 2007) 
using the available second generation AEDs during the study period i.e. 2000 – 2003 
compared to the more commonly prescribed first generation drugs before 2000. 
Considering a particular patient as drug resistant does not necessarily imply that the patient 
will never achieve complete seizure control after further AED therapy manipulation 
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(Callaghan et al., 2007;Luciano and Shorvon, 2007;Schiller and Najjar, 2008). This is 
because drug responsiveness in epilepsy should be considered as a dynamic process.   
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Figure 27. Outcome of newly diagnosed epilepsy patients.  
 
 
There may be other factors not related to drugs that participated in the improvement of 
outcome of epilepsy after long duration of follow up such as improvement of patients’ 
awareness of this disease and the necessity to take treatment in order to avoid its negative 
consequences. Health education programs could have played a major role in this regard. In 
some patients, the improvement may be part of the natural history of the disorder.  
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Treatment 
regimens 
Type of 
treatment 
Number of 
patients Responders (%) 
First  Monotherapy 1098 544 (50%) 
Monotherapy 254 101 (40%) 
Polypharmacy 144 45 (31%) Second 
Total 398 146 (37%)  
Monotherapy 64 26 (41%) 
Polypharmacy 104 15 (14%) Third 
Total 168 41 (24%) 
Monotherapy 17 6 (35%) 
Polypharmacy 51 5 (10%) Fourth 
Total 68 11 (16%)  
Monotherapy 3 1 (33%) 
Polypharmacy 29 3 (10%) Fifth 
Total 32 4 (13%)  
Monotherapy 3 1 (33%) 
Polypharmacy 13 1 (8%) Sixth  
Total 16 2 (13%)  
Monotherapy 2 1 (50%) 
Polypharmacy 7 1 (14%) Seventh  
Total 9 2 (22%)  
Monotherapy 0 0 
Polypharmacy 3 0  Eighth  
Total 3 0 
Monotherapy 1 0 
Polypharmacy 1 0  Ninth  
Total 2 0 
Table 65. Remission rate of both both monotherapy and polypharmacy in all treatment 
regimens.  
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Figure 28. Outcome of epilepsy by number of regimens taken.       
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The concept of “adequately tried AEDs” is an important factor in the definition of 
refractory epilepsy as failure of a certain treatment schedule may not be only due to lack of 
efficacy of that particular AED/s combination against a certain seizure type, but also could 
be due to the development of intolerable side effects making the AED/s combination 
poorly tolerated and subsequently withdrawn.  
The rate of development of complete seizure control following failure of a particular 
regimen due to poor tolerability tends to be higher than remission after failure due to lack 
of efficacy. This finding was observed after failure of the first and also second schedule. 
The small number of patients in the subsequent schedules limited the ability to analyze 
their rates of seizure freedom. This pattern of remission was observed in almost all three 
levels of cut off points of the recommended daily defined doses of AEDs applied as 
monotherapy (Table 66). Statistical analysis of the remission rate following failure of the 
first treatment regimen demonstrated a significant difference between the three cut off 
levels (25%, 50% and 75%) in term of types of treatment failure i.e. failure due to lack of 
efficacy and failure due to poor tolerability (p-value = 0.01). These observations are in 
agreement with the findings of Kwan and Brodie who reported that seizure freedom on the 
second regimen following failure of treatment due to poor tolerability tends to be higher 
than that failure due to lack of efficacy (Figure 29) (Kwan and Brodie, 2000b). The small 
number of patients with remission following failure of two treatment regimens has limited 
the ability to perform a statistical analysis. The higher remission rate following failure of a 
previous regimen due to poor tolerability supports the idea that treatment failure because of 
poor tolerability does not represent refractory epilepsy because the development of 
intolerable side effects shortly after the prescription made withdrawal of that particular 
drug an essential step. This is consistent with Kwan and colleagues who reported that a 
pharmacological intervention can only be considered if it was “appropriate” for the patient 
epilepsy and seizure type and applied “adequately” in terms of strength/ dosage for a 
sufficient length of time (Kwan et al., 2009).   
Instead of the three levels of cut off points of the recommended daily defined doses of 
AEDs, using simple calculations of patients who failed treatment with the first schedule 
due to ongoing seizures (regardless of the dosing) or withdrawal of treatment due to side 
effects, the remission rate on subsequent schedules was 10% (n = 109). This value is 
almost identical to Kwan and Brodie who showed a value of remission rate of 11% on 
subsequent regimens in this group of patients(Kwan and Brodie, 2000a).  
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Percentage of 
DDD 
Type of 
failure 
Remission 
following one 
regimen failure 
Remission 
following two 
regimens failure 
LOE 34% 25% 
25% 
PT 50% 0% 
LOE 31% 19% 
50% 
PT 45% 25% 
LOE 29% 13% 
75% 
PT 42% 33% 
Table 66. Remission rates following the two types of treatment failure (lack of efficacy (LOE) 
and poor tolerability (PT)) based on 25%, 50% and 75% of the daily defined dose (DDD) in 
epilepsy patients on monotherapy.  
 
 
 
Figure 29. Response to the second antiepileptic drug according to reason for failure of the 
first drug (Kwan and Brodie, 2000b).  
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Based on findings of this study and other related ones, longer duration of follow up of 
epilepsy patients appears to be associated with a modest improvement in the ultimate 
outcome as it will be accompanied by the application of more regimens most of which will 
include second generation AEDs. Therefore, it appears that the availability of wide range 
of these agents with variable mechanisms of action has contributed to this outcome 
improvement. In addition, improvement of patients’ awareness about epilepsy could have 
contributed to the improvement of outcome.  
The modest improvement in the outcome of epilepsy was in patients with complete seizure 
control. It is also possible that there might be an improvement in patients with ongoing 
seizures. This improvement might take the form of reduced seizure frequency and/or 
seizure severity but unfortunately this study was not able to show this due to lack of 
required data. Again, there is a chance that such improvement might be at least partially 
attributable to second generation AEDs.  
Failure of two consecutive schedules was associated with a lower chance to develop 
seizure freedom subsequently. Thus, development of refractory epilepsy is more likely to 
take place following failure of the first two treatment regimens. Failure of these two 
regimens is more likely to be due to lack of efficacy rather than poor tolerability.   
4.6. AEDs response and doses 
The response to individual AEDs does not seem to be constant but varies according to 
sequence of prescription e.g. efficacy of carbamazepine when applied as a first treatment 
schedule differs from when given in any other regimens. This variability is observed not 
only for efficacy of AEDs but also for tolerability. Compared with variability in efficacy, 
differences in tolerability profiles of AEDs between first regimen and other regimens were 
smaller. This phenomenon was observed for most of the AEDs applied in this study as 
monotherapy. Bogg and colleagues have linked the reduction in the sensitivity to AEDs 
with the prolonged application of these agents (Bogg et al., 2000), perhaps due to 
overlapping effects of other previous AEDs already applied or prolonged exposure to these 
agents that results in brain morphological or physiological changes leading to alteration in 
the response to these drugs. This has also been shown by Frey and colleagues who showed 
a reduced severity of side effects of AEDs following prolonged use of these drugs (Frey et 
al., 1986). Based on these observations, it might be concluded that the response to the first 
AED prescribed is the corner stone for determining the ultimate outcome of epilepsy. 
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Consequently, failure to respond to the first AED therapy is associated with a poor 
prognosis of epilepsy in the future while patients with a good response on the first regimen 
are more likely to develop complete seizure control eventually, an observation that was 
also reported by other investigators (Kwan and Brodie, 2000a). In this study, patients who 
responded to the first AED therapy comprised 50% of the total number who achieved 
remission by the end of this investigation in comparison to the subsequent treatment 
regimens that showed a continuous reduction in the remission rate. These findings are 
similar to those of Kwan and Brodie who observed a decline in the rate of developing 
complete seizure control following failure of the first treatment regimen (Figure 30) (Kwan 
and Brodie, 2000b). Ma and colleagues also observed that majority of epilepsy patients 
achieved seizure freedom while on the first treatment regimen (Ma et al., 2009). Among 
patients with partial epilepsy, the rate of complete seizure control after failure of the first 
regimen was found to be around 14% in patients on monotherapy (Kwan and Brodie, 
2000a;Schmidt, 1986;Schmidt and Richter, 1986) and between 3% and 11% in case of 
combined therapy (Kwan and Brodie, 2000a;Mattson et al., 1985). The current 
investigation demonstrated a rate of remission after failure of the first regimen of 9% in 
patients on monotherapy and 5% in case of combined therapy among patients with partial 
seizures.  
It may be that the response to first drug is important because the brain has never been 
exposed to these agents before maximising effects on brain targets without the chance to 
develop drug tolerance through brain target modifications that may alter the brain 
response. This might be the reason for variation in response to the same drug in two 
different patients according to its sequence of prescription. Individual differences can also 
be an important factor in this regard as there might be some degree of cellular differences 
in the brain among patients that control the response to AEDs.   
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Figure 30. Remission rate of epilepsy following failure of the first regimen (Kwan and 
Brodie, 2000b).  
 
 
Based on the results obtained in this study and according to the recommendations of the 
World Health Organization (WHO), it was observed that seizure freedom state was 
reached using a relatively moderate dose of the six commonly prescribed AEDs i.e. 
lamotrigine, sodium valproate, carbamazepine, topiramate, oxcarbazepine and 
levetiracetam in majority of the responder patients without the need to reach high dose 
concentrations (Table 67). Even in case of carbamazepine and topiramate, most of the 
patients who achieved complete seizure control (92% and 97%, respectively) were found 
to be taking lower than the daily defined dose recommended by WHO (Table 67). A 
similar pattern was observed in case of tolerability profiles of these six commonly applied 
agents. It was observed that the majority of patients who discontinued these drugs due to 
side effects were receiving doses lower than the recommended daily defined doses rather 
than high doses (Table 67). Therefore, it can be concluded that the response to initial doses 
of AEDs can be assumed as an indicator of the overall response at least in the commonly 
prescribed AEDs.    
These findings are in agreement with other researchers who reported a high proportion of 
patients with complete seizure control while on moderate doses of AEDs without 
developing intolerable side effects (Kwan and Brodie, 2001;Ma et al., 2009;Ryvlin, 2005).   
Chapter 4. Discussion.  206 
Adjusting AEDs dose within the low to moderate range without reaching the high 
concentrations will lower the risk of developing side effects. In addition, this will lead to 
saving time required in the treatment of patients as the opportunity to move to another 
treatment regimen (by substitution or combination) will be more rapid. Another advantage 
is lowering the cost and various other resources needed to provide medical care for patients 
with epilepsy. Improvement of the patients’ compliance is a likely consequence of 
restriction of AEDs dose to low and moderate ranges as the patients do not need to persist 
on a particular AED treatment without improvement of seizures. In addition, there might 
be a risk of developing tolerance to a particular AED or other future drugs as remaining on 
the same agent for a long period of time may result in morphological and physiological 
changes in the brain (Bogg et al., 2000). However, some investigators believe that seizures 
do not beget seizures except in rare cases with extremely prolonged seizures (Berg and 
Shinnar, 1997). It would be appropriate to establish a predefined period of time for the 
application of each AED with failure to obtain seizure freedom or at least 50% or 75% 
seizures reduction within this period necessitating introduction of a new AED treatment 
regimen either through substitution or combination.    
 
 
 
 
 
 
 
 
 
 
Chapter 4. Discussion.  207 
 
 
AED DDD 
Dose required to 
reach a certain 
remission rate  
Dose required for 
a certain 
withdrawal rate  
Lamotrigine 300 mg/day 
≤ 400 mg/day 
(94%) 
≤ 300  mg/day 
(94%) 
Sodium 
valproate 
1500 mg/day 
≤ 2000 mg/day 
(95%) 
≤ 1500 mg/day 
(92%) 
Carbamazepine  1000 mg/day 
≤ 800 mg/day 
(92%) 
≤ 600 mg/day 
(97%) 
Topiramate  300 mg/day 
≤ 200 mg/day 
(97%) 
≤ 200 mg/day 
(100%) 
Oxcarbazepine  1000 mg/day 
≤ 1200 mg/day 
(96%)  
≤ 900 mg/day 
(91%) 
Levetiracetam  1500 mg/day 
≤ 2000 mg/day 
(91%) 
≤ 1000 mg/day 
(86%) 
Table 67. Remission and withdrawal rates due to side effects among certain dose ranges.  
 
 
 
 
 
As it has been discussed earlier, three different patterns of response were observed in the 
patients recruited to this study. These included patients who developed complete seizure 
freedom after a period of ongoing seizures (66%), those with intractable seizures despite 
various AED treatment regimens either as monotherapy or combined therapy (25%). The 
last group of patients consisted of those who had a fluctuation in response to AEDs with 
periods of remission and relapse (9%). With the exception of the third category of this 
study (patients with fluctuating response to AEDs), the other two groups (patients with 
remission and those with intractable seizures) were similar to those studied by Kwan and 
Sander who categorised the prognosis of epilepsy into three groups i.e. excellent prognosis 
with or without treatment (around 30%), good prognosis only with treatment (30% 
approximately) and poor prognosis with continuous seizures despite AEDs treatment 
(around 40%) (Kwan and Sander, 2004). When adding the percentages of the first two 
remission groups of Kwan and Sander together i.e. 60% approximately, these findings are 
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similar to those of the first group of this current investigation (remission after a period of 
ongoing seizures) i.e. 66% (Figure 31).    
 
 
 
Remission
with or without
treatment
Remission
only on
treatment
Intractable
seizures
despite
treatment
A
B
25%66%
40%
30%
30%
A
B
 
Figure 31. A comparison regarding the natural history of epilepsy between A: (Kwan and 
Sander, 2004) and B: this study.   
 
 
Reanalysis of these three groups by splitting patients in the first category (patients with 
complete seizure control) into two groups based on the timing of starting seizure freedom 
in relation to the beginning of AEDs treatment resulted in four categories:   
1. Patients with excellent prognosis who developed complete seizure control 
immediately after starting treatment with AEDs. 261 patients in this group 
constituted 24% of the total study population. It is assumed that this group of 
patients included those who would achieve remission even without AED treatment 
because spontaneous remission of the underlying epileptogenic process has taken 
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place (Sander, 1993). The issue of spontaneous remission has not attracted a lot of 
attention because of the ethical difficulty in conducting a study without supplying 
essential treatment to these patients (Kwan and Sander, 2004).  
2. Patients with good prognosis of epilepsy who needed time to achieve seizure 
freedom using either single or multiple treatment regimens with AEDs. Some of 
these regimens may be in the form of monotherapy while others might be 
combined therapy. This group was represented by 467 patients (43%). Other 
studies have observed a remission range of 65-80% in this group of patients in 
whom it is believed the epileptogenic process does not remit and seizures will 
recur after AED withdrawal (Sander, 1995).  
3. Patients with intractable seizures who did not have a period of at least 12 months 
seizure freedom during their follow up despite using multiple AED treatment 
regimens. They constituted 25% of the study population (n = 272). This confirms 
other hospital based (Sander and Sillanpaa, 1997;Sander, 1993) and community 
based studies (Annegers et al., 1979;Goodridge and Shorvon, 1983) which 
demonstrated that around 20-30% of newly diagnosed epilepsy patients do not 
enter remission (Kwan and Brodie, 2006). Some of these patients might have one 
of the epilepsy syndromes associated by low response rate to pharmacological 
intervention e.g. mesial temporal lobe epilepsy; these patients will need a surgical 
intervention that demonstrated a high remission rate in many cases (Engel and 
Shewmon, 1993;Hennessy et al., 2001;Holmes et al., 1997;Wieser et al., 1993). In 
patients with these syndromes, the intractable seizures will be of genetic origin. 
Genetic factors can also lead to refractory epilepsy as a result of recognised 
mechanisms i.e. multi-drug transporter hypothesis (Loscher and Potschka, 2002) 
and drug target hypothesis (Vreugdenhil and Wadman, 1999). Other explanations 
for these refractory seizures include epilepsy related factors such as early onset of 
seizures (Camfield et al., 1993;Casetta et al., 1999) or type of seizures (Aikia et al., 
1999;Mattson et al., 1996) or family history of epilepsy (Berg et al., 2001;Elwes et 
al., 1984). Intractable seizures might also be due to reduced responsiveness to 
AEDs following prolonged exposure to these agents (Bogg et al., 2000;Frey et al., 
1986).  
Patients with focal epilepsy are known to have a lower remission rate in 
comparison to those with idiopathic generalised epilepsy (Aikia et al., 1999;Kwan 
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and Brodie, 2000a;Mattson et al., 1996;Perucca, 2001b;Reutens and Berkovic, 
1995). The underlying brain lesion may be one of the main responsible factors in 
this regard (Loiseau et al., 1990). In this current investigation, 82% (n = 222) of 
patients with refractory epilepsy had focal epilepsy with those with symptomatic 
epilepsy in which identified brain pathology was comprised 48% (n = 130).   
4. 98 patients (9%) had fluctuation in response to AEDs between remission and 
relapse. Although some patients of this group developed remission of seizures as 
an ultimate outcome, they had some recurrences of seizures during their follow up 
course. Berg and colleagues reported up to five periods of remission interrupted by 
intervals of relapses with a greater risk of relapses after remissions in patients with 
idiopathic epilepsy (Berg et al., 2009). Patients with idiopathic generalised 
epilepsy comprised 26% of patients with a fluctuation in AED response in this 
study. Instead of being constant, Berg et al., also reported the fluctuation in AED 
responsiveness that might be due to shifts in the pathophysiological features on the 
underlying cerebral lesion (Berg et al., 2009).  
Analysis of AED response among all patients on monotherapy on their last visit to the 
Epilepsy Unit demonstrated insignificant differences with regard to the ultimate outcome 
of epilepsy among the two generations of AEDs, and also among the two primary 
mechanisms of action (sodium channels blockage and potentiation of GABA inhibitory 
effect) whether analysed in terms of the ultimate outcome of epilepsy or rate of response of 
a particular regimen following failure of previous schedule acting by the same primary 
mechanism of action.   
In conclusion, it seems that the first AED applied to newly diagnosed epilepsy patients is 
the major predictor of the ultimate outcome of epilepsy probably because it is the first 
exposure of the brain to AEDs leading to the highest observed response. In prolonged drug 
exposure, the brain might develop adaptation to these agents or pathophysiological changes 
of the underlying disorder might take place with subsequent variation in the drug response 
among the following treatment regimens. This could be the reason for the variation in the 
effectiveness of AEDs according to their order of prescription indicating that the 
effectiveness to these agents is a dynamic rather than a fixed process.  
Complete seizure control was obtained in the majority of patients with most of the AEDs 
in this study using moderate doses of these agents. The same pattern was observed in case 
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of the tolerability. Therefore, it might be useful to restrict the use of these drugs to a 
slightly higher than moderate doses without reaching higher concentrations, while 
specifying a certain period of time for the trial of particular AEDs. The four patterns of 
response to AEDs observed in this study link some of the well known aspects of epilepsy 
together such as pathophysiology of seizures, biological basis of pharmacoresistance, 
prognosis, epileptogenesis process, genetics and epilepsy syndromes.   
Insignificant differences were noticed among the two generations of AEDs and also among 
the two primary mechanisms of action of AEDs (sodium channels blockage and 
potentiation of GABA inhibitory effects) in terms of the ultimate outcome of epilepsy.  
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Conclusion 
This is a large-scale retrospective study that followed up newly diagnosed epilepsy patients 
for almost 26 years. Patients were referred to the Epilepsy Unit of the Western Infirmary in 
Glasgow, Scotland between 1982 and 2005. Among around 1500 patients, 1098 met the 
inclusion criteria and were recruited. The ultimate outcome of epilepsy and effectiveness 
of AEDs applied were identified for the whole study population. Consequently, analysis 
was conducted in relation to a variety of demographic, clinical and pharmacological 
aspects.  
A comparison has been made between the first and second generation AEDs in terms of 
efficacy and tolerability in special populations and regarding the ultimate outcome of 
epilepsy. Such a comparison has not been addressed previously in clinical trials as most of 
studies have concentrated on comparison between individual drugs rather than groups of 
drugs (generations). The efficacy of first generation AEDs were found to be significantly 
higher in elderly patients with epilepsy (≥ 65 years old) than the second generation drugs. 
Other age groups (adolescents and adults) demonstrated insignificant difference between 
older and modern AEDs. Gender analysis showed a significantly higher efficacy and 
tolerability of both generations of AEDs in males than females. Insignificant difference 
was noticed between the older and newer AEDs in terms of idiopathic generalised and 
focal epilepsy. With regard to the ultimate outcome of epilepsy, there was insignificant 
difference between first and second generation AEDs.  
Analysis of the ultimate outcome of epilepsy by the end of study was calculated. Among 
the various age groups, elderly patients demonstrated a higher seizure freedom rate 
compared to adolescents and adults. In terms of gender, male patients with epilepsy had a 
remission rate higher than females. Regarding epilepsy classification, patients with 
idiopathic generalised epilepsy had a rate of complete seizure control higher than those 
with focal epilepsy.  
The ultimate outcome of epilepsy of patients recruited to this study demonstrated a modest 
improvement over the last two decades; this may be assumed to be due to the longer 
duration of follow up of these patients accompanied by the application of wide range of 
available second generation AEDs and the various treatment regimens with different 
combination strategies. Therefore, it can be concluded that the newer AEDs have 
contributed to the modest improvement in the prognosis of epilepsy. The correlation 
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between the duration of follow up and the ultimate outcome of epilepsy was observed in 
elderly patients with focal epilepsy. These patients demonstrated an elevation in the total 
remission rate associated with an extension of their period of follow up following an initial 
analysis.  
Observations from this study were consistent with findings from other studies regarding 
the number of AED treatment regimen failures needed before a patient can be considered 
as drug resistant. It was observed that failure of two appropriately selected and adequately 
tried AED treatment schedule was associated with a small opportunity to develop complete 
seizure control subsequently, keeping in mind that considering a patient as 
pharmacoresistant does not necessarily mean that seizure freedom state will never be 
achieved as AEDs can show fluctuation of response that is difficult to predict.    
This study also provided an opportunity to analyse the response to AED therapy based on 
the mechanism of action, an issue that was addressed in a limited number of studies.  Male 
patients with idiopathic generalised epilepsy showed a higher response rate to AEDs acting 
primarily by sodium channels blockage than females. For AEDs working mainly by 
potentiation of GABA inhibitory effect, males with IGE also had a significantly higher 
response rate than females. Among focal epilepsy patients, similar response rates were 
detected in males and females with regard to these two mechanisms of action. Patients with 
idiopathic generalised epilepsy generally had a higher remission rate on AEDs acting 
mainly by potentiation of GABA inhibitory effect than those acting by sodium channels 
blockage. In contrast, similar response rates were observed for these two mechanisms of 
action among all patients with focal epilepsy.  Analysis of the ultimate outcome of epilepsy 
did not reveal any difference between these two mechanisms of action.   
Response to the first ever AED therapy was found to be associated with the highest 
response rate with a gradual decline in the subsequent schedules. The variability in the 
response to AEDs might be explained by changes that take place in the brain. In 
association with genetic background and other factors such as seizures type and epilepsy 
syndrome, the variability of AED response has been found to follow multiple patterns of 
response. Minimizing the application of AEDs used as monotherapy to a moderate or 
slightly higher than moderate dose range has been shown to be sufficient to predict the 
response to these drugs eventually in terms of efficacy and tolerability.   
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Being a retrospective study, this has lowered the power of this investigation to detect a true 
difference between patient groups and to give a clear interpretation of results and 
recommendations because of the information bias associated with the lack of some 
required data. Therefore, the application of a prospective type of analysis would be a better 
alternative in this regard although this may require a long follow up of patients. Applying a 
retrospective study was the only way to follow up these recruited patients for such a long 
period of time (26 years approximately). Conducting an appropriately designed prospective 
study is therefore strongly recommended to obtain a good accuracy of data collection with 
accurate results consequently.   
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Appendices 
 
Regimens AEDs 
combination 1 2 3 4 5 6 7 8 9 
Total Efficacy 
CBZ + FBM - 
0  
(1) 
- - - - - - - 
0 
(1) 
0 
CBZ + GBP - 
1  
(7) 
0  
(5) 
- 
1 
(1) 
- - - - 
2 
(13) 
15 % 
CBZ + LEV - 
1  
(5) 
0  
(3) 
1 
(2) 
0 
(1) 
- - - - 
2 
(11) 
18 % 
CBZ + LTG - 
0  
(8) 
0  
(1) 
0 
(3) 
- - - - - 
0 
(12) 
0 
CBZ + PGB - 
2  
(4) 
0  
(1) 
- - - - - - 
2 
(5) 
40 % 
CBZ + PHT - - 
0  
(1) 
- - - - - - 
0 
(1) 
0 
CBZ + TGB - 
0  
(1) 
1  
(1) 
- - - - 
0 
(1) 
- 
1 
(3) 
33 % 
CBZ + TPM - 
1  
(3) 
0  
(3) 
0 
(1) 
0 
(2) 
- - - - 
1 
(9) 
11 % 
CBZ + VGB - 
1  
(4) 
0  
(2) 
- - - - - - 
1 
(6) 
17 % 
CBZ + VPA - 
1  
(5) 
0  
(2) 
- - - 
0 
(1) 
- - 
1 
(8) 
13 % 
CBZ + ZNS - - - 
0 
(1) 
- - - - - 
0 
(1) 
0 
CBZ + AZM + 
TPM 
- - - - - - - 
0 
(1) 
- 
0 
(1) 
0 
CBZ + CLB + 
LEV 
- - - - - 
0 
(1) 
- - - 
0 
(1) 
0 
CBZ + CLB + 
VPA 
- - - - - - 
0 
(1) 
- - 
0 
(1) 
0 
CBZ + GBP + 
LEV 
- - - 
0 
(1) 
- - - - - 
0 
(1) 
0 
CBZ + GBP + 
LTG 
- - - 
0 
(1) 
- - - - - 
0 
(1) 
0 
CBZ + GBP + - - 1  0 0 - - - - 1 20 % 
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TPM (2) (2) (1) (5) 
CBZ + LEV + 
TPM 
- - 
0  
(1) 
0 
(1) 
0 
(1) 
0 
(1) 
- - - 
0 
(4) 
0 
CBZ + LTG + 
LEV 
- - 
0  
(1) 
- - - - - - 
0 
(1) 
0 
CBZ + LTG + 
PHT 
- - - 
0 
(1) 
- - - - - 
0 
(1) 
0 
CBZ + LTG + 
TPM 
- - 
0  
(1) 
- - - - - - 
0 
(1) 
0 
CBZ + LTG + 
VGB 
- - 
0  
(1) 
- - - - - - 
0 
(1) 
0 
CBZ + PGB + 
TPM 
- - - - - 
0 
(1) 
- - - 
0 
(1) 
0 
CBZ + TPM + 
PGB 
- - 
0  
(1) 
- - - - - - 
0 
(1) 
0 
CBZ + AZM + 
TPM + ZNS 
- - - - - - - - 
0 
(1) 
0 
(1) 
0 
CBZ + LEV + 
TPM + PGB 
- - - 
0 
(1) 
- - - - - 
0 
(1) 
0 
VPA + CLB - - - - 
0 
(1) 
- - - - 
0 
(1) 
0 
VPA + FBM - - 
0  
(1) 
- - - - - - 
0 
(1) 
0 
VPA + GBP - - 
1  
(3) 
- 
0 
(2) 
- - - - 
1 
(5) 
20 % 
VPA + LEV - 
2  
(5) 
1  
(6) 
1 
(2) 
- - - - - 
4 
(13) 
31 % 
VPA + LTG - 
27 
(58) 
5 
(18) 
0 
(2) 
0 
(3) 
- - - - 
32 
(81) 
40 % 
VPA + OXC - - 
0  
(1) 
- - - - - - 
0 
(1) 
0 
VPA + PGB - - 
0  
(1) 
0 
(1) 
- 
0 
(1) 
- - - 
0 
(3) 
0 
VPA + TPM - 
0  
(1) 
1  
(5) 
2 
(4) 
0 
(1) 
0 
(1) 
- - - 
3 
(12) 
25 % 
VPA + VGB - - 
0  
(1) 
- - - - - - 
0 
(1) 
0 
VPA + ZNS - - 1  - - - - - - 1 100 % 
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(1) (1) 
VPA + CLB + 
LEV 
- - - - - 
0 
(1) 
- - - 
0 
(1) 
0 
VPA + CLB + 
LTG 
- - - 
0 
(1) 
- 
0 
(1) 
- - - 
0 
(2) 
0 
VPA + GBP + 
TPM 
- - - - - 
0 
(1) 
- - - 
0 
(1) 
0 
VPA + LEV + 
TPM 
- - - - 
1 
(1) 
- - - - 
1 
(1) 
100 % 
VPA + LTG + 
ZNS 
- - 
0  
(1) 
- - 
0 
(1) 
- - - 
0 
(2) 
0 
VPA + LTG + 
GBP 
- - 0 (1) - 
0 
(1) 
- - - - 
0 
(2) 
0 
VPA + LTG + 
LEV 
- - 
0  
(4) 
0 
(2) 
0 
(1) 
- - - - 
0 
(7) 
0 
VPA + LTG + 
PHT 
- - - 
0 
(1) 
- - - - - 
0 
(1) 
0 
VPA + LTG + 
TPM 
- - 
0  
(4) 
0 
(1) 
0 
(1) 
- - - - 
0 
(6) 
0 
VPA + PGB + 
ZNS 
- - - - - - 
0 
(1) 
- - 
0 
(1) 
0 
VPA + GBP + 
LEV + LTG 
- - - 
0 
(1) 
- - - - - 
0 
(1) 
0 
VPA + LEV + 
LTG + PGB 
- - - - 
0 
(1) 
- - - - 
0 
(1) 
0 
VPA + LEV + 
LTG + TPM 
- - - 
1 
(2) 
- - - - - 
1 
(2) 
50 % 
VPA + LTG + 
PGB + TPM 
- - - - 
0 
(1) 
- - - - 
0 
(1) 
0 
LTG + AZM - - - - - - - 
0 
(1) 
- 
0 
(1) 
0 
LTG + GBP - 
0  
(2) 
0  
(1) 
0 
(2) 
- - - - - 
0 
(5) 
0 
LTG + LEV - 
2 
(18) 
1  
(8) 
- 
0 
(1) 
- - - - 
3 
(27) 
11 % 
LTG + OXC - 0 (1) - - - - - - - 
0 
(1) 
0 
LTG + PGB - - - 0 1 - 0 - - 1 33 % 
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(1) (1) (1) (3) 
LTG + PHT - - - 
0 
(1) 
- - - - - 
0 
(1) 
0 
LTG + TGB - - - - - 
0 
(1) 
0 
(1) 
- - 
0 
(2) 
0 
LTG + TPM - 
5 
(11) 
0  
(7) 
0 
(3) 
0 
(1) 
1 
(1) 
- - - 
6 
(23) 
26 % 
LTG + VGB - 
0  
(2) 
- - 
0 
(1) 
- - - - 
0 
(3) 
0 
LTG + ZNS - - 
1  
(2) 
- - 
0 
(1) 
- - - 
1 
(3) 
33 % 
LTG + GBP + 
LEV 
- - - - 
0 
(1) 
- - - - 
0 
(1) 
0 
LTG + LEV + 
PGB 
- - - 
0 
(1) 
- - - - - 
0 
(1) 
0 
LTG + LEV + 
TPM 
- - 
0  
(3) 
0 
(2) 
- - - - - 
0 
(5) 
0 
LTG + LEV + 
ZNS 
- - - 
0 
(1) 
- - - - - 
0 
(1) 
0 
LTG + TGB + 
VGB 
- - 
0  
(3) 
- - - - - - 
0 
(3) 
0 
LTG + TPM + 
ZNS 
- - - - 
0 
(1) 
- - - - 
0 
(1) 
0 
LTG + VGB + 
CLB 
- - - - 
0 
(1) 
- - - - 
0 
(1) 
0 
LTG + VGB + 
TPM 
- - - 
0 
(1) 
- - - - - 
0 
(1) 
0 
LTG + VGB + 
ZNS 
- - - - - 
0 
(1) 
- - - 
0 
(1) 
0 
FBM + PHT - - - 
0 
(1) 
- - - - - 
0 
(1) 
0 
GBP + LEV - - 
1  
(1) 
0 
(1) 
- - - - - 
1 
(2) 
50 % 
GBP + OXC - - - 
0 
(1) 
- - - - - 
0 
(1) 
0 
GBP + PHT - - 
0  
(1) 
- - - - - - 
0 
(1) 
0 
GBP + TPM - - - - - - 1 - - 1 100 % 
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(1) (1) 
LEV + OXC - 
1  
(3) 
1  
(2) 
- 
0 
(1) 
- - - - 
2 
(6) 
33 % 
LEV + PGB - - 
0  
(1) 
- - - - - - 
0 
(1) 
0 
LEV + TPM - 
1  
(2) 
- 
0 
(1) 
- - - - - 
1 
(3) 
33 % 
LEV + ZNS - 
0  
(1) 
- - - - - - - 
0 
(1) 
0 
LEV + PGB + 
ZNS 
- - - 
0 
(1) 
- - - - - 
0 
(1) 
0 
LEV + PGB + 
TPM + ZNS 
- - - - 
0 
(1) 
- - - - 
0 
(1) 
0 
OXC + PGB - 
0  
(2) 
0  
(1) 
- 
0 
(1) 
- - - - 
0 
(4) 
0 
OXC + TPM - - 
0  
(1) 
- - - - - - 
0 
(1) 
0 
OXC + ZNS - - - 
0 
(2) 
- - - - - 
0 
(2) 
0 
Total of 
responders on 
polypharmacy 
- 45 15 5 3 1 1 0 0 70 - 
Total of Non-
responders on 
polypharmacy 
- 99 89 46 26 12 6 3 1 286 - 
Total - 144 104 51 29 13 7 3 1 356 - 
Appendix 1. Efficacy of AEDs combinations in patients on polypharmacy.  
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